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Neisseria meningitidis and meningococcal disease 
 
Neisseria meningitidis is one of the major causes of bacterial meningitis and 
sepsis worldwide [1]. N. meningitidis isolates can be divided into thirteen serogroups 
based on the structure of the capsular polysaccharide [2]. Five serogroups (A, B, C, 
Y and W135) virtually account for all disease-causing isolates [3,4]. In Europe, 
approximately two thirds (63%) of the reported cases of meningococcal disease are 
attributable to serogroup B strains, and most of the remainder to serogroup C strains 
(30%), with very low incidence of the other serogroups (data 1999-2000) [5]. In the 
Netherlands the incidence of serogroup B is even higher, accounting for almost 77% 
of the cases, while serogroup C is found in 19% of all isolates (data 2000) [6]. In the 
USA the serogroup distribution differs, with 32% of the cases caused by serogroup B, 
35% by serogroup C and 26% by serogroup Y (data 1996) [7]. Serogroup A isolates 
are predominantly found in sub-Saharan African countries (so-called meningitis belt 
countries) and cause frequent epidemics. Disease caused by serogroup W135 has 
been associated with the Haji pilgrimage in Saudi Arabia [3].  
In non-epidemic situations, the nasopharynx of 10-25% of the general 
population is colonized by meningococci [8,9,10]. Increased carrier rates have been 
observed during epidemics and crowding [11]. Meningococcal carriage is a natural 
immunizing process resulting in the induction of systemic protective antibody 
responses [12]. Despite the high rate of colonization, meningococcal disease is quite 
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rare [13], and the mechanism by which bacteria invade the mucosal barrier and get 
access to the blood stream remains unknown. The highest incidence of 
meningococcal disease occurs in young children under the age of four [5]. An 
incidence peak is also observed among teenagers, probably due to an increased 
exposure to environmental risk factors [14,15]. 
Meningococcal disease is characterized by a variety of clinical symptoms 
[16,17] and the early phase resembles the disease caused by ordinary influenza. The 
mild symptoms can change rapidly (within hours) in a life-threatening disease 
displaying two clinical pictures, i.e. sepsis and/or meningitis. In approximately 10% of 
the cases of meningitis and 20% of sepsis, the disease is fatal despite antibiotic 
treatment [18]. Without antibiotics, death rates increase up to 80% [19]. Of the 
surviving patients, 5-20% experiences permanent damage, such as amputation of 
necrotic extremities, mental retardation or deafness [1,19]. The rapid onset of 
invasive meningococcal disease, the high incidence in childhood, the severity of the 
sequellae and the high mortality rate clearly indicate the importance of vaccine 
development against Neisseria meningitidis.  
 
Surface structures of meningococci and vaccine candidates 
 
Meningococci display a double-membrane structure typical of gram-negative 
bacteria (Fig. 1), with a peptidoglycan layer embedded between the cytoplasmic and 
the outer membrane [20]. A polysaccharide capsule covers the outer membrane of 
meningococci. The different polysaccharide structures are used to classify 
meningococci in thirteen serogroups (see above) [2]. The polysaccharide capsule is 
a virulence factor for meningococci and, although capsular-deficient strains are 
commonly isolated, these are non-infectious [10]. Vaccines based on 
polysaccharides against meningococci of groups A, C, Y and W135 are being 
developed or are already licensed and available worldwide [21,22,23,24,25]. Efforts 
to use the capsular polysaccharide of group B meningococci have been hampered by 
its poor immunogenicity, even when conjugated with a carrier protein [26,27]. This 
poor immunogenicity is probably due to immunological tolerance induced by cross-
reactive polysialylated glycoproteins that are especially abundant in fetal neural 
tissue [28,29]. A list of antigens located in the outer membrane that have been 
investigated as vaccine candidates against type B meningococci is shown in Table 1. 
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Figure 1. Surface structures of Neisseria meningitidis. The cell envelope is composed of an outer 
membrane (OM) and an inner membrane (IM), separated by a periplasmic space (PS) containing a 
peptidoglycan layer (PG) and proteins. The OM is an asymmetric bilayer with lipopolysaccharide 
(LPS) and phospholipids (PL) in the outer leaflet and PL in the inner leaflet. In the OM, LbpA and LbpB 
represent the integral outer membrane protein (OMP) and the cell-surface exposed protein 
respectively, wich together constitute the lactoferrin receptor. CPS: capsular polysaccharide; Opa: 
Opacity protein (class 5 OMP); PorA: porin protein A (class 1 OMP); RmpM: reduction modifiable 
protein M (class 4 OMP). The IM is a symmetric bilayer of PL with proteins [30]. 
 
Table 1. Major meningococcal outer membrane components. 
Name Characteristics Vaccine potential Ref 
Type IV pili Adhesion to epithelium Low, high variability [20,33] 
LPS Endotoxin Only in detoxified form [40] 
PorA (class 1) Porin Induces protective Ab [49,50] 
PorB (class 2/3) Porin No protective response [56] 
RmpM (class 4) Reduction modifiable protein No protective response [64] 
Opa/Opc (class 5) Opacity proteins,  
Involved in adhesion/invasion 
Induces protective Ab [70] 
LbpA/LbpB Lactoferrin receptor,  
Iron-regulated 
Induces protective Ab [71] 
NspA Neisseria surface protein A Induces protective Ab [74] 
Various Proteins obtained by  
reverse vaccinology 
Induction of protective Ab [79] 
 
Fimbriae or type IV pili are filamentous protein projections from the 
meningococcal cell surface [31,32]. Type IV pili consist of at least two distinct 
proteins, the highly variable major subunit PilE forming the pilus fiber and the tip-
associated adhesin PilC that contributes to the initial attachment of bacteria to 
CHAPTER 1 
 
 12 
epithelial, or endothelial host cells and erythrocytes [33,34]. Type IV pili show a high 
degree of antigenic variability [20] which makes them unsuitable as vaccine 
candidates.  
The outer membrane is composed of phospholipids, outer membrane proteins 
(OMPs) and lipopolysaccharide (LPS). The outer membrane of N. meningitidis is 
typical of gram-negative bacteria and has an asymmetrical organization, with the 
outer leaflet primarily composed of LPS and proteins and the inner leaflet composed 
of phospholipids [35]. The major phospholipids of N. meningitidis are 
phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) with variable fatty acyl 
substituents, including C16:1, C16:0, C18:1, C14:0, C14:1 and C12:0 [36].  
 
Figure 2. Schematic representation of N. meningitidis immunotype L3 LPS [37]. The lipid A moiety 
and the oligosaccharide core are indicated. Kdo: 2-keto-3-deoxyoctulonosic acid; Hep: heptose; 
GlcNac: N-acetyl-glucosamine; Gal: galactose; Glc: glucose.  
 
Neisseria LPS (Fig. 2) is composed of a hydrophobic lipid A part, which 
anchors it in the outer membrane. Lipid A is also named endotoxin and is responsible 
for toxic effects, like septic shock [38]. The head group consists of a core region 
(oligosaccharide), and lacks the O-antigen, a polymer of repeating units, each of 
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them containing three to six sugar residues. Because of the absence of the O-
antigen, N. meningitidis LPS is also referred to as lipooligosaccharide. The core 
region of meningococcal LPS is variable and is the basis of the classification of 
meningococci in twelve different immunotypes [39]. It has been shown that vaccines 
based on detoxified LPS or LPS-toxoid conjugates are able to induce 
immunotype-specific immune responses [40]. Also, conserved inner core epitopes of 
LPS are able to elicit protective immune responses in animals and may have 
potential as a cross-reactive vaccine component [41]. 
Bacterial OMPs are used for nutrient acquisition and protein secretion, and 
can play a role in the adhesion and invasion of host tissues or have an enzymatic 
function. The major OMPs of N. meningitidis have been divided into five classes on 
the basis of molecular weight [42].Class 1 OMP, also called PorA (44-47 kDa) and 
the mutually exclusive class 2 and 3, also called PorB (37-42 kDa) are porins. PorA 
forms cation-selective pores in the OM, whereas PorB forms anion-selective pores 
[43,44]. For both porins, topology models have been described [45,46], based on 
sequence comparisons and on the structure of PhoE, an outer membrane porin from 
Escherichia coli [47]. According to these models, each porin monomer consists of a 
16-stranded anti-parallel β-barrel enclosing a transmembrane pore (Fig. 3). 
The β-strands are amphipatic with the hydrophobic amino acid residues 
exposed to the membrane and the hydrophilic amino acid residues exposed to the 
interior of the channel. Short turns connect the strands at the periplasmic side and 
eight large loops are exposed to the external medium. In the OM, porins are 
assembled forming trimers. The surface-exposed loops of PorA and PorB show high 
sequence variability, and form the basis for sero-subtyping and subtyping of 
meningococci, respectively [48]. PorA is still recognized as an immunodominant 
antigen of N. meningitidis and induces strong bactericidal responses [49,50], with 
antibodies mainly directed against the hypervariable regions VR1 and VR2 located in 
loop 1 and 4, respectively [51,45]. Although it has been demonstrated that PorA 
undergoes high antigenic and phase variation [52], it is the basis of outer membrane 
vesicle (OMV) vaccines developed in various groups [49,53,54,55]. In contrast to 
PorA, PorB is not able to induce a protective bactericidal response [56], although it 
has been successfully used as carrier protein for polysaccharide conjugates [57]. 
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Figure 3. Structure of PorA outer membrane protein of Neisseria meningitidis. Left: molecular 
surface of a porin monomer from the PorA model. The positions of the external loop regions are 
indicated as I, II, and so forth, with the exception of loop III which lies inside the protein (broken line). 
The longer loops (I, IV and V) are not based on computer modeling and are therefore drawn as broken 
lines. Right: model of PorA trimer, viewed from above. The positions of the external loop regions are 
marked as in the monomer (left), with the subunits designated a, b, c. Adapted from [44]. 
 
The vaccine developed at the Netherlands Vaccine Institute (former part of the 
National Institute for Public Health and the Environment, RIVM) consists of three 
OMV preparations, each containing three different PorA serosubtypes (trivalent 
OMV) representing the majority of circulating serosubtypes in the Netherlands and 
other countries in Europe [58]. This vaccine has been tested in phase I and II trials 
and has been proven to be safe and immunogenic [50,55]. Since PorA serosubtype 
P1.7-2,4 is the cause of a current epidemic in New Zealand and is the most prevalent 
serosubtype in the Netherlands, a monovalent vaccine strain with double expression 
of this PorA was also constructed at the RIVM. This vaccine appeared to be safe and 
immunogenic in toddlers [59]. 
Class 4 OMP (33-34 kDa) or RmpM (Reduction-modifiable protein M) is highly 
conserved, shows minor sequence variation among strains and shares sequence 
homology with the N. gonorrhoeae PIII protein and E. coli OmpA [60]. RmpM is firmly 
associated to porins [61] and to iron-limitation inducible proteins [62], and it is not 
accessible on the cell surface [63]. Antibodies raised against purified RmpM are not 
bactericidal and they showed to block the bactericidal activity of antibodies directed 
against PorA [64]. Although these results have been questioned [63], RmpM will 
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probably never be a vaccine candidate. On the other hand, its presence in PorA-
based vaccines may improve the stability of PorA trimers [61]. 
Class 5 OMP, also called opacity proteins (26-32 kDa) includes two groups: 
Opa and Opc proteins. Neisseria meningitidis can carry up to four opa genes, which 
can be independently switched on or off [20], whereas only a subset of 
N. meningitidis expresses the Opc protein [65]. Opa proteins are predicted to form 
8-stranded β-barrels in the outer membrane, with four surface-exposed loops [66], 
while Opc spans the membrane 10 times, forming five surface-exposed loops [67]. 
Both Opa and Opc play an important role in the adhesion to and invasion of host 
cells, but only in the absence of a polysaccharide capsule [68,69]. Although Opa and 
Opc proteins have been shown to elicit a strong bactericidal response [70], their 
phase and antigenic variabilities are a drawback for their use in meningococcal 
vaccines. 
In addition to the major OMP, N. meningitidis expresses numerous other 
OMPs, in some cases under special growth conditions. For example, growth in an 
iron-limiting environment results in the expression of receptors for heme 
(iron-porphyrin complex) and for the host iron-binding proteins lactoferrin, transferrin, 
hemoglobin and haptoglobin-hemoglobin [71]. The bactericidal activity of antibodies 
elicited against these proteins is comparable with those against class 1 OMPs. 
Therefore, these iron-regulated proteins have attracted considerable attention as 
vaccine candidates [72].  
Neisserial surface protein A (NspA) is a recently discovered, highly conserved 
membrane protein that is present in small amounts in the outer membrane. NspA 
elicits serum bactericidal antibodies that are protective in animal models of 
meningococcal group B bacteremia [73,74]. However, there are large differences in 
the accessibility of NspA on the surface of different encapsulated meningococcal 
strains [75,76]. Moreover, mouse polyclonal and monoclonal antibodies that have 
been raised against recombinant NspA are bactericidal against only about 50% of 
group B meningococcal strains [75]. In patients recovering from meningococcal 
disease NspA is a weak immunogen [77]. 
A novel approach in the development of vaccines against meningococci is 
called reverse vaccinology. This approach consists of the analysis of sequences of 
meningococcal unassembled DNA fragments with computer algorithms to identify 
open reading frames that potentially encode surface-exposed proteins. Proteins that 
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are thought to be surface-exposed and conserved are then cloned, expressed in 
E. coli, and tested in mice. This resulted in the finding of 28 newly discovered 
proteins, some of which elicited antibodies that bound to the bacterial surface or had 
bactericidal activity against group B meningococci [78,79,80]. However, the 
bactericidal titers induced by these proteins were lower as compared to those elicited 
by an OMV vaccine, and probably resulted from cross-reactivity with some PorA 
serosubtypes [81]. 
 
Antigen presentation and the immune response 
 
A natural infection will mostly cause a specific response of the immune 
system. This response clears the pathogen and also causes immunity towards it. The 
specific immune response consists of two components: a humoral (antibody-
mediated) and a cell-mediated component. The key cells in the specific immune 
response are antigen presenting cells (APC) and lymphocytes. For a successful 
vaccination the vaccine antigens have to be presented by APC that activate the 
effector cells of the immune system: naïve T-cells and B-cells. B-cells are 
responsible for antibody production and T-cells are responsible for cell-mediated 
reactions, like the induction of cytotoxic T-cells. Vaccination aims to stimulate a 
specific immune response and induce a long lasting immunological memory to 
protect against subsequent disease.  
Induction of an immune response against protein antigens requires the partial 
intracellular degradation of the antigen in APC [82]. Antigens can follow two 
degradation pathways in APC. Endogenous antigenic peptide fragments generated in 
the cytoplasm of cells (e.g. after virus infection) by the proteasome are presented by 
the major histocompatibility complex (MHC) class I molecules and stimulate cytotoxic 
T lymphocytes (CTL). Specific class I restricted CD8+ T-cells can recognize APC 
presenting MHC class I-peptide complexes on the surface and lead to lysis of the 
target cell. Peptide fragments of exogenous protein acquired from outside the cell are 
presented by MHC class II molecules and stimulate CD4+ T-helper cells, that will 
activate B-cells to become antibody-secreting plasma cells. However, this traditional 
mechanism is now being reviewed due to evidence of cross-talk between these two 
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pathways, which allows certain types of exogenous antigens to be presented by 
MHC class I molecules [83,84]. 
There are different, specialized APC, like macrophages, dendritic cells (DC), 
or even B-cells. Of these cell types, only DC are efficient stimulators of primary 
immune responses and subsequent establishment of immunological memory [85]. 
Dendritic cells (Fig. 4) take up antigens in peripheral tissues, process them into 
peptides and load these peptides onto MHC class I and II molecules. Dendritic cells 
then migrate to secondary lymphoid organs and become competent (i.e. mature) to 
present antigens to naïve T-cells, thus initiating antigen-specific immune responses 
[88]. One can then hypothesize that one of the ways to improve the immune 
response induced by certain antigens (e.g. PorA) might be achieved by their 
targeting to DC. 
Figure 4. Maturation and migration of DC upon uptake of exogenous antigens. In the periphery, 
immature DC have a high phagocytic activity. Upon antigen uptake, DC migrate towards lymph nodes, 
and they ‘mature’, with up-regulation of co-stimulatory molecules such as CD80, CD86, CD40. 
Efficient maturation results in the production of cytokines (e.g. IL-12) by DC. The exogenous antigen is 
hydrolyzed in endocytic compartments, and the formed immunogenic peptides are presented in MHC 
class II complex to T-cells. Interaction of MHC class II-peptide with the T-cell receptor (TCR) leads to 
T-cell stimulation, which will stimulate B-cells and results in an antigen-specific immune response. The 
uptake of self-antigens leads DC to a semi-mature state that is unable to initiate an immune response. 
Adapted from [86]. 
 
At least two signals are required for stimulation of naïve T-cells by APC. The 
first signal is the presentation of antigenic peptide fragments on the surface of APC in 
the context of the MHC class I or class II for the recognition of the T-cell receptor 
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(TCR) on T-cells. The second signal is given by co-stimulatory molecules on the APC 
surface that are recognized by receptors on the T-cell surface [87,88]. 
Non-professional APC lack co-stimulatory signaling and can therefore not stimulate 
naïve T-cells to become effector T-cells. It is believed that in the absence of 
appropriate co-stimulatory signals, TCR recognition of peptides presented by MHC 
leads to anergy, which would constitute a mechanism for tolerization to self-antigens 
[89]. 
Two major subsets of CD4+ T-cells have been described in mice and humans: 
T-helper 1 (Th1) and Th2 and can be characterized based on the secretion of 
different cytokine patterns [90,91]. Th1 responses are characterized by the induction 
of delayed-type hypersensitivity responses and the secretion of interferon-γ (INF-γ), 
interleukin-2 (IL-2) and IL-12. Th2 responses are characterized by the induction of 
circulating or secretory antibodies and the secretion of IL-4, IL-5, IL-6 and IL-10. The 
different cytokine secretion patterns are mutually antagonistic, and upregulation of 
one type of response normally results in downregulation of the alternative. In mice, 
the production of IgG2a antibody isotype is characteristic of a Th1 response, 
whereas a Th2 response is associated with the induction of IgG1 [92,93]. 
The activation of B cells is based on the recognition of native antigens through 
their B-cell receptor (BCR). However, the recognition event by itself does not induce 
full cell activation. Therefore it needs the interaction of primed T-cells with 
antigen-specific B-cells plus additional co-stimulatory signals provided by the T-cell 
(e.g. CD40/CD40L interaction). This interaction induces B-cell differentiation, 
germinal center development, isotype switching and memory B-cell development 
[94]. 
Protective immunity against meningococcal disease mainly relies on 
antibody-mediated effector functions as serum bactericidal activity and 
opsonophagocytosis [95]. A Th2 type immune response should be advantageous, as 
it results in the production of circulating or secretory antibodies. However, 
complement-activating antibodies are necessary in immune responses against 
Neisseria meningitidis, as they induce killing of bacteria, considered one of the 
correlates of protection against N. meningitidis [96,97]. Murine IgG of the isotypes 2a 
and 2b induce complement-mediated killing of meningococci. The production of 
IgG2a is associated with a Th1 type response [93]. Probably a combination of Th2 
responses, with induction of high antibody titers and Th1 responses, with the 
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preferred production of IgG2a, is the preferred immune response for vaccines against 
Neisseria meningitidis. T-cells also play an important role in the regulation of the 
immune response, including stimulation of B-cells for antibody production. Moreover, 
T-cells are necessary for the establishment of immunological memory and to promote 
activation of phagocytic cells, thereby facilitating the uptake and destruction of 
meningococci. Both the measurement of antibodies in sera and T-cell stimulation 
assays are indirect ways to measure protection against meningococcal disease. An 
important barrier in the development of vaccines against type B meningococci is the 
lack of a good animal model for human meningococcal disease and active 
immunization. Without this model, the correlates of protection remain indirect 
measures of the vaccine potential  
 
Antigen delivery systems: OMV, liposomes and microspheres  
 
Antigen delivery systems are necessary for optimal presentation of many 
subunit vaccines (e.g. proteins). They have the advantage of being naturally targeted 
for uptake to APC to facilitate the induction of potent immune responses. Several 
particulate systems have been studied for the delivery of subunits antigens, e.g. 
liposomes, ISCOMs and microparticles [98,134]. These delivery systems have 
comparable dimensions to pathogens and allow the inclusion of immunostimulatory 
adjuvants.  
For antigens such as PorA, localized in the outer membrane of N. meningitidis, 
the most straightforward delivery systems consist of outer membrane vesicles 
extracted from bacteria. Meningococcal cells contain large amounts of loosely bound 
outer membranes, and during normal growth meningococci release large amounts of 
these membranes in the form of vesicles  (OMV) [99]. OMV are a natural 
environment for meningococcal outer membrane proteins. However, the composition 
of the OMV is poorly defined and is difficult to vary in a controlled way, as it is 
governed by the strain from which OMV are purified and the growth conditions.  
 
Liposomes 
Liposomes are artificial vesicles, with particle sizes ranging between 30 nm to 
several microns, consisting of one (unilamellar vesicle) or more (multilamellar vesicle) 
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concentric bilayers enclosing one or more aqueous compartments. Liposomes can 
either incorporate hydrophilic drugs in the aqueous compartment(s), hydrophobic 
drugs in the lipid bilayer(s) or amphipatic compound that partition between both 
phases (Fig. 5). The composition of the lipid bilayer consists of (natural or synthetic) 
phospholipids and cholesterol, and can be manipulated to influence the 
physicochemical characteristics of the liposomes (e.g. bilayer rigidity, surface charge, 
pH sensitivity) [100,101]. Liposomes have been used as membrane models, e.g. to 
study membrane proteins [102], to study the immune system [103,104] and as drug 
delivery systems [105,106,107]. A number of parenterally administered liposomal 
products were approved by the FDA for use in humans [108]. The idea to use 
liposomes as antigen presentation forms was already tested in the early 1970’s [109]. 
Liposomes allow the study of the immunogenicity of antigens in a well-defined 
presentation form, as well as the investigation of particle characteristics on the 
antigen immunogenicity. Other advantages of the use of liposomes as antigen 
formulations are their low intrinsic immunogenicity [110], the fact that they can easily 
be prepared with varying composition [111], their ability to function as multivalent 
presentation forms for subunit antigens [112] and allow the co-encapsulation of other 
adjuvants [113]. Also, targeting moieties can be attached to the outside of the 
liposomal bilayer, allowing specific uptake by cell types involved in the immune 
response [112,114]. Furthermore, the insertion of virus fusion proteins into a lipid 
bilayer creates fusogenic liposomes, also known as virosomes [115]. Virosomes are 
used to encapsulate protein antigens for delivery to the cytosol and/or into the 
endosomal route of APC. Therefore, virosomes are able to load antigens both in 
MHC class I and II molecules, resulting in both cytotoxic and helper responses [116]. 
There are numerous literature reports on the use of liposomes as antigen 
presentation forms in vaccines against viral, bacterial and parasitic infections or 
against tumors [110,117,118] as well as in genetic vaccines [119]. The immune 
response generated by liposomal vaccines can be further enhanced by incorporation 
of adjuvants in the liposomes [120,121], or by incorporation of antigen-carrying 
liposomes in microspheres [122]. 
For purified antigens that are vaccine candidates against type B meningococci 
(e.g. PorA) liposomes are potentially suitable presentation forms, as the bilayer 
structure mimics their native outer membrane environment to a certain extent. It has 
been demonstrated that meningococcal outer membrane antigens, when 
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administered in a purified form, are not able to induce a protective immune response 
[123,124]. The humoral reaction against liposome-associated antigens from 
Neisseria species has been studied in detail [125,126,127,128]. However, it is difficult 
to determine the formulation parameters that result in an improved immune response 
for Neisseria antigens, as variables such as the composition of the bilayer, the type 
of antigen, or the animal models used for testing of liposomal vaccines are far from 
being standardized and no systematic studies have been done on the influence of 
these variables on the immunogenicity of meningococcal antigens. 
Figure 5. Schematic representation of the structure of a unilamellar liposome (left) and an outer 
membrane vesicle (right). The lipid bilayer of liposomes is composed of phospholipids, with their 
hydrophilic head group facing the aqueous phases. In the aqueous compartment, hydrophilic 
compounds can be encapsulated, whereas lipophilic compounds will be localized in the bilayer. By 
incorporation of targeting moieties on the surface of liposomes, specific cell types can be targeted. In 
OMV, the outer membrane is composed of a phospholipid bilayer containing lipopolysaccharide in the 
outer leaflet. 
 
Microspheres 
Biodegradable polymeric microspheres have been investigated in the last 
decade as antigen delivery systems for a variety of (model) antigens [129,130]. Two 
approaches have been followed: the development of pulsed release and sustained 
release systems. The pulsed release of vaccine antigens could be achieved by 
selecting polymers and encapsulation conditions yielding microspheres with different 
degradation rates. Microspheres with different, pulsatile antigen release rates could 
be mixed and the antigen would then be released at defined intervals, mimicking the 
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multiple doses given in conventional vaccination (“built-in booster”) [131,132]. In 
general, however, the encapsulation of antigens in microspheres provides sustained 
antigen release rather than distinct pulses. Moreover, this strategy has not (yet) 
resulted in the development of single-shot vaccine formulations.  
The second approach is the continuous release of antigen for prolonged 
periods. This could result in high levels of antibodies usually observed after multiple 
injections. Also in this approach, the characteristics of the polymer affect the release 
profile of antigens. The release time can last from a few days to several months 
[130]. Contrary to conventional thinking in immunology, continuous antigen delivery is 
able to produce immunity, as it results in affinity maturation, isotype switching and 
immune memory [133].  
The rational manipulation of delivery methods is likely to result in significant 
improvement in the effectiveness of existing vaccines. For Neisseria meningitidis, 
neither pulsed, nor sustained antigen release systems have been described before in 
the literature. 
 
Adjuvants in vaccine formulations against type B meningococci 
 
Adjuvants are a heterogeneous group of substances used to enhance the 
immune response of antigens [134]. At the moment, the only adjuvants regularly 
used in humans are aluminum salts (a Th2-type adjuvant), which are also used in 
vaccines developed against type B meningococci [59]. However, more potent 
adjuvants than aluminum salts are needed, as three to four doses of the vaccine are 
required to induce an effective antibody response [55,135]. Adjuvants can improve 
the immune response by increasing cellular infiltration, inflammation, and trafficking 
to the injection site (particularly for APC), promoting the activation state of APC by 
upregulating costimulatory signals or MHC expression, enhancing antigen 
presentation, or inducing cytokine release for indirect effects [134].  
The most appropriate adjuvant for a given vaccine will depend to a large 
extent on the type of immune response that is required for protective immunity. In 
vaccines against N. meningitidis mixed Th1/Th2 responses are probably preferred, 
as they result, respectively, in B cell isotype switching to IgG2a production [93] and 
increased production of antibodies [90]. Lipopolysaccharide (LPS) has been 
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recognized as a very potent Th1 adjuvant [136]. LPS present in the outer membrane 
of meningococci has been suggested to bind to OMP, thereby probably having a 
stabilizing effect. Moreover, LPS is a vaccine candidate because of its ability to 
induce a LPS-specific immune response in humans [137]. The endotoxic activity of 
LPS has limited its use in vaccines [138]. Although the toxicity induced by LPS can 
be strongly reduced by incorporation into liposomes [139], a lot of work has been 
done to develop less toxic derivatives of LPS. 
An example of such a derivative is monophosphoryl lipid A (MPL) that has 
been widely tested in man [140,141], frequently formulated into liposomes [120] and 
that results in an increased function of APC [142]. More recently, lipid A biosynthesis 
has been genetically modified in Neisseria meningitidis, resulting in an lpxL1 mutant 
with penta- instead of hexa-acylated lipid A. This mutant LPS possesses adjuvant 
activity similar to that of meningococcal wild-type LPS, but shows a reduced toxicity 
[143]. Therefore, this lpxL1 mutant of neisserial LPS is a promising candidate to be 
used in novel type B meningococcal vaccines.  
Novel adjuvants can be included in different ways in PorA-based vaccines. 
Adjuvants derived from meningococcal LPS can be included in the vaccine by 
preparing OMV derived from mutant meningococcal strains containing a less toxic 
derivative (e.g. the lpxL1 mutant). Also, purified adjuvants can be included in 
formulations such as liposomes. This second possibility is preferred, as the 
characteristics of the formulation (e.g. adjuvant/antigen ratio) can be easily varied 
and better defined systems can be obtained.  
 
Aims and outline of this thesis 
 
Many efforts are being made to develop potent vaccines against Neisseria 
meningitidis serogroup B strains. Class 1 OMP or PorA formulated in OMV, is one of 
the most promising vaccine candidates for this purpose. Among the PorA 
serosubtypes, the serosubtype P1.7-2,4 is present in up to 40% of the serogroup B 
strains causing bacterial meningitis [6]. Thus, a PorA-based vaccine should cover at 
least this subtype. On the other hand, the immunogenicity of PorA P1.7-2,4 is not yet 
optimal in its present formulation as OMV vaccine [55,144]. Therefore we selected 
PorA P1.7-2,4 as a model for our studies. The primary goal of the investigations 
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described in this thesis was to establish the formulation parameters that result in an 
improved immune response against PorA. 
In Chapter 2, the long-term stability of OMV derived from three different 
meningococcal strains, all containing PorA serosubtype P1.7-2,4 were studied. The 
aim of this study was to find out the storage conditions that provide optimal stability 
for the vaccine formulations, and to investigate which degradation mechanism(s) lead 
to loss of immunogenicity of PorA. The effects of storage of OMV formulations at 
different temperatures on both physico-chemical and immunological characteristics of 
PorA were studied, paying special attention to the thermal degradation of PorA. Both 
trivalent and monovalent OMV were sensitive to elevated temperatures, but fairly 
stable in the frozen state (-70ºC) or when stored at 4ºC in the liquid or freeze-dried 
state. 
Chapter 3 describes the efforts to obtain a well-defined and immunogenic 
PorA formulation. In these studies, PorA subtype P1.7-2,4 was purified from OMV 
and compared for structure and immunogenicity with both OMV and outer membrane 
complexes (OMCs). Although a detailed characterization of the formulations did not 
reveal major differences in the conformation of non-purified and purified PorA, the 
purification of PorA resulted in a total loss of its capacity to induce a bactericidal 
immune response in mice. This capacity was restored by the incorporation of purified 
PorA into liposomes. Liposomal PorA, in the absence of other adjuvants, was as 
immunogenic as (LPS-containing) OMV.  
As described above (Antigen presentation and the immune response section) 
DC are one of the most powerful APC. In chapter 4, PorA-liposomes targeted to DC 
were designed in order to improve the immunogenicity of liposomal PorA. The results 
in vitro indicated that targeting results in an increased uptake of liposomal PorA by 
DC as compared to non-targeted liposomes, and also induced effective maturation of 
DC. In vivo, targeted liposomes showed improved localization in APC in the lymph 
nodes. Although the bactericidal response induced by targeted liposomes was not 
improved with respect to that of OMV, an increased number of responding mice per 
group was obtained with targeted PorA-liposomes as compared to OMV and non-
targeted liposomes.  
In chapter 5, the interaction of (targeted) PorA-liposomes with human 
monocytes-derived DC and murine bone marrow-derived DC was studied in vitro. 
The results indicated that in both the human and the murine system, the liposome 
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bilayer composition had a major and comparable effect on the uptake of the 
formulations by DC.  
In line with the previous experiments, the objective of chapter 6 was to 
improve the immunogenicity of liposomal PorA. Here, the effect of co-encapsulation 
of LPS-derived adjuvants was studied. Various LPS-derived adjuvants were studied 
for their effect on the immunogenicity of liposomal PorA formulations. The use of 
galE LPS or lpxL1 LPS mutants resulted in an improved humoral immune response 
in mice. PorA-specific cellular responses for lpxL1 LPS-adjuvated liposomes were 
also investigated. This adjuvant induced an improved PorA-specific proliferation of 
cells in the lymph nodes as compared to non-adjuvated PorA-liposomes. 
In chapter 7 the possibility to encapsulate PorA-liposomes and OMV in 
biodegradable dextran and mannan microspheres was studied. The aim of this study 
was to determine whether the microsphere-encapsulated antigens were able to 
induce a similar or even improved immune response as non-encapsulated antigen, 
by attracting APC and triggering internalization. Furthermore, an adjuvant effect 
related to the use of mannan was investigated. Microspheres, containing 
PorA-liposomes and OMV, with similar release profiles were prepared from 
derivatized mannan or dextran. In vitro release studies showed partial release of 
antigen, within 10-11 days. The immunogenicity of the formulations was maintained 
upon encapsulation. 
The final chapter of this thesis, chapter 8, provides a summary and general 
discussion of the results. Moreover, suggestions are made for future investigation of 
PorA formulations for vaccines against type B meningococcal disease. 
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Abstract 
 
The stability during storage of outer membrane vesicles (OMV) of Neisseria 
meningitidis group B was studied. Three types of OMV were compared for their 
stability, containing either one (monovalent) or three different PorA subtypes 
(trivalent), the latter with and without class 4 outer membrane protein (RmpM). 
Aqueous formulations were stored at -70ºC, 4ºC, 37ºC and 56ºC. Some of the 
observed, unexpected changes in fluorescence characteristics were studied in more 
detail with tryptophan and tyrosine derivatives incubated at 56ºC. Furthermore, the 
possibility to freeze-dry OMV was investigated.  
The conformation of PorA and the physicochemical properties of the OMV 
were monitored during one year by electron microscopy, dynamic light scattering, 
fluorescence spectroscopy, and electrophoretic methods. The antigenicity of the 
PorA subtype P1.7-2,4, present in all formulations, was studied by ELISA with a 
bactericidal anti-P1.4 monoclonal antibody. The immunogenicity of OMV (i.e. 
bactericidal response) was determined in Balb/c mice.  
When stored at -70ºC or 4ºC, the structure and immunogenicity of OMV was 
preserved. In contrast, storage of OMV at higher temperatures (37ºC or 56ºC) 
induced destruction of the OMV structure and denaturation of PorA, followed by 
chemical degradation, as well as a decrease or complete loss of immunogenicity. 
Changes observed in the fluorescence spectra of degraded OMV were also seen in 
tryptophan and tyrosine derivatives incubated at 56ºC, indicating the occurrence of 
chemical degradation of tryptophan and tyrosine residues in PorA. Trivalent OMV 
were slightly more stable at 37ºC than monovalent OMV as assessed by in vitro 
methods, but these observations did not result in differences in the measured 
immunogenicity. The stability of trivalent OMV was not affected by the presence of 
RmpM. Both trivalent and monovalent OMV could be freeze-dried with preservation 
of their immunogenicity.  
In conclusion, OMV are sensitive to degradation at elevated temperatures, but 
are fairly stable in the frozen state (-70ºC) or when stored at 4ºC in the liquid or 
freeze-dried state.  
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Introduction 
 
Neisseria meningitidis is a human pathogen and one of the major causes of 
bacterial meningitis and sepsis [1]. Vaccines against meningococci of serogroups A, 
C, Y and W-135 are based on capsular polysaccharides. However, the 
polysaccharide of group B meningococci is poorly immunogenic and cross-reactive 
with human tissues [2]. Vaccines containing outer membrane proteins (OMP) have 
been developed and have shown to induce protective immune reponses [3,4]. The 
vaccines developed at the Netherlands Vaccine Institute (NVI, formerly a division of 
the National Institute of Public Health and the Environment, RIVM) consist of outer 
membrane vesicles (OMV) purified from genetically modified meningococcal strains 
expressing either one (monovalent) or three (trivalent) subtypes of class 1 OMP 
(PorA). Two different trivalent OMV are mixed to form a hexavalent vaccine that 
represents the majority of circulating subtypes in Western Europe. This vaccine has 
been proven to be safe and immunogenic [5]. The monovalent OMV vaccine contains 
PorA P1.7-2,4, the most prevalent subtype in The Netherlands and the subtype 
causing an epidemic in New Zeeland [1,9]. This vaccine is also safe and 
immunogenic in toddlers [6]. The trivalent strains contain class 4 outer membrane 
protein (RmpM). RmpM is firmly associated to PorA in the bacterial outer membrane, 
which is probably essential for the localization and the stability of the PorA trimers in 
the outer membrane [15]. 
In previous studies, we have shown that both the conformation and the 
presentation form determine the quality of the immune response against PorA [7]. 
Thus, both characteristics have to be maintained upon storage in order to preserve 
the vaccine functionality.  
The composition of OMV is complex. The main constituents are: PorA, 
phospholipids, lipopolysaccharide (LPS), residual DNA, RmpM, and residual 
detergent [12]. The interaction of these compounds with each other through various 
non-covalent forces determine the physicochemical properties and stability of OMV. 
Diverse degradation processes may occur simultaneously during storage of OMV 
vaccines. Not only can the protein undergo chemical and conformational changes, 
but the OMV structure may also change or even be destroyed. However, it is not 
clear if changes in OMV affect the potency and efficacy of meningococcal vaccines. 
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The bactericidal activity of sera from humans after vaccination with OMV is accepted 
as correlate for protection [8]. 
To our knowledge, no studies on long-term stability of protein-containing 
vesicular systems such as PorA-OMV have been reported. In this study, trivalent 
OMV containing PorA subtypes P1.7-2,4, P1.5-2,10 and P1.12,13 were compared to 
monovalent OMV containing PorA subtype P1.7-2,4. The possible stabilizing effect of 
RmpM on trivalent OMV was also investigated. OMV containing subtype P1.7-2,4 
were chosen, since 43% of all strains causing bacterial meningitis in The Netherlands 
belongs to this subtype [9]. At the same time, P1.7-2,4 is one of the weakest 
immunogens in multivalent OMV vaccines [5].  
The stability of liquid (stored 4ºC, 37ºC and 56ºC) and frozen (-70ºC) PorA-
OMV has been assessed during 12 months of storage. The possibility to freeze-dry 
OMV preserving its physicochemical and immunogenic characteristics was also 
studied. The stability of the presentation form was assessed with electron microscopy 
and dynamic light scattering measurements. The physicochemical stability of PorA 
was monitored by fluorescence spectroscopy, SDS-PAGE and ELISA. The functional 
immunogenicity (i.e. bactericidal response) of the vaccines was evaluated in vivo. 
The storage conditions for functionally stable OMV were determined.  
 
Materials and methods 
 
Bacterial strains and growth conditions 
N. meningitidis strain F91 (P1.7-2,4, PorB-, RmpM-, low expression of 
Opa/Opc) was used for the production of monovalent PorA-OMV. Strains JB10124 
(P1.5-2,10, P1.12,13, P1.7-2,4, PorB-, RmpM-, low expression Opa/Opc) and 
HP10124 (P1.5-2,10, P1.12,13, P1.7-2,4, PorB-, RmpM+, low expression Opa/Opc) 
were used for the production of trivalent PorA-OMV. Bacteria were grown in a 
defined medium, with as main components L-glutamic acid, glucose, L-cysteine and 
ammonium chloride, at 35ºC for 15 h in a 40 L stirred fermentor under pH and pO2 
control. 
 
Preparation of OMV formulations 
PorA-OMV were prepared as previously described [7]. Briefly, PorA-OMV 
were extracted from bacteria with EDTA. DNA was partially removed by DNase 
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treatment. Lipopolysaccharide (LPS) was partly depleted by gel permeation 
chromatography (GPC) in the presence of deoxycholate (DOC). In order to remove 
DOC, a second GPC step was performed, which also served to formulate the OMV in 
10 mM Tris-HCl, 3% sucrose pH 7.4.  
OMV derived from the three strains were stored at –70, 4, 37 and 56ºC in 2 ml 
plastic tubes with screw caps (Greiner, Alphen a/d Rijn, The Netherlands). For 
storage at 37ºC and 56ºC, 0.01% sodium azide was added. For fast freezing of OMV, 
2 ml samples were submerged in an ethanol/dry ice mixture and immediately stored 
at –70ºC. 
Freshly prepared OMV were freeze-dried in aliquots of 2 ml in 5-ml glass vials. 
The rubber stoppers were dried at 85ºC for 2 days prior to use. The vials containing 
the OMV formulations were placed directly on the shelf of a Leybold GT 4/6 freeze-
dryer with a temperature of -35ºC. In the first step of the freeze-drying process, the 
temperature of the shelf was maintained at –35ºC and the chamber pressure set at 
20 Pa. After 1-3 hours, the shelf temperature was raised to –25ºC and the pressure 
set to 5-6 Pa. These conditions were maintained for 65 hours, followed by additional 
secondary drying steps at plate temperatures of –20ºC, -5ºC, 10ºC, 25ºC and 35ºC, 
each for at least 5 hours at a pressure of 4-5 Pa. At the end of the freeze-drying 
process the vials were closed under vacuum with the dried rubber stoppers and 
capped with aluminium seals. 
Freeze-dried OMV were stored at 4ºC until reconstitution. Analysis of frozen 
and liquid formulations was performed before storage (t=0) and after 3, 6 and 12 
months. Freeze dried OMV were reconstituted and analyzed after 3 months storage. 
 
Composition of OMV 
The protein content of the OMV was measured according to Peterson [10] with 
BSA as standard. The PorA content (relative to total protein content) was determined 
by SDS-PAGE (see below). The presence of LPS was analyzed by gas 
chromatography (GC). In short, LPS was hydrolyzed in 3.45 M NaOH in 50% (v/v) 
methanol. Then, the fatty acids were methylated in 5.5 M HCl in 27% (v/v) methanol 
and extracted with a hexane/methyl tert-butyl ether mixture (1/1, v/v). Methylated 
fatty acids were separated and quantified by GC on an HP Ultra column (25 m x 0.2 
mm, Agilent). The different fatty acids were identified based on their retention time 
using a calibration mixture of known fatty acids (Calmix, Midi, Newark, DE). The 
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amount of C14:3OH fatty acids was calculated with a calibration curve of Serratia 
marcensens LPS. As internal standard, C14:2OH was used. DNA content was 
determined by an ethidium bromide assay [11] with salmon sperm DNA (ICN, 
Rotterdam, The Netherlands) as standard. 
The water content of freeze-dried OMV was measured with the Karl-Fisher 
method using a Mitshubishi Moisture analyzer. Differential scanning calorimetry was 
performed to determine the glass-transition temperature of the freeze-dried OMV 
directly after drying and after 12 months of storage at 4ºC.  
 
Physical characteristics of OMV 
To check the OMV structure after freeze-drying and storage, electron 
microscopy (EM) was performed as described by Claassen et al. [12]. The particle 
size of monovalent and trivalent OMV was measured by dynamic light scattering 
(DLS) at 25ºC with a Malvern 4700 system equipped with a 75 mW Argon ion laser 
(488 nm, Uniphase, San José, CA, USA), a remote interface controller and PCS 
software, version 1.35 (Malvern Ltd., Malvern, UK). For refractive index and viscosity 
the values of water were used. The particle size distribution was reflected in the 
polydispersity index (PD), which ranges from 0.0 for a monodisperse to 1.0 for a 
heterodisperse dispersion. The zeta potential of the OMV was measured with a 
Malvern Zetasizer 2000 with an aqueous dip-in cell and a computer with PCS 
software (version 1.35, Malvern). 
 
Fluorescence measurements and guanidine denaturation assay 
The local environment of tryptophan (Trp) in PorA was monitored with 
fluorescence spectroscopy. Steady-state fluorescence measurements were 
performed with an LS-50B Luminescence spectrophotometer (Perkin Elmer, Norwalk, 
CT, USA).  
Fluorescence emission spectra after excitation at 295 nm were recorded from 
300-450 nm at 150 nm/min, with excitation and emission band widths of 2.5 and 5 
nm, respectively. Samples contained either 25 µg/ml protein (F91, JB10124) or 20 
µg/ml (HP10124). Sets of 5 spectra were averaged and corrected for buffer 
background.  
Upon incubation with increasing concentrations of guanidinium hydrochloride 
(Gnd-HCl), PorA in OMV denatures, causing increased exposure of fluorescent 
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groups (Trp), which results in a shift of the fluorescence maximum towards higher 
wavelengths [13]. Samples were diluted with Gnd-HCl to final Gnd-HCl 
concentrations ranging from 1 M to 5 M, and incubated for 2 hours at room 
temperature before measurement. Fluorescence spectra of these samples were 
measured as described above. Sets of 5 spectra were averaged and corrected for 
buffer/Gnd-HCl background. The emission maximum was plotted against the 
Gnd-HCl concentration. The curves obtained were fitted, assuming a two-state 
equilibrium between the native and the denatured protein [14]. The concentration of 
Gnd-HCl necessary to obtain 50% denaturation of PorA was determined based on 
the midpoint of the denaturation curve.  
 
Analysis of the denaturation of model compounds 
N-acetyl tryptophan amide (NATrA), N-acetyl tyrosine amide (NATyA) were 
dissolved in 10 mM Tris-HCl, 3% sucrose pH 7.4 plus 0.01% sodium azide and 
incubated at 56ºC. Spectral properties of the samples were monitored during 6 
months. UV spectra (200-400 nm) of samples were taken with a Perkin-Elmer 
spectrophotometer and normalized (Abs280 = 1). Samples used for fluorescence 
measurements had an absorbance maximum ≤ 0.1. Fluorescence emission spectra 
after excitation at 295 (for tryptophan) and 280 nm (tyrosine) were recorded as 
described above.  
 
SDS-PAGE and Western blotting 
The trimeric folding of PorA was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) in ‘native’ gels as described by 
Jansen et al. [15]. Prior to electrophoresis, samples were incubated for 10 min at 
room temperature or 100ºC in sample buffer [16] containing 0.05% SDS. 
Polyacrylamide gels were prepared as described [16], except that SDS was omitted 
from the stacking and running gels. The acrylamide concentration of the running gel 
was 12%. Gels were run at 20 mA in a temperature-controlled room (4ºC) to prevent 
denaturation of the formulations containing folded PorA. Gels were stained with 
Coomassie Brilliant Blue.  
Relative PorA content was measured by SDS-PAGE under denaturing 
conditions [16]. Gels were scanned after running and staining in an Agfa Fotolook 3.5 
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scanner and analyzed with Phoretix 1D Quantifier software (version 5.10, Biozym, 
Landgraaf, The Netherlands) for determination of the relative PorA content. 
Western blotting was performed as described [17] after SDS-PAGE under 
denaturing conditions. The monoclonal antibodies (mAb) used to detect the different 
PorA subtypes were MN20B9.34 (anti-P1.4); MN20F4.17 (anti-P1.10); MN20A7.10 
(anti-P1.12) and MN3B9F (anti-RmpM).  
 
PorA inhibition ELISA 
Antigenicity of the P1.4 epitope of PorA P1.7-2,4 in OMV was tested by an 
inhibition ELISA as previously described using the mAb MN20B9.34 [7]. Briefly, a 
dilution series of the sample was incubated with a fixed concentration of mAb. Free 
mAb was quantified with an OMV-coated ELISA plate. The coating OMV batch 
contained at least 90% PorA, as determined by SDS-PAGE. The results are shown 
as the ratio between the PorA concentration determined by ELISA and the protein 
concentration determined by Peterson (total protein) corrected for protein impurities. 
As a reference, the antigenicity of freshly produced monovalent OMV was arbitrarily 
set at 1. 
 
Immunization experiments 
Balb/c mice, 6 to 8 weeks old (10 animals in each group) were immunized 
subcutaneously on day 0, 14 and 28. PorA (1.5 µg/subtype) in OMV were 
administered adjuvated with 1.5 mg AlPO4 (NVI) (0.25 ml/mouse) (see Table 3). The 
mice were bled on day 42, and sera were collected and stored at -20ºC until analysis.  
 
Anti-PorA whole-cell ELISA 
The antibody titer (total IgG) of each individual mouse serum was determined 
by whole cell ELISA as described [18]. Neisseria meningitidis isogenic H44/76-based 
strains (B:15P1.7,16:L3,7,9) expressing P1.7-2,4 (H44/76 7-2,4), P1.12,13 (H44/76 
12,13) or P1.5-2,10 (H44/76 5-2,10), and the H44/76-derived mutant strain HI5 
(lacking PorA) were used. Titers were determined with goat anti-mouse (GAM) total 
IgG conjugates, labeled with horseradish peroxidase (HRP) (Southern Technology 
Associates; dilution 1/5000). The titer is defined as the dilution of the serum where 
50% of the ODmax in the assay is reached.  
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Serum bactericidal assay 
The serum bactericidal activity was measured as previously described [19] 
against the four N. meningitidis strains: H44/76 7-2,4; H44/76 12,13; H44/76 5-2,10 
and HI5 (PorA-). From each group of 10 mice, 2 pools were made (5 mice/pool) and 
every pool was tested at least twice. Pooled sera were heat inactivated for 30 min at 
56ºC prior to use. Serum samples and bacteria were incubated for 10 to 15 min at 
room temperature before the addition of complement. A final concentration of 80% 
(v/v) rabbit serum was used as complement source. As positive controls, the 
bactericidal anti-P1.4 (MN20B9.34) and anti-LPS (MN15A17F12) monoclonal 
antibodies were used. Also, test sera were incubated without complement as a 
negative control. The serum bactericidal titer was measured as the reciprocal serum 
dilution showing more than 90% killing of the number of bacteria used.  
 
Statistical methods 
Before statistical analysis, antibody and bactericidal titers were log10 
converted. IgG titers are expressed as the mean log10 titer of ten independent 
observations. Bactericidal titers are expressed as the mean log10 titer of at least four 
independent observations. Analysis of variance was used for statistical evaluation of 
the data. The significance of the differences between the mean values of the 
antibody and bactericidal titers was determined by the least-significant-difference 
(LSD) test at a confidence level of 95%.  
 
Results 
 
Characterization of OMV 
The composition of the OMV derived from the three strains (F91, JB10124 and 
HP10124) is shown in Table 1. The protein present in all OMV was mainly PorA. 
Most impurities were found in OMV from strain JB10124. OMV had a negative 
surface charge (zeta potential) ranging between -40 and -50 mV. 
The average particle size of freshly prepared OMV ranged between 150-350 
nm, with a rather high polydispersity around 0.4, typical of OMV (Table 1). Both 
particle size and polydispersity were smaller for OMV derived from the trivalent strain 
JB10124, indicating a more homogenous particle size distribution for these OMV. 
The presence of partly aggregated vesicles with a diameter around 80 nm for all 
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OMV was shown by electron microscopy (see Fig. 2 A for a representative picture). 
Both freezing and freeze-drying of OMV induced the formation of large aggregates, 
accompanied by an increase of the polydispersity index (see Fig. 1 A-D). The size of 
the aggregates was smaller in freeze-dried OMV than in freeze-thawed OMV. A 
representative picture of the aggregates present after freeze and thawing can be 
observed in Fig. 2 B.  
 
Table 1. Physicochemical characteristics of the OMV used in this study 
Strain % PorAa,b PorA 
subtypes 
Class 4 
proteinc
LPS content 
(%)b 
DNA content 
(%)b 
Particle size 
(nm) 
PDd Zeta 
potential 
(mV) 
F91 
(monovalent) 
 
94 P1.7-2,4 - 9.4 7.7 362 0.42 -49.4 
JB10124 
(trivalent) 
76 P1. 7-2,4 
P1.12,13 
P1.5-2,10 
- 10.6 19.2 138 0.22 -41.8 
HP10124 
(trivalent) 
87 P1.7-2,4 
P1.12,13 
P1.5-2,10 
+ 3.7 8.2 304 0.45 -47.5 
a Determined by scanning the SDS-PAGE profile.  
b Relative to the total amount of protein present in the formulation. 
c The presence of class 4 protein was demonstrated by Western blotting with monoclonal antibody 
MN3B9F. 
d Polydispersity: indication of the size distribution of the OMV; ranges from 0.0 for a monodisperse to 
1.0 for an entirely heterodisperse dispersion. 
 
The water content of freeze-dried OMV was below 3% for all formulations. 
Freeze-dried OMV showed a glass transition temperature of ca. 50ºC. These 
characteristics were maintained over one year of storage at 4ºC. 
The fluorescence emission spectrum of PorA was similar in OMV derived from 
the three different strains studied. The emission maximum was around 338 nm, 
indicating a relatively hydrophobic environment of the tryptophan residues [13]. Upon 
titration with Gnd-HCl, a shift in the fluorescence maximum was observed from ca. 
338 nm to ca. 350 nm. This shift was similar in magnitude for OMV from the three 
strains. The denaturation midpoint was at 3.8 M Gnd-HCl for monovalent OMV and 
slightly higher (4.1 M) for both trivalent OMV.  
The trimeric structure typical of native PorA was monitored by ‘native’ SDS-
PAGE (Fig. 3) [15]. Freshly prepared PorA-containing OMV showed the presence of 
a high molecular weight band (~130 kDa) corresponding to PorA trimers (Fig. 3 A, 
lanes a); no monomers were visible. In samples incubated at 100ºC prior to 
electrophoresis the trimers were converted to monomers (41 kDa) (Fig. 3 A, lanes b). 
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Freeze-drying of OMV did not induce changes in the electrophoretic characteristics of 
PorA in the three OMV studied (not shown). 
 
Figure 1. Panels A, B, C: effect of storage on the particle size of OMV of strains F91 (A), JB10124 
(B) and HP10124 (C). Frozen samples were stored at -70ºC (squares); liquid samples at 4ºC 
(diamonds), 37ºC (triangles) or 56ºC (cross). Bars indicate SD (n=3). Panel D: effect of freeze drying 
on the particle size of OMV. The bars indicate the particle size ± SD (n=3) of OMV before (grey) and 
after (white) freeze-drying and reconstitution after 3 months storage at 4ºC. The numbers above the 
bars indicates the polydispersity of the samples. 
 
 
Figure 2. Electron micrographs of OMV stored at 4ºC (A: strain JB10124), -70ºC (B: strain F91) and 
56ºC (C: strain HP10124) during 6 months. The bar indicates 0.2 µm. Micrographs are representative 
for all three OMV stored at the indicated temperature. 
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Figure 3. SDS-PAGE under mild conditions (see materials and methods) of OMV after production (A), 
after 6 months storage (B) or after 12 months storage (C). In panel A is indicated the molecular weight 
of PorA monomers (43 kDa) and trimers (~130 kDa). The OMV strains and the storage temperature 
are indicated above the gels. Each sample was mixed with sample buffer containing 0.05% SDS and 
incubated either at room temperature (lanes a) or at 100ºC (lanes b).  
 
The interaction of PorA P1.7-2,4 with the bactericidal mAb MN10B9.34 
(directed against loop 4 of this PorA subtype) was studied by ELISA (Fig. 4). When 
assuming that the ratio of the three PorA subtypes in trivalent OMV is 1:1:1, the 
antigenicity of PorA P1.7-2,4 in trivalent OMV is expected to be one third of that of 
monovalent OMV. However, the results show that the antigenicity of PorA P1.7-2,4 in 
trivalent OMV was only 1/8 and 1/4 for strains JB10124 and HP10124, respectively, 
as compared with monovalent OMV. Freeze-drying and reconstitution of OMV did not 
significantly reduce the antigenicity of PorA P1.7-2,4 in any of the OMV (Fig. 4 D).  
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Figure 4. Panels A, B, C: Effect of storage on the antigenicity of PorA P1.7-2,4 in OMV of the strains 
F91 (A), JB10124 (B) and HP10124 (C). Samples were stored at -70ºC (squares), 4ºC (diamonds), 
37ºC (triangles) or 56ºC (cross). Panel D: effect of freeze drying and storage on the antigenicity of 
PorA P1.7-2,4 in OMV. The bars indicate the antigenicity of PorA P1.7-2,4 in OMV before (grey) and 
after (white) freeze-drying in samples stored for 3 months at 4ºC. The results are shown as mean 
values (±SD) of at least 3 measurements. 
 
Effect of storage on the physicochemical characteristics of OMV 
During 12 months, the pH of the preparations increased from 7.4 to 8.1 for 
almost all the formulations studied, except for trivalent OMV incubated at 56ºC, 
where the solution acidified, reaching pH values around 6. The zeta potential of OMV 
did not change upon storage under different conditions (not shown). 
OMV stored at –70ºC and thawed (at 37ºC, 10 min) showed aggregation, 
which tended to increase with storage time (Fig. 1), parallel to an increase in the 
polydispersity index. The size of OMV in liquid formulations did not change during 
storage at 4ºC. At higher temperatures (37ºC, 56ºC), the average particle size of 
OMV derived from the three strains gradually decreased (Fig. 1 A, B, C). After 6 
months, the particle size and zeta potential of samples incubated at 56ºC could not 
be measured anymore, as the scatter intensity had become too low. This indicates 
total destruction of the OMV, as confirmed by the presence of amorphous granular 
material in electron micrographs (Fig. 2 C).  
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The concentration of Gnd-HCl necessary to induce a shift in the fluorescence 
emission maximum decreased in liquid samples of all three strains incubated at 
37ºC, as compared to non-treated OMV. This indicates a decreased stability of these 
samples. The red shift of samples stored at 56ºC could not be measured, as in the 
absence of Gnd-HCl they showed a broadened emission spectrum with a maximum 
above 350 nm after 3 months. After 6 and 12 months totally different fluorescence 
spectra were observed: the tryptophan emission peak disappeared and a new 
spectrum was formed instead with an emission maximum of ca 405 nm (Fig. 6). In 
these degraded samples, the fluorescence spectra were similar when measured at 
an excitation wavelength of 280 or 295 (not shown). The newly formed spectra, 
which cannot originate from natural aromatic amino acids, indicate the formation of 
(fluorescent) chemical degradation products due to storage at high temperatures. To 
study these observations in more detail, the fluorescent amino acids N-acetyl 
tryptophan (NATrA) and N-acetyl tyrosamine (NATyA) were used as model 
compounds. Solutions of these amino acids in the same buffer as OMV were stored 
for 6 months at 56ºC, and their fluorescence (λexc 295 and 280 nm, respectively) and  
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Figure 5. Effect of time and storage
conditions on the concentration of Gnd-
HCl needed for 50% red shift of λmax of
PorA in OMV from strain F91 (A), JB10124
(B) and HP10124 (C). Samples were
stored at -70ºC (squares), 4ºC (diamonds)
or 37ºC (triangles). In samples stored at
56ºC, a shift at 0 M Gnd-HCl comparable
to the one obtained in samples at t=0 with
4 M Gnd-HCl was already observed after 3
months storage. The results are shown as
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Figure 7. Panels A and B. Fluorescence spectra of NATyA (A, λexc: 280 nm) and NATrA (B,  λexc: 295 
nm) freshly prepared (thick black line) and after 3 (thin black line) and 6 months (thick gray line) 
incubation at 56ºC. See materials and methods for details. Panels C and D: normalized UV spectra of 
NATyA (C) and NATrA (D) freshly prepared (thick black line) and after 3 (thin black line) and 6 months 
(thick gray line) incubation at 56ºC.  
 
UV spectra were monitored (Fig. 7). The intensity of the maximum fluorescence 
signal decreased in all model compounds and a new fluorescence emission peak 
was formed at higher wavelengths (ca. 405 nm for NATyA, 375 nm for NATrA). As 
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Figure 6: Fluorescence emission spectra
of monovalent OMV stored at 56ºC. Thin
black line: before storage; thin gray line:
after 3 months storage; thick black line:
after 6 months storage; thick gray line:
after 12 months storage. 
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expected (because NATyA does not absorb at 295 nm), when freshly prepared 
NATyA was excited at 295 nm, no emission spectra could be observed. After 3 and 6 
months of incubation at 56ºC, however, the NATyA sample did absorb at 295 nm 
(Fig. 7A, inset) and showed an emission spectrum with a maximum around 405 nm 
upon excitation at 295 nm (not shown), indicating the formation of a fluorescent 
degradation product. 
The trimeric structure of PorA was still present in frozen and liquid OMV stored 
at 4 and 37ºC after 3 months (not shown). At this time point no protein bands were 
observed for samples incubated at 56ºC. Samples incubated at 56ºC were not 
studied further by SDS-PAGE. After 6 months, part of the trimeric PorA was 
converted to monomers for all OMV stored at –70, 4 and 37ºC (Fig. 3B). In trivalent 
OMV (JB10124 and HP10124) incubated at 37ºC, extra bands with lower molecular 
weights appeared below the monomer band (43 kDa) and this band was separated in 
two bands (Fig. 3 B, lanes b). The structural changes of PorA were clearer after 12 
months of incubation at all temperatures (Fig. 3 C). In native samples (lanes a), 
trimers and monomers were still observed, and an extra band appeared at ~ 80 kDa, 
indicating the presence of PorA dimers. Degradation bands at lower molecular weight 
were also observed. This degradation pattern was most apparent for samples 
incubated at 37ºC, especially for monovalent OMV, where the intensity of the trimer 
band had strongly decreased (Fig. 3 C, F91). For all samples incubated at 37ºC, a 
smear could be observed. The presence of P1.4, P1.5-2 and the P1.12 epitopes in 
degradation bands was checked by Western blotting. No degradation bands were 
observed for PorA subtypes P1.7-2, 4 and P1.5-2,10. Only in the case of the 
P1.12,13 subtype one minor degradation band in addition to the original band was 
observed containing the P1.12 epitope (not shown). 
 
Effect of storage on the immunochemical characteristics of OMV  
The antigenicity of liquid samples stored at 4ºC was preserved in time. Frozen 
monovalent OMV showed a slight decrease in the antigenicity, which was not 
observed for trivalent samples stored at –70ºC. When OMV were incubated at 37ºC 
the antigenicity decreased to (almost) zero within 6 months of incubation. When 
samples were incubated at 56ºC the antigenicity disappeared within 3 months (Fig. 4 
A, B, C).  
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Effect of storage on the immunogenicity of OMV 
The ability of monovalent and trivalent OMV stored at –70ºC, 4ºC, and 37ºC to 
induce high IgG titers against the different PorA subtypes did not decrease with time 
(Table 2). A pronounced decrease in the ability to elicit an IgG response was only 
observed with OMV stored at 56ºC. Antibodies induced by monovalent OMV and 
trivalent OMV from strain HP10124 (containing RmpM) were mainly PorA-specific, as 
demonstrated by the low titers against the PorA-lacking strain HI.5. OMV from strain 
JB10124 induced the formation of antibodies against other structures than PorA, 
probably LPS or impurities (cf. Table 1). The antibody titers against other structures 
than PorA were fairly constant for samples stored during 12 months at –70ºC and 
4ºC, but the titers were lower in sera of mice immunized with OMV stored at 37ºC 
and 56ºC.  
Sera of animals were also tested for the presence of bactericidal antibodies 
(Table 3). Only antibodies directed against PorA were bactericidal, as determined by 
the lack of bactericidal serum activity against meningococci of strain HI.5 (not 
shown). The capability of monovalent OMV to induce a bactericidal response against 
the PorA P1.7-2,4 was unchanged in samples stored at –70 or 4ºC, and significantly 
reduced in OMV stored at 37ºC for 12 months. OMV of strain F91 stored for 3 
months at 56ºC did not induce a bactericidal response at all. The P1.7-2,4 specific 
bactericidal activity induced by OMV from strain JB10124 was weak or absent. OMV 
from strain HP10124 induced anti-P1.7-2,4 bactericidal antibodies only in samples 
stored at –70ºC. OMV from this strain stored at 4ºC did not induce bactericidal anti-
P1.7-2,4 antibodies after 3 or 6 months storage. Surprisingly, after 12 months 
storage at 4ºC this formulation induced again significant bactericidal antibodies. This 
is probably due to the variability in the test and the fact that the titers against this 
subtype are low [5]. Although samples incubated at 37ºC induced detectable 
bactericidal titers after 6 and 12 months, these titers were not significantly above the 
background (LSD of 0.4 and 0.6, respectively). The PorA P1.5-2,10 induced the 
highest bactericidal titers of all three subtypes in both trivalent strains. Also, the anti-
P1.5-2,10 bactericidal titers were maintained for OMV of both strains (JB10124 and 
HP10124) upon storage at all temperatures except 56ºC, where bactericidal activity 
of these formulations dropped to undetectable levels after 3 months storage. A 
similar trend was observed for the P1.12,13-specific bactericidal response. The anti-
P1.12,13 bactericidal titers induced by trivalent OMV after 12 months were relatively 
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high (i.e. ≥ 2.7); the OMV from strain HP10124 induced a bactericidal response that 
was even higher than the one induced by the same OMV freshly prepared.  
Freeze-drying and reconstitution did not affect the immunogenicity of 
monovalent OMV and trivalent OMV of strain JB10124 (without RmpM) (Table 4). 
Surprisingly, in trivalent OMV containing RmpM, only PorA subtype P1.5-2,10 
preserved the capacity to induce a bactericidal response after freeze-drying. 
 
Discussion 
 
The stability of three types of outer membrane vesicle vaccines from Neisseria 
meningitidis was studied, with a detailed in vitro and in vivo characterization of these 
OMV. The preservation of the native PorA conformation as well as the structure of 
the presentation form were monitored, as both are crucial for the quality of the 
immune response [7]. PorA is a porin, belonging to a class of membrane proteins 
that appear to be exceptionally stable [20]. The physical stability of purified 
recombinant PorA has been previously studied, showing its ability to maintain its 
trimeric membrane arrangement in the presence of low SDS concentrations [15].  
As expected, the physicochemical characteristics of PorA-OMV were best 
preserved by storage at 4ºC. However, partial unfolding of PorA was observed in all 
three OMV formulations stored at this temperature after 12 months (Fig. 3). Although 
this unfolding did not measurably affect the antigenicity or the protective 
immunogenicity generated by OMV, it may be a first step in the degradation leading 
to decreased immunogenicity of PorA during storage.  
Only the incubation of OMV at high temperatures (56ºC) resulted in the total 
destruction of both the OMV structure and the protein conformation (DLS, EM, SDS-
PAGE, ELISA), accompanied by change of the pH. The modification of the PorA 
structure was accompanied by a dramatic change in the fluorescence emission 
maximum towards higher wavelengths (from 338 nm to ca. 405 nm), reflecting 
chemical modifications of PorA, with formation of new fluorescent degradation 
product(s). This was confirmed using NATrA and NATyA as model compounds. 
Similar changes in the fluorescence spectrum have been reported for tetanus toxoid 
incubated at pH 2.5 and 37ºC for 14-28 days [21] and tetanus and diphtheria toxoids 
stored at 60ºC for 21 days [22]. The modifications of Trp and Tyr described in 
literature that lead to fluorescence shift are oxidation of Trp or dimerization of Tyr 
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[23]. Other oxidation reactions (e.g. methionine, histidine) as well as other chemical 
degradation reactions (e.g. deamidation, chain scission) may also have occurred 
[24,25], but this was not investigated in this study. 
Unfolding of PorA and degradation of the OMV structures was also observed 
at 37ºC but obviously, much more slowly than at 56ºC. At this temperature, the 
change in the conformation of PorA could also be observed by SDS-PAGE, with 
monomerization of PorA (Fig. 3). This was also translated in a drastic drop in 
antigenicity (Fig. 4). However, a decrease in functional immunogenicity could not be 
detected, indicating that the epitope investigated in our ELISA system is not the only 
epitope important for the development of a protective immune response. The 
unfolding of PorA was accompanied by a reduced stability of the OMV structure, as 
their particle size decreased (Fig. 1).  
Freezing or freeze-drying of OMV resulted in aggregation (Fig. 1). Probably, 
the freezing step is responsible for this aggregation. During freezing, ice crystal 
formation may partially rupture the vesicle structure, resulting in formation of larger 
vesicles and/or aggregates after thawing or reconstitution. The presence of 3% 
sucrose that could act as cryoprotectant or lyoprotectant was not enough to prevent 
this aggregation. However, the conformation of PorA did not change upon freeze-
thawing and freeze-drying/reconstitution, which may explain the fact that the 
immunogenicity of aggregated OMV was not decreased. Although the functional 
immunogenicity of monovalent OMV and trivalent OMV from strain JB10124 was 
maintained when freeze-dried, lyophilized OMV from strain HP10124 induced a 
decreased P1.7-2,4- and P1.12,13-specific bactericidal response upon reconstitution. 
This difference can be related to the strain or the batch. No attempts were made to 
improve the freeze-drying process by adding other lyoprotectants or cryoprotectants 
than sucrose.  
The trimeric PorA association was more stable in trivalent OMV than in 
monovalent OMV. This is shown by the relatively higher amounts of trimeric PorA in 
trivalent OMV incubated at 37ºC (Fig. 3 B, C) and the higher concentration of Gnd-
HCl necessary to unfold PorA in trivalent OMV (Fig. 5). As the composition of both 
trivalent and monovalent OMV is similar, i.e. most of the protein is PorA, this 
increased physicochemical stability of trivalent OMV could be due to differences in 
the stability among PorA serosubtypes or differences among strains in the quality of 
the membrane association of PorA. 
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It is difficult to correlate physicochemical characteristics of trivalent and 
monovalent OMV with immunogenicity, as the PorA subtype present in monovalent 
OMV (P1.7-2,4) is the least immunogenic subtype in trivalent OMV [6]. Antigenicity 
could not help to predict the bactericidal response induced by OMV stored at high 
temperatures. Whereas the antigenicity of the P1.4 epitope in all OMV was 
decreased or completely absent in OMV stored at 37ºC, these OMV were still able to 
induce polyclonal bactericidal antibodies in mice. Possibly, the immune response 
was directed against other epitopes of PorA subtype P1.7-2,4 than the epitope 
recognized by the monoclonal antibody used for the antigenicity test. Also, as 
previously shown in man [27], the presence of IgG in mice serum was not always 
accompanied by a bactericidal activity. 
The ELISA data (relative to epitope P1.4 of PorA P1.7-2, 4) show that the 
antigenicity of this epitope was lower than expected in trivalent OMV than in 
monovalent OMV. This may be due to a lower P1.7-2,4 expression in trivalent OMV, 
or to a decreased accessibility of the P1.4 epitope in these OMV for the monoclonal 
antibodies used in the assay. Moreover, the P1.7-2,4-mediated bactericidal serum 
activity induced by trivalent OMV was reduced as compared to the bactericidal 
activity induced by monovalent OMV. It was previously shown that bactericidal 
activity induced by the P1.7-2,4 subtype in trivalent OMV and mixtures of three 
monovalent OMV was decreased in both cases [26]. This indicates that the exposure 
of this PorA subtype is similar in trivalent and monovalent OMV, but that P1.7-2,4 –
when simultaneously administered with other subtypes– is less efficiently processed 
and/or that P1.7-2,4 epitopes generate antibodies with low affinity. From the other 
PorA subtypes in trivalent OMV, P1.5-2,10 induced the highest bactericidal serum 
activity. This subtype was also previously found to induce the highest bactericidal 
response in toddlers and school children [27]. Even after 3 months incubation at 
56ºC, still bactericidal activity was detected against this subtype. This is very 
surprising, as no PorA could be seen by SDS-PAGE and samples incubated at 56ºC 
showed no antigenicity. This bactericidal activity could be due to the presence of a 
non-detectable fraction of intact, denatured or fragmented PorA in the formulations.  
The low molecular weight bands observed by Western blotting, indicating the 
presence of degradation products containing epitopes located in the variable regions 
1 and 2 (VR1 and VR2, respectively) [28], was observed for PorA subtype P1.12,13 
in trivalent OMV stored for 12 months at –70ºC, 4ºC or 37ºC. The fragmentation of 
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PorA did not affect the immunogenicity of this PorA subtype in trivalent OMV, 
probably because the fragmentation was incomplete. 
The presence of RmpM in the OMV from strain HP10124 did not improve their 
long-term stability. On the contrary, the immunogenicity induced by these OMV was 
decreased upon freeze-drying (Table 4). It was not expected that these OMV were 
less stable (after freeze-drying) than trivalent OMV that do not contain RmpM, as this 
protein has an important role in the localization and stability of PorA trimers in the 
outer membrane [15]. The yield (by means of the amount of total protein) of OMV 
purified from HP10124 strain (RmpM+), was also 3-fold lower than the yield in RmpM- 
strains (not shown), and the amount of RmpM present in OMV was very low, only 
detectable by Western blotting. A reason for these relatively low yields may be the 
strong effect of RmpM on the structure of the bacterial outer membrane. RmpM+ 
bacteria form a well fitted, tight outer membrane, whereas the outer membrane of 
RmpM- stains has an ‘over-sized’ appearance [29]. The RmpM seems to influence 
the attachment of the outer membrane to the underlying peptidoglycan layer. The 
result is that the OMV yield of the RmpM- strains is higher, at least in the case of 
detergent-free extraction. 
In conclusion, trivalent OMV appeared slightly more stable than monovalent 
OMV, although these differences are not reflected in the in vivo activity. All OMV are 
stable for at least one year if stored at 4ºC or frozen. Freeze-drying provides a good 
alternative to storage in the liquid state and may be advantageous for long-term (> 1 
year) storage.  
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Abstract 
 
The impact of the conformation, LPS-depletion and the presentation form of 
outer membrane protein PorA from Neisseria meningitidis (PorA) subtype P1.7-2,4 
on the immune response in mice was studied. Native PorA was purified from outer 
membrane vesicles (OMV) derived from meningococci and reconstituted into 
liposomes. The conformation of PorA after purification from OMV and reconstitution 
in liposomes was monitored by use of electrophoretic and spectroscopic techniques 
and compared with the conformation of PorA in outer membrane complexes (OMC) 
and heat-denatured PorA. The antigenicity of the PorA formulations was measured 
by ELISA by using a bactericidal anti-P1.4 monoclonal antibody. Immunogenicity was 
determined in Balb/c mice. PorA-specific IgG, isotype distribution and bactericidal 
activity were measured after subcutaneous immunization. In all formulations except 
in heat-denatured OMV, PorA was present as trimers. The lipopolysaccharide (LPS) 
content was reduced by 96% in the purified protein with respect to the original OMV. 
The antigenicity of purified PorA (i.e. ELISA response) was substantially higher as 
compared to PorA in liposomes, OMV or OMC. The results of the immunogenicity 
studies showed that all formulations were able to induce comparable IgG titers. 
However, whereas the antibodies raised by OMV were bactericidal, the antibodies 
elicited by immunization with purified PorA were unable to kill meningococci. 
Remarkably, the ability to induce bactericidal antibodies was fully recovered by 
incorporation of the purified PorA into liposomes, in the absence of other adjuvants, 
as compared to LPS-containing OMV.  
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Introduction 
 
Neisseria meningitidis is one of the major causes of bacterial meningitis [1]. 
Vaccines based on capsular polysaccharides offer no protection against serogroup B 
meningococci, the predominant cause of meningococcal infection in the western 
world. Other major surface components, such as the outer membrane protein PorA 
(class 1 protein, a porin) have been evaluated as vaccine candidates [2,3,4,5,6], 
mostly formulated in outer membrane vesicles (OMV). Among the PorA subtypes, the 
subtype P1.7-2,4 is present in up to 43% of the strains causing bacterial meningitis 
[7]. Thus, a PorA-based vaccine should cover at least this subtype. On the other 
hand, the immunogenicity of PorA P1.7-2,4 is not yet optimal in its present 
formulation as OMV vaccine [5,6].  
The vaccines against type B meningococci that are being developed by 
various groups [8,9,10] consist of OMV extracted from (sometimes genetically 
modified) meningococcal strains, with one or more PorA subtypes embedded in it 
[11,12]. Moreover, OMV contain neisserial lipopolysaccharide (LPS), which could 
play a role as immunogen, adjuvant [13] and stabilizer [14], but is also responsible for 
reactogenicity due to the presence of lipid A [37]. This last characteristic makes the 
presence of LPS in the vaccine undesired. Another drawback of OMV is the difficulty 
to optimize the immunogenicity by manipulating the composition, because the latter 
is governed by the strain from which they are purified. Components in the outer 
membrane may affect the immunogenicity by inducing non-bactericidal antibodies. 
Besides OMV, outer membrane complexes (OMC) have been extensively 
used in preclinical studies. These OMC are obtained by a simple outer membrane 
extraction with sarcosyl [15]. However, the structure and composition of these OMC 
is poorly defined and, like OMV, they contain LPS.  
During the past few decades, as a consequence of improved immunological 
insights and more strict regulatory requirements, there is a continuous trend towards 
better-defined vaccines in order to guarantee safety and efficacy [16]. Our aim is to 
obtain PorA vaccines that are better defined than OMV and OMC, in the absence of 
toxic components (e.g. LPS) and that induce an adequate immune response. 
Physicochemical characteristics of PorA and PorB (class 3) of Neisseria 
meningitidis have previously been studied but only in their purified form [17,18]. 
Native PorA forms relatively stable trimers [17]. Although the crystal structure of PorA 
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has not yet been elucidated, PorA is believed to resemble the PhoE protein of E. coli 
[19], consisting of a β-barrel formed by 16 membrane spanning regions. Protruding 
loops contain functional (i.e. bactericidal) epitopes. In PorA the epitopes on loops 1 
and 4 are immunodominant [20].  
It has been previously shown that SDS-denatured recombinant PorA fails to 
induce a bactericidal immune response in the absence of LPS as adjuvant [14]. This 
indicates that monitoring the preservation of the PorA conformation should be an 
integral part of formulation studies. Preservation of the native structure alone, 
however, is not sufficient to warrant the immunogenicity of antigens. For instance, the 
immunogenicity of purified PorA is lower as compared to PorA in OMV [35] and the 
use of adjuvants is often required [21]. A reduced immunogenicity of purified PorA is 
expected to be reversible, provided that the protein is reconstituted in its native 
conformation in an adequate presentation form (e.g. liposomes). The incorporation of 
membrane proteins into liposomes has frequently been used with success, also for 
other (recombinant) PorA subtypes [21,39]. Liposomes offer various advantages with 
respect to other formulations. First, lipid bilayers resemble the ‘natural’ environment 
of membrane proteins such as PorA. Second, liposomes are well-defined systems 
and their characteristics are easily varied. This would allow systematic studies on the 
effect of incorporated adjuvants (e.g. detoxified lipid A derivatives, CpG, cytokines, 
QuilA) or targeting devices (e.g. to direct the antigen efficiently to antigen-presenting 
cells) attached to the liposome surface.  
In this study, native PorA P1.7-2,4 has been purified from OMV and 
incorporated into liposomes. A detailed characterization of the protein in OMV, OMC 
(i.e. membrane-embedded), in purified (i.e. micellar) form and in denatured OMV has 
been carried out. We pay special attention to the preservation of the protein 
conformation upon purification and reconstitution into liposomes. The effects of 
purification, protein conformation and presentation form on the immune response are 
discussed. It is demonstrated that reconstitution of purified native PorA leads to a 
functional immune response similar to that of (LPS-containing) OMV. 
 
Materials and methods 
 
Bacterial strains and growth conditions 
N. meningitidis strain F91 (P1.7-2,4, PorB-, RmpM-, low expression of Opa/Opc) was 
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used for the production of monovalent PorA-OMV, PorA-OMC and purified PorA. 
Bacteria were grown in a defined medium, with as main components L-glutamic acid, 
glucose, L-cysteine and ammonium chloride. Cells were cultivated at 35ºC for 15 h in 
a 40-L stirred fermentor under pH and pO2 control. 
 
PorA-OMV and OMC 
PorA-OMV were prepared according to a modification of the procedure 
described by Claassen et al. [8]. Briefly, PorA-OMV were extracted from bacteria by 
EDTA extraction. DNA was partially removed by DNase treatment. LPS depletion 
was achieved by gel permeation chromatography (GPC) in the presence of 
deoxycholate (DOC). DOC was removed by a second GPC step. 
PorA-OMC from Neisseria meningitidis strain F91 were isolated by sarcosyl 
extraction as described by Poolman et al. [15]. To obtain denatured (monomeric) 
PorA, OMV were heated in a boiling waterbath for 5 min. 
 
Purification of PorA 
PorA-OMV were used as starting material to obtain pure PorA P1.7-2,4, by 
using a modification of the procedure described by Poolman et al. [22]. In short, 1 
volume of OMV containing 0.5 mg/ml protein was disrupted by incubation overnight 
in 1 volume of 50 mM Tris-HCl, 10 mM EDTA, 0.05% (w/v) Zwittergent 3,14, pH 8.0. 
The mixture was centrifuged at 120 000 g and 4ºC for 20 min. The supernatant was 
treated overnight with DNase (Benzonase, Merck) and centrifuged at 2900 g and 4ºC 
for 1 h. The supernatant was further purified by anion-exchange chromatography on 
a Q-Sepharose column (Pharmacia), which had been equilibrated with 50 mM Tris-
HCl, 0.05% (w/v) Zwittergent 3,14, pH 8.0. The protein was eluted with a linear 
gradient of 0-1 M NaCl in the same buffer. Fractions containing protein were pooled 
and dialyzed overnight at 4ºC against 50 mM Tris-HCl, 0.05% Zwittergent 3,14, 
pH 8.0 before use. 
 
Reconstitution of PorA into liposomes 
In order to incorporate the purified protein into liposomes, PorA was 
precipitated in 80% (v/v) ethanol and dissolved in 50 mM Tris-HCl, 150 mM NaCl, pH 
7.4 (TBS) containing 150 mM n-octyl β-d-glucopyranoside (OG) to a final 
concentration of 200 µg/ml. Liposomes were made of dimyristoylphosphatidylcholine 
Restored immunogenicity of purified meningococcal PorA 
 
 69
(PC, Rhône-Poulenc Rorer, Köln, Germany), dimyristoylphosphatidylglycerol (PG, a 
gift from Lipoïd GmbH, Ludwigshafen, Germany) and cholesterol (Chol, SIGMA, 
Zwijndrecht, The Netherlands) in a 8:2:2 mol ratio. PorA-liposomes were prepared 
according to the detergent dilution method [23]. In short, appropriate amounts of 
each lipid were dissolved in chloroform/methanol (2:1, vol:vol) in a round bottom flask 
and a lipid film was obtained by solvent evaporation in a rotavapor under reduced 
pressure. The film was resuspended in the PorA solution (lipid concentration 6 mM) 
and the resulting mixed micelles were rapidly diluted 11-fold in TBS, allowing the 
formation of liposomes. Subsequently, the liposomes were pelleted by 
ultracentrifugation (160,000 g, 1 hour) and resuspended in TBS, yielding PorA-
containing liposomes with a protein/lipid ratio of 25 (µg/µmol). 
 
Characterization of PorA formulations 
The particle size of PorA-OMV, OMC and liposomes was measured by 
dynamic light scattering (DLS) at 25ºC with a Malvern 4700 system equipped with a 
75 mW Argon ion laser (488 nm, Uniphase, San José, CA, USA), a remote interface 
controller and PCS software, version 1.35 (Malvern Ltd., Malvern, UK). For refractive 
index and viscosity the values of pure water were used. The particle size distribution 
was reflected in the polydispersity index (PD), which ranges from 0.0 for a 
monodisperse to 1.0 for an entirely heterodisperse dispersion. Electron microscopy 
was performed as described by Claassen et al. [8]. 
The protein content was measured according to Peterson [24] with bovine 
serum albumin as standard. LPS was measured by keto-deoxyoctonate (KDO) 
determination [25] with KDO as standard (Sigma). The corresponding amount of 
Neisseria meningitidis LPS was calculated (2 mol KDO / mol LPS) for a LPS 
molecular weight of 3,380 Da. DNA content was determined by an ethidium bromide 
assay [26] with salmon sperm DNA (ICN, Rotterdam, The Netherlands) as standard. 
 
SDS-PAGE 
The protein composition was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) in ‘native’ gels as described by 
Jansen et al. [17]. Prior to electrophoresis, samples were incubated for 10 min at 
room temperature or 100ºC in sample buffer [27] containing 0.05% SDS. 
Polyacrylamide gels were prepared as described [27], except that SDS was omitted 
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from the stacking and running gels. The acrylamide concentration of the running gel 
was 12%. Gels were run at 20 mA in a temperature-controlled room (4º C) to prevent 
denaturation of the formulations containing folded PorA. Gels were stained with 
Coomassie Brilliant Blue. 
 
Circular dichroism measurements  
Circular dichroism (CD) was used to detect differences in secondary structure 
of PorA. Spectra were recorded at ambient temperature with a dual-beam DSM 1000 
CD spectrophotometer (On-Line Instrument Systems, Bogart, GA). The subtractive 
double-grating monochromator was equipped with a fixed disk and holographic 
gratings. Gratings with 2400 lines/mm (blaze wavelength 230 nm) and 1.24-mm slits 
were used. Spectra were recorded from 260-200 nm (path length 0.5 mm). Each 
measurement was the average of at least ten repeated scans (step resolution 1 nm) 
from which the corresponding buffer spectrum was subtracted. The measured CD 
signals were converted to molar extinction difference (∆ε  based on an average amino 
acid residue weight of 115).  
 
Fluorescence measurements  
The local environment of tryptophan in PorA was monitored with fluorescence 
spectroscopy. Steady-state fluorescence measurements were performed with an LS-
50B Luminescence spectrophotometer (Perkin Elmer, Norwalk, CT, USA).  
Fluorescence emission spectra after excitation at 295 nm were recorded from 
300-450 nm, with excitation and emission bands 4 and 8 nm, respectively. Samples 
containing 10 µg/ml protein were measured at 150 nm/min. Sets of 5 spectra were 
averaged and corrected for buffer background.  
Quenching of tryptophan fluorescence by acrylamide in the range of 0 to 0.7 M 
was performed by adding aliquots of acrylamide (1.4 M in the corresponding buffer) 
to samples containing 100 µg/ml protein. In order to avoid interference with 
acrylamide absorption, the excitation wavelength used was 300 nm. The 
fluorescence intensity was monitored at 350 nm and corrected for buffer background, 
with excitation and emission bands 4 and 20 nm, respectively. The data were 
analyzed by a modified form of the Stern-Volmer equation: 
F0/∆F=1/ƒa+1/(ƒa*KSV*[Q]), where F0 is the fluorescence intensity in the absence of 
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the quencher (acrylamide) and ∆F is the difference between fluorescence intensities 
in the absence and presence of the quencher at a concentration [Q]. KSV is the Stern-
Volmer constant for dynamic quenching and ƒa is the fraction of tryptophan 
fluorescence that is accessible to the quencher [28]. 
 
PorA inhibition ELISA 
Antigenicity of OMV, OMC, liposomes and purified PorA was tested by an 
inhibition ELISA analogous to a method previously described for Bordetella pertussis 
antigens [29]. In short, samples were serially diluted in 96-well microtiter plates and 
incubated overnight at room temperature with a fixed dilution (1:1000, v:v) of the 
bactericidal monoclonal antibody MN20B9.34 directed against the P1.4 epitope of 
PorA. OMV of strain F91 containing 2 µg/ml protein in phosphate-buffered saline 
(PBS), were used for coating a separate plate overnight at room temperature. After 
incubation, the OMV-coated plate was washed and aliquots of the pre-incubation 
plate were added. After incubation for 2 h at room temperature, plates were washed 
again and incubated for 1.5 h at room temperature with peroxidase labeled goat anti-
mouse (GAM) IgG, IgA, IgM (Cappel, Organon Teknika, dilution 1/5000). Plates were 
washed and the color reaction was performed as described [29]. The reference OMV 
batch contained at least 90% PorA, as determined by SDS-PAGE. The results are 
shown as the ratio between the protein concentration determined by ELISA and the 
protein concentration determined by Peterson. As a reference, the antigenicity of 
OMV was arbitrarily set at 1. 
 
Immunization experiments 
Procedure A: Balb/c mice, 6 to 8 weeks old (8 animals in each group) were 
immunized subcutaneously on day 0, 14 and 28. Either 1.5 µg or 10 µg PorA in OMV, 
OMC, purified micelles or denatured OMV were administered (0.25 ml/mouse) (see 
Table 3). The mice were bled on day 42, and sera were collected and stored -20ºC 
until analysis. AlPO4 (RIVM) was added to all preparations (1.5 mg/dose).  
Procedure B: Balb/c mice, 6 to 8 weeks old (8 animals in each group), were 
immunized subcutaneously on day 0, 14 and 28 with PorA in OMV or liposomes. 
Samples (0.25 ml/mouse) were administered in the absence of other adjuvants and 
increasing protein doses were tested for the liposomal formulation (see Table 4).  
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Anti-PorA whole-cell and OMV-ELISA 
The antibody titers (total IgG and individual isotypes) in mouse sera were 
determined by whole-cell ELISA as described [30]. N. meningitidis strain 
H44/76(B:15P1.7b,4:L3,7,9) and the H44/76-derived mutant strain HI5 (lacking PorA) 
were used. The titer is defined as the dilution of the serum where 50% of the ODmax 
in the assay is reached. Isotypes were determined with goat anti-mouse (GAM) Ig 
isotype-specific conjugates, labeled with horseradish peroxidase (HRP) (Southern 
Technology Associates; dilution 1/5000, except for IgG1 1/2500). In a similar manner 
an OMV-ELISA was performed, for which plates were coated with OMV purified from 
several strains, diluted to a protein concentration of 3 µg/ml.  
 
Serum bactericidal assay 
The serum bactericidal activity was measured as previously described [31] 
against the N. meningitidis strains: H44/76 7b,4 and HI5 (PorA-) (see section 2.11 for 
details). Sera from mice were heat inactivated for 30 min at 56ºC prior to use. For 
blocking experiments, 5 µl of bactericidal antiserum (i.e. from mice immunized with 
PorA-OMV) were mixed with increasing volumes (ranging from 1 to 45 µl) of non-
bactericidal (blocking) antisera (i.e. from mice immunized with purified PorA). The 
total volume was adjusted to 50 µl with Gey’s balanced salt solution (Sigma) 
containing 0.5% (w/v) bovine serum albumin (BSA, Sigma) and the samples were 
incubated at room temperature for 10 min before inactivation. Serum samples and 
bacteria were incubated for 10 to 15 min at room temperature before the addition of 
complement. A final concentration of 80% (v/v) rabbit complement was used. As 
controls, the bactericidal anti-P1.4 (MN20B9.34) and anti-LPS (MN15A17F12) 
monoclonal antibodies were used. Also, test sera were incubated without 
complement as a negative control. The serum bactericidal titer was measured as the 
reciprocal serum dilution showing more than 90% killing of the number of bacteria 
used.  
 
Statistical methods 
Before statistical analysis, antibody and bactericidal titers were log10 
converted. Antibody titers are expressed as the mean log10 titer of eight independent 
observations. Analysis of variance was used for statistical evaluation of the data. The 
significance of the differences between the mean values of the antibody titers was 
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determined by the least-significant-difference (LSD) test at a confidence level of 95%. 
This test could not be used for bactericidal titers, as some groups included both 
responders and non-responders. Values given are the average of the indicated 
responders ± SD. 
 
Results  
 
PorA in OMV, OMC and denatured OMV 
The composition of the PorA-containing OMV, OMC and denatured PorA-
OMV is given in Table 1. Lipids, LPS and other bacterial components such as DNA 
are still present in both OMV and OMC. OMV were further characterized by electron 
microscopy, which yielded images similar to those published before [8], i.e. partly 
aggregated vesicles with a diameter of around 80 nm (not shown). The presence of 
aggregated material was confirmed by DLS: OMV typically showed an average 
particle size of 270 nm with a relatively high polydispersity index (PD) of 0.43. OMC 
showed a larger size than OMV (i.e. 612 nm) and the PD was also increased (Table 
1). In denatured PorA samples, both intact OMV and amorphous material were 
visualized by electron microscopy (data not shown). Apparently, in addition to 
aggregated OMV, fragmented material was formed upon heat treatment, which 
explains the decrease in the observed averaged size (DLS) and the highly increased 
PD (Table 1). 
 
Table 1. Composition of the formulations used in this study. 
Formulation LOS content 
(%)a 
DNA 
content(%)a 
Particle size 
(nm) 
PDb Antigenicityc 
OMV 4.6 1.3 270  0.43 1.00 ± 0.00
OMC 0.5 0.4 612  0.58 0.77 ± 0.17
Purified PorA 0.3 n.d.d - e -  e 1.64 ± 0.31
Liposomes 0.3 n.d.d 215 0.30 1.01 ± 0.18
Denatured OMV 5.3 4.6 105  0.83 0.09 ± 0.02
a Percentage refers to the total amount of protein present in the formulation. 
b Polydispersity index (see materials and methods section).  
c Antigenicity (relative to that of OMV) as determined with MN20B9.34 monoclonal antibody in an 
inhibition ELISA. The results are shown as mean values (±SD) of at least 3 measurements. 
d n.d.: not detected (i.e. <0.25 µg/ml). 
e Signal too low for measurement. 
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Purification of PorA from OMV 
Purified PorA elutes from the anion-exchange column in one peak (Fig. 1). 
The purification of PorA, with OMV as starting material, yielded protein trimers (see 
3.3) with a high degree of purity (Table 1). The DNA present in the original OMV was 
below the detection limit in the purified (micellar) form. The amount of LPS present 
after purification was reduced with 94% with respect to the original OMV (Table 1).  
 
Effect of purification on the conformation of PorA P1.7-2,4 
In order to observe the folding into trimers of the protein in all the formulations, 
SDS-PAGE electrophoresis was performed under mild conditions (Fig. 2) [17]. 
Purified PorA incubated with loading buffer at room temperature shows the presence 
of a high molecular weight band (~120 kDa) corresponding to PorA trimers (lane 3-a). 
Upon incubation of the purified PorA at 100ºC (lane 3-b), the trimers were converted 
to monomers (43 kDa). This pattern is also observed in the OMV and OMC (lanes 1, 
2). The denaturation of PorA in OMV was confirmed by SDS-PAGE, as only 
monomers were present at both incubation temperatures (lane 4). In samples 
containing LPS (OMV, OMC) a smear is observed above the position of the trimers 
(lanes 1,2,4), which disappears upon purification of the protein (lane 5). This 
suggests that the smear represents assembled PorA-LPS complexes.  
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Figure 1. Typical anion-exchange elution
chromatogram of disrupted and DNase-
treated OMV containing PorA P1.7-2,4.
Squares: protein elution pattern, solid line:
NaCl gradient, expressed as the
percentage of elution buffer containing 1
M NaCl. Fractions 16 to 24 were pooled
and dialyzed overnight against elution
buffer without NaCl. 
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 Figure 2. SDS-PAGE of PorA P1.7-2,4 in different formulations. The samples were dissolved in 
sample buffer containing 0.05% SDS and incubated either at room temperature (a) or 100ºC (b). The 
molecular weight of reference proteins are indicated at the left (kDa). Lane 1: PorA-OMV, lane 2: 
PorA-OMC, lane 3: purified PorA, lane 4: denatured PorA-OMV, lane 5: liposomes. 
 
 
Figure 3. Fluorescence emission spectra of PorA P1.7-2,4 formulations, excited at 295 nm. Closed 
diamonds: PorA-OMV, open diamonds: purified PorA, closed triangles: denatured PorA-OMV, open 
triangles: PorA-OMC. 
 
Fluorescence spectroscopy allows to study the local tryptophan environment 
and the accessibility of tryptophan to a quencher, in our case acrylamide. The 
intrinsic fluorescence of the four tryptophan residues that the protein contains 
showed a similar fluorescence emission spectrum in all the formulations (Fig. 3), with 
an emission maximum (λmax) at 342 nm for PorA-OMV and PorA-OMC and at 340 nm 
for the purified protein and denatured PorA-OMV, which corresponds with a relatively 
hydrophobic environment [28]. This is in accordance with the topology model 
0
5
10
15
20
25
300 350 400 450
Wavelength (nm)
Fl
uo
re
sc
en
ce
 (A
.U
.)
CHAPTER 3
 
 76 
described by van der Ley et al. [32], where the four tryptophan residues are located 
in or near the highly conserved trans-membrane regions: two in the membrane-
spanning regions and the other two in the vicinity of the bilayer. None of the 
tryptophans are located in the subtype specific epitopes. The intensity of the 
fluorescence signal was decreased in the PorA-OMV (both native and heat 
denatured) as compared with the other formulations (Fig. 3). This suggests that in the 
OMV formulation quenching compounds are present, which are removed after 
purification.  
Figure 4. Modified Stern-Volmer plots of the quenching of PorA fluorescence by acrylamide. 
Quenching experiments were performed by adding aliquots of acrylamide to PorA formulations (ca. 
100 µg/ml). The data were fitted by linear regression of 4 sets of measurements and analyzed with a 
modification of the Stern-Volmer equation: F0/∆F=1/ƒa+1/(ƒa*KSV*[Q]). See for more details materials 
and methods. Closed diamonds: PorA-OMV, open diamonds: purified PorA, closed triangles: 
denatured PorA-OMV, open triangles: PorA-OMC. 
 
Table 2. Summary of fluorescence quenching studies with acrylamide1) 
Formulation Ksv (M-1) fa r2 
OMV 3.47 ± 0.84 0.72 ± 0.06 0.9985 
Purified P1.4 3.95 ± 0.45 0.62 ± 0.07 0.9995 
OMC 3.95 ± 0.48 0.59 ± 0.01 0.9981 
Denatured OMV 4.91 ± 0.81 0.65 ± 0.05 0.9989 
1) Data were fitted by linear regression. From the fitted line and according to F0/∆F=1/ƒa+1/(ƒa*KSV*[Q], 
ƒa and Ksv were obtained. The tryptophan residues were excited at 300 nm, and the intensity was read 
at an emission wavelength of 350 nm. The results are shown as mean values (±SD) of 4 
measurements. See materials and methods for further details.  
 
To examine the accessibility of the tryptophan residues in PorA P1.7-2,4, 
acrylamide was used as a non-charged quencher. The modified Stern-Volmer plots 
for the quenching of PorA-OMV, PorA-OMC and purified PorA do not show major 
differences (see Fig. 4), indicating that the accessibility of the tryptophan residues to 
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acrylamide is comparable in the different formulations. Only for heat-denatured PorA-
OMV, a slightly different slope of the modified Stern-Volmer plot was obtained. As 
shown in Table 2, the accessible fraction (ƒa) calculated from the modified Stern-
Volmer plot suggests that, on the average, 59-72% of the tryptophan fluorescence 
can be quenched. As the fractional contribution of the individual tryptophans to the 
total fluorescence is not known, these results do not show which of them are 
accessible to acrylamide. Logically, the two tryptophans that are located near the 
trans-membrane region of the protein are fully accessible, whereas the tryptophan 
residues inside the trans-membrane region are partly or not accessible to acrylamide. 
In the purified form, PorA is formulated with a detergent in a micellar form (without a 
membrane). Nevertheless, even in the solubilized (trimers) and in the denatured 
(monomers) form the quencher could not reach all tryptophan residues. This 
indicates that, although only monomers are observed by SDS-PAGE for the heat-
denatured OMV (see Fig. 2, lane 4), these are not completely unfolded. 
Figure 5. Far-UV CD spectra of PorA P1.7-2,4. Closed diamonds: PorA-OMV, open diamonds: 
purified PorA, closed triangles: denatured PorA-OMV, open triangles: PorA-OMC. 
 
Far-UV circular dichroism measurements were performed to study the 
secondary structure of PorA P1.7-2,4. The far-UV CD spectra (Fig. 5) of PorA are 
similar in all native formulations, and resemble the spectra obtained for PorB class 3 
protein of Neisseria meningitidis [28]. In all formulations containing trimeric PorA the 
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spectrum has a similar shape, with a minimum around 220 nm and a maximum 
around 200 nm, indicative of the predominant presence of antiparallel ß-sheets [33]. 
Heat-denatured PorA-OMV, however, show a different shape, with a minimum shifted 
down to 214 nm, indicating an altered, but not random secondary structure.  
For PorA, 8 surface-exposed, variable loops have been predicted [32,34]. In 
bacteria containing PorA P1.7-2,4, loop 1 is hidden (i.e., not surface-exposed), 
leaving as the most immunogenic region loop 4, where the epitope P1.4 is located. 
The antigenicity of the P1.4 epitope in the different formulations was quantified by 
ELISA. The results (Table 1) show that both OMV and OMC have a lower antigenicity 
than the purified PorA. This may be due to the steric hindrance caused by other 
components than PorA present in OMV and OMC. On the other hand, the interaction 
in solution of the anti P1.4 monoclonal antibody with denatured PorA-OMV is 
(almost) completely absent. 
 
Reconstitution of purified PorA into liposomes  
Purified, LPS-depleted PorA was incorporated into liposomes. The bilayer 
compostion was PC:PG:Chol with a molar ratio of 8:2:2. PorA-containing liposomes 
had a particle size around 200 nm and a lower polydispersity as compared to OMV 
(Table 1). Fluorescence and CD measurements of liposomal PorA were not 
performed because of too much interference from light scattering by the liposomes, 
as a result of relatively low protein/lipid ratios as compared to OMV. 
The trimeric structure of purified PorA was preserved upon reconstitution in 
liposomes (Fig. 2, lane 5a). The increase in antigenicity of PorA was decreased to 
the level of OMV by its incorporation into liposomes (Table 1). 
 
Effect of purification on the immunogenicity of PorA 
Balb/c mice (eight mice per group) were immunized with Por A-OMV, PorA-
OMC, purified PorA P1.7-2,4 and denatured PorA-OMV according to procedure A. 
AlPO4 was used as adjuvant (see materials and methods). The purified protein was 
expected to have a lower immunogenicity as compared to the formulated PorA, as 
previously shown with other PorA subtypes [14,35]. Therefore, two doses of purified 
PorA were tested: 1.5 and 10 µg/mouse. The results of the serum analysis for this 
immunization are shown in Table 3. All sera showed significant IgG titers. The 
antibody titers raised by PorA-OMV, PorA-OMC and denatured PorA-OMV were 
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comparable. Purified PorA at the same protein concentration (1.5 µg/mouse) induced 
the lowest amount of total IgG. The titer was restored when the dose was raised to 
10 µg/mouse.  
 
Table 3. Humoral immune response induced by PorA P1.7-b,4 adjuvated with AlPO4: effect of the 
presentation form. 
 
Whole-cell ELISA titerb Antigena Dose
(µg) 
IgG IgG1 IgG2a IgG2b IgG3 
Bactericidal 
titerc 
Responders 
OMV 1.5 4.5 3.7 4.2 4.4 0.8 2.40 ± 0.49 6/8 
OMC 1.5 4.0 2.3 3.6 4.0 1.7 2.07 ± 0.48 5/8 
Pure PorA 1.5 3.3 3.3 2.5 3.0 0.3 <1.0 0/8 
Pure PorA 10 4.2 4.3 3.7 4.1 0.4 <1.0 0/8 
Denatured 
OMV 
1.5 4.3 4.0 3.6 4.4 0.9 1.35 ± 0.25 4/8 
a Group 5 was measured in a separate experiment. As bridging group OMV were used, giving similar 
results as in the previous experiment.  
b The titer of each anti-P1.7-2,4 IgG isotype was determined by whole-cell ELISA and is expressed as 
the mean log10 titer. The means were compared by the LSD test with a confidence level of 95%: 
LSD0.05 (IgG) = 0.4; LSD0.05 (IgG1) = 0.8; LSD0.05 (IgG2a) = 0.5; LSD0.05 (IgG2b) = 0.6; LSD0.05 
(IgG3) = 1.5.  
c The bactericidal titer was determined as the reciprocal value of the serum dilution that effectuates 
>90% killing of strain H44/76 7-2,4 and is expressed as the averaged mean log10 titer of the 
responders ± SD. 
 
Determination of the relative subclass distribution of the anti-PorA specific 
antibodies in the sera showed that PorA-OMV and PorA-OMC induced relatively high 
IgG2a and IgG2b titers (Table 3). Both purified PorA and denatured PorA-OMV 
showed a shift towards the production of IgG1.  
To make sure that the antibody response as measured by whole-cell ELISA 
was PorA-specific, an OMV-ELISA was performed. In this way, cross-reactivity of the 
sera with capsular polysaccharide, other proteins and LPS present on the bacterial 
surface is largely avoided. The titers obtained with this method were slightly lower, 
but showed the same trend as those obtained with whole-cell ELISA (not shown). 
Cross-reactivity of the antisera with OMV from the PorA negative strain HI5 was 
almost completely absent. Only purified PorA at the highest dose induced antibodies 
that interacted weakly with these OMV (not shown). 
The bactericidal activity of antibodies is a good measure for protective 
immunity [36]. Each individual mouse serum was tested for bactericidal activity with 
strain H44/76 7-2,4 (Table 3). The anti-OMV and OMC sera had the highest 
bactericidal titers (Table 3), confirming the observation that bactericidal antisera 
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contain significant titers of the complement-binding IgG2a and 2b isotypes [31,37]. In 
mice immunized with PorA-OMV, sera of six out of eight mice showed bactericidal 
activity. Also PorA-OMC induced bactericidal antibodies (5/8 responders). Neither the 
purified LPS-depleted PorA at the two doses tested in the presence of adjuvants nor 
the denatured protein (OMV) induced significant amounts of bactericidal antibodies. 
None of the formulations elicited bactericidal antibodies against strain HI5, which 
excludes the presence of bactericidal antibodies against components other than 
PorA. 
In order to investigate the nature of the non-bactericidal antibodies, an 
inhibition study with a bactericidal serum was done. By mixing bactericidal sera (from 
mice immunized with PorA-OMV and AlPO4 as adjuvant) with non-bactericidal sera 
containing similar antibody levels (from mice immunized with purified PorA, high 
dose), the bactericidal activity was completely inhibited (Fig. 6).  
 
Effect of reconstitution into liposomes on the immunogenicity of PorA 
From the results presented above, it can be concluded that upon purification 
PorA lost its capacity to induce bactericidal antibodies, despite the preservation of its 
conformation. In order to investigate whether the functional immunogenicity could be 
restored after incorporation of PorA into liposomes, a separate immunization 
experiment was done (procedure B, see materials and methods). Animals were 
vaccinated with OMV and liposomes, and a liposomal dose-response was generated. 
To prevent any masking effects caused by AlPO4, immunizations were performed 
without adjuvant (Table 4). In the absence of AlPO4, OMV still induced substantial 
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Figure 6: Effect of blocking antibodies
elicited with purified PorA (table 3, group
4 pooled sera) in bactericidal response
of anti-OMV antiserum (table 3, group 1
pooled sera). Bactericidal antiserum (5µl)
was diluted 10-fold in buffer containing
increasing volumes of the blocking
antiserum. The results are shown as
mean values (±SD) of 3 measurements. 
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total IgG titers. Also high titers were obtained with liposomes at all concentrations 
used (1.5, 3, 6 and 12 µg/mouse). 
 
Table 4. Recovery of the the immunogenicity of purified PorA by incorporation into liposomes 
 
Whole-cell ELISA titera Antigen Dose 
(µg) IgG IgG1 IgG2a IgG2b IgG3 
Bactericidal 
titerb 
Responders 
OMV 1.5 3.7 2.8 3.0 3.2 0.4 1.67 ± 0.86 5/8 
Liposomes 1.5 3.7 2.6 3.3 3.1 0.3 1.91 ± 0.56 6/8 
Liposomes 3 3.8 2.9 3.3 3.3 2.0 1.95 ± 0.74 7/8 
Liposomes 6 3.9 3.2 3.6 3.4 1.9 1.94 ± 0.37 8/8 
Liposomes 12 4.1 3.1 3.9 3.6 2.4 1.98 ± 0.56 6/8 
a The titer of each anti-P1.7-2,4 IgG isotype was determined by whole-cell ELISA and is expressed as 
the mean log10 titer. The means were compared by the LSD test with a confidence level of 95%: 
LSD0.05 (IgG) = 0.4; LSD0.05 (IgG1) = 0.5; LSD0.05 (IgG2a) = 0.2; LSD0.05 (IgG2b) = 0.2; LSD0.05 
(IgG3) = 0.9. 
b The bactericidal titer was determined as the reciprocal value of the serum dilution that effectuates 
>90% killing of strain H44/76 7-2,4 and is expressed as the averaged log10 titer of the responders ± 
SD. 
 
Both OMV and liposomes induced high IgG2a and IgG2b titers (Table 4). 
Antisera raised by liposomal PorA showed a similar relative subclass distribution as 
compared to PorA-OMV, with only a significant increase in the IgG3 titer observed for 
liposomes when the dose was increased. 
Sera of 5/8 animals immunized with OMV in the absence of AlPO4 showed 
bactericidal activity. Remarkably, in the groups immunized with the LPS-depleted 
PorA incorporated into liposomes the number of responders and the bactericidal 
titers were at least as high as the ones obtained with LPS-containing OMV. For 
liposomal PorA there was no clear effect of the dose on the number of responders or 
average bactericidal titer (Table 4). Again, in this experiment none of the formulations 
elicited bactericidal antibodies against strain HI5, excluding the presence of 
bactericidal antibodies against components other than PorA. 
 
Discussion 
 
To determine the preferred characteristics of a PorA formulation for an 
effective immune response, both the conformation of the antigen and the 
presentation form have to be well defined. The combined physicochemical 
techniques used in this study indicated that the conformation of PorA P1.7-2,4 in 
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OMV and OMC was similar. Purification of the protein did not induce measurable 
conformational changes. Only a clear change in the conformation was observed 
upon heat treatment, as detected by circular dichroism and fluorescence quenching 
studies. Both circular dichroism and fluorescence studies indicated that heat-
denatured PorA was misfolded rather than completely unfolded. The circular 
dichroism spectrum of heat-denatured PorA (Fig. 5) suggests an altered, but non-
random secondary structure. The fluorescence spectrum does not show a spectral 
shift (Fig. 3), indicating that the average hydrophobicity of the local environments of 
the four tryptophans has not changed. In contrast, in the presence of 5 M 
guanidinium hydrochloride (a common protein denaturant) the fluorescence spectrum 
of PorA shifts to 353 nm (unpublished results), indicating a more hydrophilic 
environment of the tryptophan residues typical of fully unfolded proteins [28]. Finally, 
although the quenching studies with acrylamide point to enhanced quenching of 
heat-denatured PorA (cf. KSV values, Table 2; Fig. 4), yet not all tryptophan residues 
were accessible to acrylamide. Improper folding of heat-treated PorA explains the 
absence of trimers (see Fig. 2, lane 7), as these will only form through specific 
hydrophobic interactions between three native PorA molecules [19].  
In line with a perturbation of the overall conformation as discussed above, 
heat-treated PorA failed to interact strongly with an anti-P1.4 antibody in vitro 
(Table 1), suggesting that the P1.4 epitope was largely destroyed. In contrast, 
purified PorA was recognized to a higher extent by the same anti-P1.4 antibody as 
compared to OMV and OMC. As we showed that the conformation of purified PorA 
was similar to that in OMV and OMC formulations, this is likely to be due to a better 
accessibility of the P1.4 epitope to the antibodies.  
When incorporated into liposomes, PorA preserved its trimeric conformation 
(Fig. 2) but the interaction with anti-P1.4 antibody was reduced to the level of OMV 
(Table 1). This supports the idea that the protein embedded in a membrane is less 
accessible to the antibodies.  
Immunization experiments were carried out to evaluate the impact of the 
purification on the immune response. Although all formulations raised significant 
antibody levels (Table 3), only mice immunized with the membrane-embedded OMV 
and OMC showed substantial bactericidal activity. In spite of its native-like 
conformation, micellar purified PorA did not induce bactericidal antibodies. 
Differences in the physicochemical properties of the presentation forms (micelles vs. 
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OMV and OMC) may be responsible for this, such as the absence of a bilayer 
structure, particle size, surface charge, as well as the reduced amount of LPS when 
compared to OMV and OMC (see Table 1) [14]. The lack of bactericidal activity of 
heat-treated PorA-OMV confirms that an appropriated conformation is necessary for 
induction of functional antibodies.  
Not only was the bactericidal activity induced by purified PorA absent, but the 
antisera elicited by purified PorA also inhibited the activity of bactericidal antibodies 
present in antisera obtained by immunization with PorA-OMV (Fig. 6). This blocking 
effect was only observed when mixing sera with IgG-titers similar to those in 
bactericidal antisera (data not shown). In the presence of 1:1 (v/v) ratio of 
bactericidal/blocking antisera, the bactericidal activity of anti-OMV antiserum 
completely disappeared. This suggests that the affinity of non-bactericidal antibodies 
for bacteria is comparable to or higher than that of bactericidal antibodies. The 
bactericidal serum used for our blocking experiments contained relatively large 
amounts of the complement-binding isotypes IgG2a and 2b [31], whereas the 
blocking antiserum contained relatively large amounts of IgG1. It has been 
speculated that the blocking effect is due to steric hindrance, induction of 
conformational changes or to antibodies binding to the same epitope but unable to 
activate complement because of a different antibody isotype [38]. Our results cannot 
exclude the first two possibilities, but clearly indicate the importance of the antibodies 
affinity together with an appropriate isotype for complement binding.  
Although these results might be discouraging for the further use of purified 
PorA, in a separate immunization and in the absence of AlPO4 as adjuvant we 
demonstrated that purified native PorA is still able to induce a bactericidal immune 
response, provided that it is reconstituted into a membrane (i.e. liposomes). This has 
been previously observed with liposomal recombinant PorA [21,39]. However, in 
these studies either the bactericidal titer raised with recombinant PorA in liposomes 
was reduced with respect to native PorA in OMV [21] or the liposome-embedded 
recombinant PorA was not compared with the native protein [39]. Our results show 
that the liposomal (LPS-depleted) PorA is capable to induce a comparable 
bactericidal response to the one of LPS-containing OMV in the absence of other 
adjuvants. The discrepancies with earlier results can be due to i) the nature of the 
protein (native vs. recombinant) ii) the sonication method used for liposome 
preparation, which may negatively affect the protein conformation, or iii) the presence 
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of residual LPS in the purified protein. We were not able to completely deplete the 
purified protein from LPS. This residual LPS could be involved in the adequate 
folding of the protein or still act as an adjuvant. The latter, however, is not likely, as 
only 0.3% LPS was present in our liposomes, which is expected to be too low to 
exert adjuvant activity. In other studies up to 25% (w/w) was used to recover the 
bactericidal activity of PorA-OMC derived from an LPS-deficient mutant [37].  
All together these results clearly indicate that both the conformation and the 
presentation form of PorA dictate the quality of the immune response. Although 
purification of the PorA adversely affected its capacity to elicit bactericidal antibodies, 
its conformation was maintained and the bactericidal response was recovered upon 
reconstitution of the purified protein in liposomes, without further need of adjuvants, 
to similar levels as LPS-containing OMV. In follow-up studies we will investigate 
which formulation parameters result in a further improvement of the functional 
immunogenicity of liposomal PorA.  
 
Acknowledgements 
 
We are grateful to Betsy Kuypers for providing the monoclonal antibodies used in 
this study. Harry van Dijken and Cees van Limpt are gratefully acknowledged for the 
assistance with the bactericidal assay and Jeroen Meijer for the help during 
purification.  
Restored immunogenicity of purified meningococcal PorA 
 
 85
References 
 
1. Diaz Romero J, Outschoorn IM. Current status of meningococcal group B vaccine 
candidates: capsular or noncapsular? Clin. Microbiol. Rev.1994; 7:559-575. 
2. Bjune G, Høiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine 
against group B meningococcal disease in Norway. Lancet 1991; 338:1093-1096. 
3. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a 
meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. 
Vaccine 1995; 13:821-829. 
4.  De Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of serogroup B 
meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-1078. 
5. de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a 
hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 
years of age. Vaccine 2000; 18:1456-1466. 
6.  Martin SL, Borrow R, van der Ley P, et al. Effect of sequence variation in 
meningococcal PorA outer membrane protein on the effectiveness of a hexavalent 
PorA outer membrane vesicle vaccine. Vaccine 2000; 18:2476-2481. 
7.  Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM). Bacterial 
meningitis in the Netherlands; annual report 1998. Amsterdam: University of 
Amsterdam, 1999. 
8.  Claasen I, Meylis Y, van der Ley P, et al. Production, characterization and control of 
a Neisseria meningitidis class 1 outer membrane protein containing vesicle vaccine. 
Vaccine 1996; 14:1001-1008. 
9.  Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and 
control of MenB-vaccine ”Folkehelsa”: an outer membrane vesicle vaccine against 
group B meningococcal disease. NIPH Annals 1991; 14:67-79. 
10  Sierra GVG, Campa HC, Varacel NM, et al. Vaccines against group B Neisseria 
meningitidis: protection trial and mass vaccination results in Cuba. NIPH Annals 1991; 
14:195-210. 
11. van der Ley P, van der Biezen J and Poolman J. Construction of Neisseria 
meningitidis strains carrying multiple chromosomal copies of the PorA gene for use in 
the production of a multivalent vesicle vaccine. Vaccine 1995; 13:401-407. 
12. Rouppe-van der Voort E, Schuller M, Holst J, et al. Immunogenicity studies with a 
genetically engineered hexavalent PorA and a wild-type meningococcal group B outer 
membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine 2000; 18: 1334-
1343. 
13.  Verheul AFM, Snippe H and Poolman JT. Meningococcal lipopolysaccharides: 
virulence factor and potential vaccine component. Microbiol. Rev. 1993;57:43-49. 
14  Nurminen M, Butcher S, Iddänpään-Heikkilä I, Wahlström E, et al. The class 1 
outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give 
rise to protective immunity. Mol. Microb. 1992; 6:2499-2506. 
15. Poolman JT, Hopman CTP and Zanen HC. Immunochemical characterization of outer 
membrane complexes from Neisseria meningitidis by the SDS-polyacrylamide-gel-
electrophoresis-immunoperoxidase technique (SGIP). FEMS Microbiol. Lett. 1978; 
4:245-248. 
16  Dellepiane N, Griffiths E and Milstien JB. New challenges in assuring vaccine 
quality. Bull. WHO 2000; 78:155-162.  
17. Jansen C, Wiese A, Reubsaet L, et al. Biochemical and biophysical characterization 
of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim. 
Biophys. Acta 2000; 1464:284-298. 
18.  Minetti CASA, Blake MS and Remeta DP. Characterization of the structure, function 
and conformational stability of PorB class 3 protein from Neisseria meningitidis. J. Biol. 
Chem. 1998; 273:25329-25338. 
CHAPTER 3
 
 86 
 
19  Cowan SW, Schirmer T, Rummel G et al. Crystal structures explain functional 
properties of two E. coli porins. Nature 1992; 358:727-733.  
20  Rouppe van der Voort E, van der Ley P, van der Biezen J, et al. Specificity of 
human bactericidal antibodies against PorA P.17,16 induced with a hexavalent 
meningococcal outer membrane vesicle vaccine. Infect. Immunity 1996; 64:2745-2751. 
21. Ward SJ, Scopes D, Christodoulides M et al. Expression of Neisseria meningitides 
class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and 
adjuvants on the production of a bactericidal immune response. Microb. Pathog. 1996; 
21:499-512.   
22.  Poolman JT, Timmermans HAM, Teerlink T and Seid Jr RC. Purification, cyanogen 
bromide cleavage, and amino terminus sequencing of class 1 and class 3 outer 
membrane proteins of meningococci. Infect. Immunity 1989; 57:1005-1007. 
23.  Jiskoot W, Teerlink T, Beuvery EC and Crommelin DJA. Preparation of liposomes 
via detergent removal from mixed micelles by dilution: the effect of bilayer composition 
and process parameters on liposomes characteristics. Pharmaceutisch Weekblad 
Scientific Edition 1986; 8:259-265. 
24. Peterson GL. A simplification of the protein assay of Lowry et al. which is more 
generally applicable. Anal. Biochem. 1977; 83:346-356. 
25. Karlhanis YD, Zeltner JY, Jackson JJ and Carlo DJ. A new an improved microassay 
to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of gram-negative bacteria. 
Anal. Biochem. 1978; 85:595-601. 
26. Sambrook S, Fritsch EF and Maniatis T. Ethidium bromide fluorescent quantitation of 
the amount of double-stranded DNA. In: Nolan E, editor. Molecular cloning: a 
laboratory manual. New York, Cold Spring Harbor Laboratory Press 1989; E-5. 
27. Lugtenberg B, Meijers J, Peters R, van der Hoek P and van Alphen L. 
Electrophoretic resolution of the ‘major outer membrane protein’ of Escherichia coli K-
12 into four bands. FEBS Lett. 1975; 58:254-258. 
28. Lakowicz, JR. Principles of fluorescence spectroscopy, 2nd Ed. New York: Kuwer 
Academic/Plenum Publishers, 1999. 
29. Westdijk J, van den IJssel J, Thalen M, Beuvery C and Jiskoot W. Quantification of 
cell-associated and free antigens in Bordetella pertussis suspensions by antigen 
bonding ELISA. J. Immunoassay 1997; 18:267-284. 
30. Abdillahi H and Poolman JT. Whole cell ELISA for typing Neisseria meningitidis with 
monoclonal antibodies. FEMS Microbiol. Lett. 1987; 48:367-371. 
31. Hoogerhout P, Donders EMLM, van Gaans-van den Brink JAM, et al. Conjugates 
of synthetic cyclic peptides elicit bactericidal antibodies against a conformational 
epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect. Immunity 
1995; 63:3473-3478. 
32. Van der Ley P, Heckels JE, Virji M, Hoogerhout P and Poolman JT. Topology of 
outer membrane porins in pathogenic Neisseira spp. Infect. Immunity 1991; 59:2963-
2971. 
33. Brahms S and Brahms J. Determination of protein secondary structure in solution by 
vacuum ultraviolet circular dichroism. J. Mol. Biol. 1980; 138:149-178. 
34. Wang J, Jarvis GA, Achtman M, et al. Functional activities and immunoglobulin 
variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA 
protein loop of Neisseria meningitidis. Infect. Immunity 2000; 68:1871-1878. 
35. Jansen C, Kuipers B, van der Biezen J, et al. Immunogenicity of in vitro folded outer 
membrane protein PorA of Neisseria meningitidis. FEMS Imm. Med. Microbiol. 2000; 
27:227-233.  
36.  Saukkonen K, Leinonen M, Abdillahi H and Poolman, JT. Comparative evaluation 
of potential components for group B meningococcal vaccine by passive protection in 
the infant rat and in vitro bactericidal assay. Vaccine 1989; 7:325-328. 
Restored immunogenicity of purified meningococcal PorA 
 
 87
 
37. Steeghs L, Kuipers B, Hamstra HJ, et al. Immunogenicity of outer membrane 
proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: Influence of 
adjuvants on the immune response. Infect. Immunity 1999; 67:4988-4993. 
38.  Virji M and Heckels JE. Nonbactericidal antibodies against Neisseria gonorrhoeae: 
evaluation of their blocking effect on bactericidal antibodies directed against outer 
membrane antigens. J. Gen. Microbiol. 1988; 134:2703-2711.  
39. Idänpään-Heikklilä I, Muttilainen S, Wahlström E, et al. The antibody response to a 
prototype liposome vaccine containing Neisseria meningitidis outer membrane protein 
P1 produced in Bacillus subtilis. Vaccine 1995; 13:1501-1508. 
 
 
 
 
 
 
 
 
 CHAPTER 4 
 
Liposomal meningococcal B 
vaccination: role of dendritic cell 
targeting in the development of a 
protective immune response 
 
 
 
Carmen Arigitaa,b, Lisette Bevaartc, Linda A. Eversea, Gerben A. Koninga,  
Wim E. Henninka, Daan J. A. Crommelina, Jan G. J. van de Winkelc,  
Martine J. van Vugtc, Gideon F. A. Kerstenb, Wim Jiskoota 
 
 
aDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences,  
Utrecht, the Netherlands 
bLaboratory for Product and Process Development, Netherlands Vaccine Institute, 
Bilthoven, the Netherlands 
cImmunotherapy Laboratory, University Medical Center Utrecht, 
Utrecht, the Netherlands 
 
Infection and Immunity, in press 
 

Targeting dendritic cells for liposomal meningococcal B vaccination 
 
 91
 
 
 
 
 
 
 
Abstract 
 
The effect of targeting strategies for improving the interaction of liposomal 
PorA with dendritic cells (DC) on the immunogenicity of PorA was investigated. PorA, 
a major antigen of Neisseria meningitidis, was purified and reconstituted in several 
types of (targeted) liposomes, i.e. by use of mannose or phosphatidylserine (PS) as 
targeting moieties or with positively charged liposomes. We studied the efficiency of 
liposome uptake and its effect on the maturation of and IL-12 production by murine 
DC. Moreover, mice were immunized subcutaneously to study the localization and 
immunogenicity of PorA-liposomes. Uptake of liposomes by DC was significantly 
increased for targeted liposomes and resulted in the maturation of DC, but to varying 
degrees. Maturation markers (CD80, CD86, MHC class II, CD40) showed enhanced 
expression on DC incubated with targeted PorA-liposomes relative to those 
incubated with non-targeted PorA-liposomes. Moreover, only the uptake of targeted 
PorA-liposomes induced production of IL-12 by DC, with levels similar to those 
produced by LPS-pulsed DC. Targeted PorA-liposomes administered 
subcutaneously had an increased localization in draining lymph nodes with respect to 
non-targeted PorA-liposomes. Liposomes in draining lymph nodes interacted 
preferentially with antigen presenting cells (APC), and this was enhanced with 
targeted PorA-liposomes. Immunization studies showed an improvement of the 
bactericidal antibody response (i.e. increased number of responders) generated by 
targeted PorA-liposomes compared to non-targeted ones or LPS-containing outer 
membrane vesicles (OMV). In conclusion, the use of targeted PorA-liposomes results 
in an improved uptake by and activation of DC and an increased localization in 
draining lymph nodes. These effects correlate with an increased percentage of mice 
showing serum bactericidal activity. 
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Introduction 
 
Infections caused by Neisseria meningitidis are a serious threat to children 
and young adults. Vaccines based on capsular polysaccharides are available against 
serogroups A, C and W135 [1]. A polysaccharide-based vaccine is not available for 
serogroup B meningococci, due to the low immunogenicity of their polysaccharides 
and the risk of induction of autoantibodies that cross-react with glycosylated host 
antigens. Still, it remains important to develop new vaccines for serogroup B 
meningococci that make use of other antigenic epitopes in the outer membrane, as 
respectively 63% and 32% of the reported cases of meningococcal disease in 
Europe and the USA are attributable to serogroup B [2,3].  
Class 1 porin protein (PorA) is a good vaccine candidate because is a major 
antigen and induces a strong bactericidal immune responses [4]. Serogroup B 
meningoccal vaccines are being developed by different groups, based on PorA 
formulated in outer membrane vesicles (OMV) [4,5,6]. However, despite purification, 
OMV still contain small amounts of toxic LPS. Furthermore, their composition is 
difficult to manipulate because it is governed by the strain from which the OMV are 
derived. As an alternative for OMV, liposomes are an attractive presentation form for 
purified membrane proteins like PorA, as the liposomal bilayer mimics the membrane 
environment Moreover, liposomes are well-defined structures allowing improvement 
of the formulation, e.g. through attachment of targeting ligands or variations in the 
(membrane) composition.  
A rational approach for making better vaccines is to improve the delivery of 
(liposomal) antigens to dendritic cells (DC). Dendritic cells are the most efficient APC, 
being able to initiate and modulate immune responses both in vitro and in vivo [7]. 
Several strategies can be conceived to target liposomes to DC. On the surface of 
DC, various receptors of the C-type lectin family are expressed, including the 
mannose receptor (MR) and DEC-205 [8]. Receptors of this family have in common 
the recognition of bacterial structures, and antigen capture by these receptors has 
been shown to result in an efficient antigen presentation [9,10]. Another efficient 
uptake mechanism by DC and other APC is the endocytosis of apoptotic bodies. This 
is probably mediated by specific recognition of phosphatidylserine (PS) at the surface 
of apoptotic cells [11].  
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The aim of this study was to design a well-defined PorA-based vaccine with 
improved immunogenicity compared to OMV by formulating PorA into liposomes 
targeted to DC. Three strategies were used to improve the uptake of PorA-liposomes 
by DC: liposomes with mannose ligands on the surface for targeting C-type lectin 
receptors; liposomes containing PS for targeting to the PS receptor; and positively 
charged liposomes to induce an efficient uptake mediated by non-specific 
electrostatic interactions with (negatively charged) DC membranes. As control, 
non-targeted negatively charged PorA-liposomes and OMV were used. In vitro, the 
uptake of targeted and non-targeted PorA-liposomes by bone marrow-derived murine 
DC was studied, as well as their ability to induce functional maturation of DC. In vivo, 
the localization of targeted liposomes (Man-liposomes) and non-targeted liposomes 
was compared in draining lymph nodes after subcutaneous immunization of mice. 
Finally, the immune response of all liposomal PorA-formulations was studied in mice 
and compared with the immune response induced by (standard) OMV. Our data 
suggest that an increased antigen loading of DC through the use of targeted 
liposomes results in an improved immune response. Therefore, targeted liposomes 
are attractive presentation forms for future development of type B meningococcal 
vaccines. 
 
Materials and methods 
 
Materials 
All phospholipids used were synthetic. Dimyristoyl phosphatidylcholine (PC) 
was purchased at Rhône-Poulenc Rorer (Köln, Germany). Dimyristoyl 
phosphatidylglycerol (PG) was a gift from Lipoïd GmbH (Ludwigshafen, Germany). 
Cholesterol (Chol) was obtained from Sigma (Zwijndrecht, The Netherlands). 
Dimyristoyl phosphatidylserine (PS), dimyristoyl phosphatidylethanolamine (PE) and 
dimyristoyl trimethylammonium propane (TAP) were purchased from Avanti Polar 
Lipids (Alabaster, AL). Mannosylated PE (Man-PE) was prepared by 
ethyldiisopropylamine-promoted coupling of PEA and mannopyranosylphenyl 
isothiocyanate (Sigma) in chloroform/methanol (7:1 v/v). The compound was purified 
by preparative TLC, and its structure was confirmed by nuclear magnetic resonance 
(1H-NMR), liquid chromatography and mass spectrometry (LC-MS).  
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PorA was purified from outer membrane vesicles obtained from Neisseria 
meningitidis strain F91 (P1.7-2,4, PorB-, RmpM-, low expression of Opa/Opc) as 
previously described [12]. Prior to incorporation of PorA into liposomes, the protein 
was precipitated with 80% (v/v) ethanol at -20ºC and solubilized in 150 mM n-octyl β-
d-glucopyranoside (Sigma) in Tris-buffered saline (TBS, containing 50 mM Tris-HCl, 
150 mM NaCl pH 7.4). 
Monoclonal antibodies against CD80 (clone 1G10), CD86 (clone GL1), FITC-
labeled mAb against CD11b (clone M1/70), phycoerythrin-labeled mAb against Gr-1 
(clone RB6-8C5) and biotinylated mAb against CD11c (clone HL3) and CD45R/B220 
(clone RA3-6B2) were obtained from BD PharMingen (San Diego, CA). 
Streptavidin-phycoerythrin was purchased from Becton Dickinson (San Jose, CA). 
Biotinylated mAb against F4/80 (clone Cl: A3-1) was obtained from Serotec (Oxford, 
UK). PE-labeled antiCD40 mAb (clone 3.23) was purchased from Immunotech 
(Marseille, France), and mouse anti-rat IgG (H+L) F(ab’)2 fragment was purchased 
from Jackson ImmunoResearch (West Grace, PA). M5/114 anti-MHC class II [13] 
was kindly provided by Dr. Georg Kraal (Vrije Universiteit, Amsterdam, The 
Netherlands). 
 
Preparation and characterization of PorA- liposomes 
Liposomes were made of PC, PG, Chol and Man-PE in a 8:2:2:0.6 mol ratio 
(Man-liposomes); PC, PS and Chol in a 8:2:2 ratio (PS-liposomes) or PC, TAP, Chol 
in a 8:2:2 ratio (TAP-liposomes). Control liposomes consisted of PC, PG and Chol in 
a 8:2:2 mol ratio (PG-liposomes). Liposomes were prepared by detergent dilution and 
characterized as previously described [12]. The initial protein/lipid ratio used was 25 
µg protein/µmol lipid. As fluorescent marker, 0.1 mol % 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD; Molecular 
Probes, Leiden, The Netherlands) was included in the bilayer when indicated. 
Liposomes were filtered through sterile 0.45-µm filters. The zeta potential of the 
liposomes in 3% sucrose, 10 mM Tris pH 7.4 was measured with a Zetasizer 2000 
with an aqueous dip-in cell and a computer with PCS software version 1.35 (Malvern 
Ltd., Malvern, UK). Protein content was determined according to Peterson [14] with 
BSA (Pierce, Rockford, IL) as standard. The phospholipid content was determined 
according to Rouser [15] with sodium phosphate (Merck, Darmstadt, Germany) as 
standard. The presence of mannose on the outside of Man-liposomes was studied by 
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monitoring liposome aggregation in time in the presence of 8 µg/ml of concanavalin A 
(ConA, Sigma) by dynamic light scattering (DLS) at 25ºC with a Malvern 4700 system 
equipped with a 75 mW Argon ion laser (488 nm, Uniphase, San José, CA), a remote 
interface controller and PCS software. 
The correct folding of PorA into liposomes was analyzed by SDS-PAGE in 
‘native’ gels as previously described [16]. Antigenicity of the P1.4 epitope of PorA 
P1.7-2,4 in liposomes was tested by an inhibition ELISA, with the monoclonal 
antibody MN20B9.34 as previously described [12]. 
 
Mice 
Balb/cOlaHsd mice were obtained from Harlan (Horst, The Netherlands) and 
maintained under conventional conditions at the Central Animal Laboratory, Utrecht 
University, the Netherlands or the Netherlands Vaccine Institute, Bilthoven, the 
Netherlands. All experiments were done with 8-12 weeks old animals and were 
approved by the Animal Ethics Committee. 
 
Generation of DC and characterization following incubation with PorA-liposomes 
Bone-marrow derived DC were obtained as described by Inaba et al. [17]. 
Briefly, bone marrow was flushed from mouse femora, erythrocytes were lysed, and 
cells were grown at 1×106/ml in filtered culture medium consisting of RPMI 1640 
medium with 10% FBS, 50 IU/ml penicillin and 50 µg/ml streptomycin in the presence 
of 10 ng/ml murine GM-CSF (Immunex, Seattle, WA) and 50 ng/ml murine IL-4 (R&D 
Systems, Minneapolis, MN). Non-adherent cells were replated on day 1, and cells 
still non-adherent at days 2 and 4 were removed from the cultures, with concomitant 
refreshment of culture medium. On day 7, non-adherent and loosely adherent cells 
were harvested. These cells were MHCII+, CD11c+and CD11b+. From these, 3×106 
cells per well were plated with fresh culture medium together with PorA-liposomes 
(80 nmol phospholipid) and further incubated for 48 hours at 37ºC. As controls, cells 
were incubated in medium, with non-labeled liposomes or with LPS (1 µg/ml). After 
incubation, cells were harvested and analyzed. The supernatants were kept at -70ºC 
until IL-12 quantitation. IL-12 was quantified in 48-hour supernatants of DC cultures 
incubated with liposomes or controls using an OptEIA ELISA kit (BD PharMingen) 
according to the manufacturer’s protocol. 
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Flow cytometry 
Cells (1×105 in 50 µl medium) were blocked with 5% heat-inactivated mouse 
serum in FACS buffer (PBS, 0.1% azide, 1% BSA) for 30 min at room temperature. 
Blocked cells were then washed with FACS buffer and incubated with relevant 
antibodies for 20 min at room temperature. After this time, cells were washed and, if 
required, incubated with a specific fluorescently labeled secondary antibody. Cells 
(1×104) were analyzed by flow cytometry using a FACS Calibur and Cell Quest 
software (BD Biosciences). Win MDI 2.8 software was kindly provided by Joseph 
Trotter and was used for further analysis. Negative controls included unstained cells, 
cells stained with isotype control Ab, and cells stained with only the secondary 
antibody.  
 
Confocal laser scanning microscopy 
Cells (1×105), incubated with PorA-liposomes under similar conditions as for 
flow cytometry studies, were washed with 2 ml PBS and subsequently fixed in 4% 
formaldehyde in PBS for 20 min at room temperature. After fixation, cells were 
washed twice with PBS and mounted on glass slides with FluorSave reagent 
(Calbiochem, San Diego, CA). Slides were examined by using a confocal laser 
scanning microscope equiped with a 488 nm Argon, 568 nm Krypton and 633 nm 
HeNe laser (Leica TCS-SP, Leica Microsystems, Rijswijk, the Netherlands). Images 
were analyzed using Leica TCS-SP Power Scan software. 
 
In vivo studies 
Localization study: mice (3 animals per group) were immunized 
subcutaneously in the groin (0.25 ml, 1000 nmol phospholipid/mouse) with 
DiD-labeled PorA-liposomes. After 48 h, popliteal and inguinal lymph nodes located 
near the injection site were removed and pooled for each mouse. Lymph nodes were 
treated with 160 U/ml collagenase type 3 (Worthington Biochemicals, Lakewood, NJ) 
and 180 U/ml DNase I (Sigma) for 45 min at 37ºC and forced through a 70-µm filter. 
The resultant cells were washed with FACS buffer and analyzed by flow cytometry as 
described above.  
Immunization study: mice (8 animals per group) were immunized 
subcutaneously (0.25 ml/mouse) on day 0, 14 and 28 with 1.5 µg liposomal PorA or 
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PorA-containing OMV. Sera were collected at day 42 and stored at -20ºC until 
analysis. 
 
Serum analysis 
The antibody titers (total IgG and individual isotypes) in mouse sera were 
determined in an ELISA as previously described [18]. Neisseira meningitidis strain 
H44/76 (B:15P1.7-2,4:L3,7,9) and the H44/76-derived mutant strain HI.5 (lacking 
PorA) were used. Isotypes were determined with goat anti-mouse (GAM) Ig isotype-
specific conjugates, labeled with horseradish peroxidase (HRP) (Southern 
Technology Associates; dilution 1/5000, except for IgG1 1/2500), using tetramethyl 
benzidine (TMB) as substrate. The titer is defined as the dilution of the serum where 
50% of the ODmax (λ=450 nm) in the assay is reached. ODmax is the absorbance 
obtained with 2-fold diluted serum.  
The serum bactericidal activity was measured as previously described [19] 
against the N. meningitidis strains: H44/76 (B:15P1.7-2,4:L3,7,9) and HI5 (PorA-). 
Sera from mice were heat inactivated for 30 min at 56ºC prior to use. Bacteria were 
incubated for 10 to 15 min at room temperature with the serum samples before the 
addition of complement. As complement source, 80% (v/v) rabbit serum was used. 
As controls, the bactericidal anti-P1.4 (MN20B9.34) and anti-LPS (MN15A17F12) 
monoclonal antibodies were used. Also, test sera were incubated without 
complement as a negative control. The serum bactericidal titer was measured as the 
reciprocal serum dilution showing more than 90% killing of the number of bacteria 
used.  
 
Statistical methods 
Antibody and bactericidal titers were log10 transformed in order to obtain a 
gaussian distribution. ANOVA was used for statistical evaluation of the data. The 
significance of the differences between the mean values of the antibody titers was 
determined by the least significant difference (LSD) test at a confidence level of 95%. 
This test could not be used for bactericidal titers, as groups included both responders 
and non-responders. Individual values are given together with the mean of the 
indicated responders. 
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Results 
 
Liposomal PorA formulations  
All liposomes had particle sizes around 200 nm (Table 1). As expected, PG-, 
PS- and Man-liposomes were negatively charged, whereas TAP-liposomes were 
positively charged, as indicated by their zeta potential. The initial protein/lipid ratio 
(25 µg protein/µmol lipid) was preserved in the resulting liposomes. The presence of 
accessible mannose residues in the surface of Man-liposomes was confirmed by 
their aggregation in the presence of the carbohydrate binding lectin ConA (Fig. 1).  
 
 
 
A correct PorA conformation is necessary in order to induce an optimal B-cell 
response that will result in the production of protective, i.e. bactericidal, antibodies. In 
order to investigate the PorA conformation, SDS-PAGE under mild conditions was 
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Figure 1. ConA mediated aggregation of Man-
liposomes measured by DLS. Squares: particle
size of Man-liposomes (closed symbols) and
(control) PG-liposomes (open symbols).
Diamonds: polydispersity index of Man-liposomes
(closed symbols) and (control) PG-liposomes
(open symbols). 
Table 1. Characteristics of PorA-liposomesa 
a Data in this table are representative for PorA-liposomes (with or without DiD) used in the 
experiments described. 
b Polydispersity: indication of the size distribution of the liposomes; ranges from 0.0 for a 
monodisperse to 1.0 for an entirely heterodisperse suspension. 
c Surface charge of liposomes. 
d Ratio between the protein concentration determined by ELISA and the protein concentration 
determined according to Peterson [21]. As a reference, the antigenicity of PorA in the outer membrane 
(OMV) was arbitrarily set at 1. * p < 0.01.
Liposome 
formulation 
Composition 
 
Particle size 
(nm) 
PDb Zeta potentialc 
(mV) 
Antigenicityd
PG-liposomes PC:PG:Chol  191  0.27 -54  0.87 
Man-liposomes PC:PG:Chol:Man-PE 201  0.34 -37  0.51* 
PS-liposomes PC:PS:Chol 228  0.35 -50  0.73 
TAP-liposomes PC:TAP:Chol 175  0.40 +44  0.57* 
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performed. In all formulations, PorA was present as trimers (Fig. 2). Even in samples 
incubated for 5 min at 100ºC, some PorA-trimers were still visible, suggesting that the 
incorporation of PorA into a lipid bilayer partially protects the protein from 
heat-denaturation.  
Figure 2. SDS-PAGE of PorA-liposomes. Each sample was dissolved in sample buffer containing 
0.05% SDS and incubated either at room temperature (lanes a) or at 100ºC (lanes b). The number on 
the right indicates the molecular weight of PorA monomers (43 kD) and trimers (130 kD). 
 
The ability of PorA-liposomes to interact with specific bactericidal mAb (i.e. 
antigenicity) was measured by ELISA. The antigenicity of PorA in PG- and 
PS-liposomes was only slightly lower than the antigenicity of the same PorA in outer 
membrane vesicles (OMV, Table 1), indicating that PorA is preferentially embedded 
in the liposomal bilayer with relevant epitopes directed to the outside. In Man- and 
TAP-liposomes the antigenicity of PorA was significantly reduced (p < 0.01), possibly 
caused by steric hindrance due to mannose molecules located on the surface and 
the positive charge, respectively. 
 
Interaction and uptake of PorA liposomes by bone-marrow derived DC 
We studied the interaction of DiD-labeled PorA-liposomes with DC. After 4 h, 
only the incubation of DC with TAP-liposomes resulted in high fluorescence levels of 
the cells (not shown). After 48 h incubation with all PorA-liposome types, almost all 
cells showed fluorescence, regardless of the targeting moiety (Fig. 3, inset). 
However, differences among mean fluorescence intensity (MFI) of cells were found. 
The use of targeted PorA-liposomes resulted in an increased fluorescence of DC as 
compared to non-targeted liposomes. The highest MFI was observed for DC 
incubated with TAP liposomes. Incubation with PS- and Man-liposomes induced 
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intermediate MFI, and cells incubated with (non-targeted) PG-liposomes showed the 
lowest MFI (Fig. 3).  
 
Figure 3. Interaction of DiD-labeled liposomes with DC after 48 h incubation. The results are indicated 
as mean fluorescence intensity (MFI), and error bars represent SEM of 10-fold measurements. Inset: 
typical example of the shift observed in the fluorescence of DC cultured for 48 h in the presence of 
fluorescent PorA-liposomes (shown: PG-liposomes). 
 
Figure 4. Internalization of PorA-liposomes by DC. Typical examples of confocal laser scanning 
micrographs (CLSM) and light microscopy images (LM) of DC after 48h incubation with PG-liposomes, 
Man-liposomes, PS-liposomes and TAP-liposomes, as indicated. Bars: 10 µm. 
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Cells were also visualized by confocal microscopy (Fig. 4). After incubation for 
48 h, bright punctate fluorescence could be observed intracellularly, indicating 
internalization of the liposomes. In agreement with the flow cytometry data, the 
fluorescence intensity was increased in cells incubated with targeted liposomes 
(Man-, PS- and TAP-liposomes). Moreover, when incubated with positively charged 
TAP-liposomes, all cells showed fluorescence. That was not the case with other 
liposome types, indicating that the positive charge on the surface of PorA-liposomes 
induced an (unspecific) electrostatic interaction with the negative surface of cultured 
cells. 
 
Maturation and IL-12 production by liposome-pulsed DC 
Bone marrow-derived DC were characterized with specific monoclonal 
antibodies (MHC Class II, CD80, CD86 and CD40) by flow cytometry (Fig. 5A). Day 7 
DC (t=0) showed moderate levels of MHC Class II and low levels of CD80, CD86 and 
CD40 expression. After 48 h incubation (day 9 DC), the levels of these markers were 
increased. LPS-pulsed DC showed a clear maturation, with increased expression of 
MHC Class II, CD80, CD86 and CD40.  
All liposomal formulations induced increased levels of maturation markers on 
DC after 48 h incubation (Fig. 5B). A substantial increase in MHC Class II 
(comparable to MHCII expression in LPS-pulsed DC), CD80, CD86 and CD40 
expression was observed with all targeted PorA-liposomes (Man-, PS- and 
TAP-liposomes). Much less pronounced effects were observed for non-targeted (PG) 
liposomes, suggesting that enhanced uptake of PorA-liposomes through targeting 
leads to increased maturation.  
The IL-12 concentration was measured in supernatants of DC pulsed with 
liposomes and LPS (Fig. 6). After 48 h incubation, only targeted PorA-liposomes 
(Man-, PS- and TAP-liposomes) had induced IL-12 production to the same extent as 
LPS. Non-targeted liposomes failed to induce IL-12 production by cultured DC. 
Differences were also found in the concentration of IL-12 in supernatants of the 
different types of targeted liposomes. For DC incubated with Man-liposomes, the IL-
12 production was significantly higher than that of DC incubated with PS- or 
TAP-liposomes (p < 0.01). These findings suggest that, besides increased 
maturation, targeted PorA-liposomes induce functional maturation of DC. 
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Figure 5. Panel A. Characterization of cultured DC. Histograms illustrate the expression of specific 
cell surface markers on cells at day 7 (t=0, filled histograms), day 9 (t=48 h, gray line) and in DC 
pulsed for 48 h with LPS (black line). Data are representative of 4 independent experiments. Panel B: 
Effect of uptake of PorA-liposomes on DC maturation. Histograms illustrate the expression of specific 
cell surface markers on DC pulsed for 48 h with the medium only (filled histograms) or with the 
indicated liposomes (black line). Data are representative of at least two experiments. 
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Figure 6. IL-12 quantitation in supernatants of DC cultured for 48 h. The results are shown as mean (± 
SEM) of at least 4 measurements. * p < 0.01; ** p < 0.001. 
 
In vivo localization of PorA liposomes 
The localization of fluorescently-labeled PG- and Man-liposomes after 
immunization was studied in draining (popliteal and inguinal) lymph nodes. The 
choice of these formulations was based on the results obtained with bone 
marrow-derived DC, where targeted liposomes showed an improved binding, uptake 
and subsequent DC maturation with respect to control PG-liposomes. From the three 
types of targeted liposomes, Man-liposomes induced the highest IL-12 production 
and therefore were chosen for the localization study.  
Figure 7. Localization of PorA-liposomes in draining lymph nodes. Panel A. Percentage of fluorescent 
cells isolated from draining lymph nodes of control mice and mice immunized with PG-liposomes and 
Man-liposomes. B. Percentage of fluorescent cells found in various cell populations. White bars: mice 
immunized with PG-liposomes; black bars: mice immunized with Man-liposomes. The results are 
shown as mean ± SEM of three mice.* p < 0.05. 
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The number of cells isolated from draining lymph nodes increased with 50% in 
mice immunized with both PG-liposomes and Man-liposomes as compared to control 
mice (injected PBS). No differences were found in the number of cells isolated from 
animals immunized with the two types of PorA-liposomes (PG- and Man-liposomes). 
The percentage of fluorescent cells found in animals immunized with Man-liposomes 
was significantly higher than in animals immunized with PG-liposomes (p = 0.031; 
Fig. 7, panel A). This indicates that Man-liposomes effectively target the draining 
lymph nodes in vivo. PorA-liposomes were preferentially associated in draining lymph 
nodes with APC. Around 30% of CD11c+ cells, 15-25% of MHC class II+, 10-15% of 
B220+ and 50-70% of F4/80+ cells showed DiD fluorescence, whereas only 5% of 
CD4+ cells were fluorescent. Interestingly, targeted liposomes (i.e. Man-liposomes) 
showed a significantly increased interaction with MHC class II+, B220+ and F4/80+ 
cells as compared with non-targeted liposomes (p < 0.05; Fig. 7, panel B), indicating 
that the use of mannosylated liposomes results in preferential uptake by APC. 
 
Immune responses generated by PorA liposomes 
The immune response generated by PorA-liposomes and OMV was studied 
in vivo. All targeted liposomes (Man-, PS- and TAP-liposomes) were tested, together 
with non-targeted liposomes and OMV as control. This choice was based on in vitro 
data, where the antigenicity of PorA in PorA-liposomes was variable (lower for Man- 
and TAP-liposomes than for PS- and PG-liposomes; Table 1). On the other hand, all 
targeted PorA-liposomes were able to improve the interaction with DC and induce 
their functional maturation (i.e. IL-12 production).  
Sera (day 42) were analyzed not only for the presence of IgG and the IgG 
isotype distribution, but also for their functionality, i.e. complement-mediated 
bactericidal serum activity. Despite the variable antigenicity, all formulations induced 
similarly high IgG titers (Table 2). No differences were found in the isotype 
distribution of IgG in sera of mice immunized with the different liposomal PorA 
formulations and OMV. In contrast with what was expected from the in vitro data, the 
mean bactericidal titers of the responding mice were similar in all groups (Table 2). 
However, the percentage of responding mice increased in the groups immunized with 
targeted liposomes with respect to PG-liposomes and OMV (both non-targeted; 
Table 2).  
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Discussion 
 
In this study, we designed well-defined liposomal PorA formulations, aiming to 
improve the immunogenicity of PorA. DC in the periphery capture and process 
antigens, express lymphocyte co-stimulatory molecules, migrate to lymphoid organs 
and secrete cytokines to initiate immune responses [7]. The question is then: does an 
enhancement of antigen loading of DC result in an improved immune response? In 
order to address this question, diverse strategies were chosen to increase the uptake 
of PorA-liposomes by DC: first, receptor-mediated targeting towards a) receptors with 
specificity for mannose (Man-liposomes) [9,10] or b) the PS receptor (PS-liposomes) 
[11]; second, increasing the uptake of PorA-liposomes by non-specific electrostatic 
interaction of positively charged liposomes (TAP-liposomes) with (negatively 
charged) DC. 
The formulation of PorA in both Man-liposomes and TAP-liposomes resulted in 
a decreased ability of PorA to interact with specific mAb (Table 1), despite the 
preservation of the trimeric protein conformation (Fig. 2). This was probably due to 
steric hindrance caused by mannose molecules at the outside of the liposomes and 
the positive charge of TAP-liposomes, respectively, which hindered the interaction of 
PorA and its specific mAb. 
Targeted PorA-liposomes showed an increased uptake by DC in vitro, as 
compared with non-targeted liposomes (Fig. 3). Increased uptake has been ascribed 
to the multivalent character of liposomal antigens as compared with soluble antigens 
[20]. More efficient antigen presentation by DC was obtained by targeting liposomes 
Table 2. Humoral immune response induced by PorA-liposomes and OMV. 
a The titer of each anti-PorA P1.7-2,4 IgG isotype was determined by whole-cell ELISA and is 
expressed as the mean log10 titer. The means were compared by the LSD test with a confidence level 
of 95%: LSD0.05 (IgG)=0.23; LSD0.05 (IgG1)=0.35; LSD0.05 (IgG2a)=0.29; LSD0.05 (IgG2b)=0.3; LSD0.05 
(IgG3)=0.35.  
b The bactericidal titer was determined as the reciprocal value of the serum dilution that effectuates 
>90% killing of strain H44/76 7-24 and is expressed as the averaged mean log10 titer of the responders 
± SD.  
Whole-cell ELISA titera Bactericidal assay Antigen 
IgG IgG1 IgG2a IgG2b IgG3 % responders titerb 
OMV 3.40 3.16 3.21 3.52 2.87 62.5 2.38 ± 0.29 
PG-liposomes 3.34 3.19 3.15 3.49 2.77 50 2.25 ± 0.52 
Man-liposomes 3.26 2.98 3.15 3.30 2.84 87.5 2.30 ± 0.49 
PS-liposomes 3.40 3.01 3.20 3.33 2.78 100 1.99 ± 0.47 
TAP-liposomes 3.34 3.09 3.51 3.56 2.71 87.5 1.88 ± 0.54 
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towards Fc receptor or Class I/Class II molecules [20]. Also, mannosylated protein 
antigen and peptides showed enhanced potency to stimulate specific T cell clones as 
compared to non-mannosylated peptides [21]. More recently, the same has been 
proven with mannosylated liposomes [22]. However, these systems have only been 
tested in vitro and with model antigens. In our study, in vivo experiments were 
included as promising in vitro results are not always predictive for improved vaccine 
efficacy in vivo. 
Our results confirmed that PorA-liposomes are efficiently internalized by 
cultured DC (Fig. 4). The uptake of PorA-liposomes induced maturation of DC (Fig. 
5). However, only targeted liposomes induced IL-12 production by DC (Fig. 6). The 
improved uptake of Man-liposomes can be explained by the interaction of mannose 
moieties with receptors of the C-type lectin family (MR, DEC-205). For PS-liposomes, 
their increased internalization with respect to non-targeted liposomes can be 
explained by an uptake mechanism similar to that of apoptotic cells. Phagocytosis of 
apoptotic cells is related to the recognition of PS exposed externally due to the loss 
of asymmetry of plasma membrane phospholipids during apoptosis [23,24], by the 
PS receptor [25]. On the other hand, the uptake of positively charged TAP-liposomes 
is probably not receptor mediated, but caused by nonspecific electrostatic 
interactions with negatively charged DC. This mechanism is just as efficient 
mediating the uptake of PorA-liposomes as receptor-mediated endocytosis. 
Moreover, the confocal micrographs indicate that electrostatic interactions of 
TAP-liposomes with the surface of DC resulted in similar punctuate fluorescence 
inside the cells as with other types of PorA-liposomes. This suggests internalization 
of all types of PorA-liposomes via an endocytotic pathway. 
The in vivo localization of targeted (i.e. Man-liposomes) and non-targeted 
liposomes was studied in afferent lymph nodes after subcutaneous administration. 
The findings of these experiments confirm some of the results obtained in vitro. 
Targeted liposomes (Man-liposomes) had an increased localization in draining lymph 
nodes with respect to non-targeted PG-liposomes (Fig. 7, panel A). Both types of 
liposomes interacted preferably with APC. However, targeted liposomes (i.e. Man-
liposomes) showed a significantly increased interaction with MHC class II+, B220+ 
and F4/80+ cells as compared with non-targeted liposomes. (Fig. 7, panel B). These 
results indicate a good correlation between the in vitro and in vivo results, as the use 
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of mannosylated liposomes resulted in both cases in an improved loading of APC as 
compared to non-targeted liposomes. 
The cytokines generated by DC are critically important for subsequent T-cell 
differentiation. IL-12 produced by DC is pivotal for the development of Th1 responses 
[26]. A Th1-type immune response can switch B-cells to IgG2a production [27]. This 
is preferable as IgG of the isotypes 2a and 2b are able to interact with complement 
and induce complement-mediated killing of bacteria [19]. Bactericidal antibody titers 
in human sera are considered one of the correlates of protection in type B 
meningococcal vaccination [28,29]. It has been demonstrated that IL-12 is required 
for development of an effective cellular and/or humoral antimicrobial defense against 
bacteria [30], parasites [31] and viruses [32]. Targeting of PorA-liposomes resulted in 
induction of IL-12 in vitro, in contrast to non-targeted PorA-liposomes. Surprisingly, 
all types of liposomes induced similarly high IgG titers in vivo. These IgG titers were 
comparable to those induced by (LPS containing) OMV. Moreover, the production of 
IL-12 in vitro induced by targeted PorA-liposomes was not translated in vivo into an 
IgG istotype switching (Table 2). Also the bactericidal titers found in serum of mice 
immunized with targeted liposomes were not improved with respect to those of mice 
immunized with non-targeted PorA-liposomes and OMV. However, the number of 
responding mice per group increased from 50-60% with non-targeted 
PorA-liposomes and OMV, to almost 100% (Fig. 9) in mice immunized with targeted 
PorA-liposomes. We can conclude that targeting of PorA-liposomes to DC resulted 
in vivo in a more homogenous immune response as compared to other vaccine 
formulations such as OMV, despite the absence of a measurable isotype switching.  
Previous studies have shown that targeting of DC results in an improved 
in vitro immune response (i.e. T-cell activation) [20,21,22]. The very different 
conditions in vivo, with complex interactions between various cell types and tissues 
complicates the extrapolation of in vitro data to the in vivo situation. This is confirmed 
by our observation that the clear improvement on the liposomal antigen uptake and 
subsequent DC maturation in vitro was only translated in a marginal improvement of 
the immune response in vivo (i.e. increase of the percentage of responders). 
Liposomes are well-defined systems composed of purified materials. In our 
experiments, liposomes contained LPS-depleted PorA and therefore offer an 
important safety advantage over LPS-containing OMV, which are the only PorA 
vaccines tested in the clinic so far [4,5,6]. LPS is a potent activator of DC [9], as 
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confirmed in this study (Fig. 5 and 6), but is also a toxic compound, which should 
preferably be absent in vaccine formulations [33]. 
In summary, targeted PorA-liposomes showed efficient loading and activation 
of cultured DC as compared to non-targeted PorA-liposomes. In line with these 
findings, improved uptake in draining lymph nodes as well as preferential uptake by 
APC was observed in vivo. Importantly, immunization with targeted PorA-liposomes 
resulted in a partial improvement of the immune response in comparison with 
non-targeted liposomes or OMV. However, the improvement in vivo is less 
pronounced that the strong effects seen in vitro. Our data encourage the 
development of meningococcal immunization strategies using antigens encapsulated 
in liposomes targeted towards APC. 
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Abstract 
 
Vaccine efficacy might be improved by exploiting the potent antigen presenting 
properties of dendritic cells (DC), since their ability to stimulate specific major 
histocompatibility complex-restricted immune responses has been well documented 
during the recent years. In that light, we investigated how the interaction of antigen-
containing liposomes with DC was affected by the bilayer composition. Monocyte-
derived human DC and murine bone marrow-derived DC were analyzed and 
compared upon in vitro incubation with liposomes by flow cytometry and confocal 
microscopy. Anionic liposomes with a bilayer composition of phosphatidylcholine, 
cholesterol and phosphatidylglycerol or phosphatidylserine interacted with a limited 
fraction of the total DC population in case of both DC types. Inclusion of 
mannosylated phosphatidylethanolamine for targeting to the mannose receptor 
increased the interaction of negatively charged liposomes with both human and 
murine DC. This increase could be blocked in human DC by addition of the 
polysaccharide mannan indicating that uptake might be mediated by the mannose 
receptor. Cationic liposomes containing trimethyl ammonium propane interacted with 
a very high percentage of both DC types and could be detected in high amounts 
intracellularly. In conclusion, liposome bilayer composition has an important effect on 
interaction with DC and might be critical for the vaccination outcome. 
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Introduction 
 
Dendritic cells (DC) are highly specialized cells of the immune system with 
antigen presenting properties important for initiating adaptive immune responses [1]. 
In the developmental state referred to as immature cells, DC patrol and take up 
antigens in peripheral tissue, and process them into peptides, which are loaded into 
MHC class I and II molecules. Upon encounter with pathogens and/or inflammatory 
stimuli, DC maturation is initiated. The cells migrate to secondary lymphoid organs 
and are turned into efficient presenters of antigens to T-cells resulting in activation of 
naïve T-cells and thereby in initiation of antigen specific immune responses or 
immunological tolerance.  
Recent advances in the research area of DC biology combined with the urgent 
need for improved vaccines regarding antigen delivery capacity and adjuvant potency 
has led to the hypothesis that exploitation of DC properties might be a rational way of 
improving vaccine efficacy [2,3]. Modulating DC features with appropriately designed 
vaccines could possibly result in the generation of enhanced specific T-cell 
responses and thereby more efficient combat of pathogens. One area of DC biology 
that is of interest when investigating the adjuvant role of DC in vaccine design is 
antigen uptake and presentation by DC. Enhancement of the interaction between the 
vaccine formulation and DC could be a potential method for increasing vaccine 
immunogenicity. In the present study we aim at investigating the interaction of 
liposomal antigen formulations containing the Neisseria meningitidis type B antigen 
PorA with human monocyte-derived DC (MoDC) and murine bone marrow-derived 
DC (BMDC) in vitro. To our knowledge, no studies so far have reported on the effect 
of liposomal lipid composition on the interaction with human MoDC and murine 
BMDC. 
Liposomes have potential as efficient presentation form for PorA in the design 
of vaccines against type B meningococcal infections [4]. Liposomes not only mimic 
the natural outer membrane environment of PorA but they also allow the 
manipulation of the formulation, by e.g. the attachment of targeting ligands or the 
variation of the (membrane) composition.  
We analyzed the interaction of different liposomal formulations of 
meningococcal PorA (see chapter 4 of this thesis) with human Mo-DC and murine 
BMDC by flow cytometry and confocal laser scanning microscopy (CLSM). 
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Negatively charged liposomes with phosphatidylglycerol (PG) or phosphatidylserine 
(PS) and cationic liposomes containing trimethyl ammonium propane (TAP) as 
charged phospholipids were used. Also, liposomes with mannosylated 
phosphatidylethanolamine (Man-PE), which is supposed to be recognized by the DC 
surface molecule mannose receptor (MR), were studied. The possibility to block the 
interaction of mannosylated liposomes with DC by addition to the culture medium of 
mannan, a polysaccharide of mannose, was investigated. The data obtained in our 
studies, and its relevance for the development of efficient vaccine formulations, are 
discussed.  
 
Material and methods 
 
Materials 
Dimyristoyl phosphatidylcholine (PC) was purchased at Rhône-Poulenc Rorer 
(Köln, Germany). Dimyristoyl phosphatidylglycerol (PG) was a gift from Lipoïd GmbH 
(Ludwigshafen, Germany). Dimyristoyl phosphatidylserine (PS), dimyristoyl 
trimethylammoniumpropane (TAP) and dimyristoyl phosphatidylethanolamine (PE) 
were obtained from Avanti Polar Lipids (Alabaster, AL, USA). Texas Red® 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine and DiD, 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindodicarbo-cyanine, 4-chlorobenzenesulfonate salt, were 
purchased from Molecular Probes (Leiden, the Netherlands). α-D-mannopyranosyl 
phenyl isothiocyanate, cholesterol (Chol), n-octyl β-d-glucospyranoside (OG) and 
Molybdenum Blue spray reagent were obtained from Sigma (Zwijndrecht, the 
Netherlands). analytical and preparative silica gel 60 F254 TLC plates were obtained 
from Merck, Darmstadt, Germany. Water purified through reversed osmosis was 
applied throughout the study. All other chemicals were of analytical grade or the best 
available. 
 
Synthesis of mannosylated-PE 
N-(3-(4-(α-D-Mannopyranosyl)phenylthiureido)-L-1,2-dimyristoyl-3-
phosphatidylethanolamine (Man-PE) was prepared by ethyldiisopropylamine-
promoted coupling of PE and α-D-mannopyranosylphenyl isothiocyanate in 
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chloroform/methanol (7:1 v/v). The compound was purified by preparative thin layer 
chromatography. Its nature was confirmed by 1H- NMR and LC-MS. 
 
Preparation of PorA-liposomes 
PorA was purified from outer membrane vesicles obtained from Neisseria 
meningitidis strain F91 (P1.7-2,4, PorB-, RmpM-, low expression of Opa/Opc) as 
previously described [4]. Prior to incorporation of PorA into liposomes, the protein 
was precipitated with 80% (v/v) ethanol at -20ºC and dissolved in 150 mM OG in Tris-
buffered saline (TBS, containing 50 mM Tris-HCl, 150 mM NaCl pH 7.4). Appropriate 
amounts of each lipid were dissolved in chloroform/methanol (2:1) in a round bottom 
flask and a lipid film was obtained by solvent evaporation in a rotavapor under 
reduced pressure. The film was re-suspended in the PorA solution and the resulting 
mixed micelles were rapidly diluted in TBS, allowing the formation of unilamellar 
vesicles [5]. Subsequently, the liposomes were pelleted by ultracentrifugation 
(160,000 g, 1 hour) and resuspended in TBS, obtaining liposomes with an epitope 
density of approximately 20 µg protein/µmol lipid. PorA liposomes were made with 
four different lipid bilayer compositions; PC:PG:Chol (8:2:2 molar ratio) (PG-
liposomes); PC:PG:Chol:Man-PE (8:2:2:0.6 molar ratio) (Man-liposomes); 
PC:PS:Chol (8:2:2 molar ratio) (PS-liposomes); PC:TAP:Chol (8:2:2 molar ratio) 
(TAP-liposomes). All formulations included 0.2 mol% Texas Red-DMPH or DiD as 
fluorescent marker in the bilayer. 
 
Characterization of PorA-liposomes 
The average particle size and polydispersity index of PorA-liposomes were 
determined by dynamic light scattering at 25ºC with a Malvern 4700 system using a 
computer with PCS software (version 1.35, Malvern). For viscosity and refractive 
index the values of pure water were used. The particle size distribution was reflected 
in the polydispersity index, which ranges from 0 for a monodisperse to 1.0 for an 
entirely heterodisperse dispersion. The zeta potential of the liposomes in 3% sucrose 
was measured with a Malvern Zetasizer 2000 with an aqueous dip-in cell and a 
computer with PCS software (version 1.35, Malvern). The phospholipid content of the 
liposomes was determined by the phosphate determination according to Rouser [6] 
The protein content was determined according to Peterson [7]. 
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Culture of human DC from peripherial blood 
DC were generated from human peripheral blood monocytes according to 
previous reports [8,9]. The study was approved by the ethics committee at the 
Karolinska Hospital, Stockholm, Sweden, and by the local ethics committee in 
Copenhagen, Denmark, (KF01-020/00). Briefly, peripheral blood mononuclear cells 
were isolated from healthy volunteer blood donors, by density gradient centrifugation 
using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). The cells were resuspended to 
5×106 cells/ml in complete medium and allowed to adhere for 35 min. at 37°C in 
tissue culture flasks. Non-adherent cells were removed by PBS washes. Adherent 
cells were cultured for 6 days in complete medium (RPMI 1640) supplemented with 2 
mM L-glutamine (GibcoBRL, Life Technologies, Stockholm, Sweden), 100 U/ml 
penicillin, 100 µg/ml streptomycin (Gibco), 10% heat inactivated fetal calf serum 
(Sigma-Aldrich, Stockholm, Sweden), in the presence of 60 ng/ml human 
recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) 
(Leucomax, Sandoz, Basel, Switzerland) and 50 ng/ml human recombinant 
interleukin 4 (IL-4) (Schering-Plough, Kenilworth, NJ, USA). For liposome uptake 
experiments, immature DC were harvested at day 6 of culture and seeded in 24-well 
tissue culture plates in 0.5 ml complete medium, 2×105 cells/well. For the mannan-
inhibition experiment, 3 mg/ml mannan (Saccharomyces cerevisiae, Sigma-Aldrich 
A/S, Denmark) was added to the medium. Liposomes were added to the wells (20, 
80 or 200 nmol lipid per well) and the mixture was incubated 2 or 4 hours at 37°C. As 
controls for endocytosis, cells were incubated in medium alone or with non-labeled 
liposomes (20 or 200 nmol lipid per well) or with Alexa-488-labeled, heat inactivated 
E. coli (Molecular Probes, Leiden, the Netherlands).  
 
Culture of murine DC 
Balb/cOlaHsd mice were obtained from Harlan (Horst, the Netherlands) and 
maintained under conventional conditions at the Central Animal Laboratory (Utrecht 
University, the Netherlands). All experiments were done with 8-12 weeks old animals 
and were approved by the Utrecht University Animal Ethics Committee. BMDC were 
obtained as described by Inaba et al. [10]. Briefly, bone marrow was flushed from 
mouse femurs, erythrocytes were lysed and cells were grown at 1×106/ml in filtered 
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culture medium consisting of RPMI 1640 medium with 10% fetal bovine serum, 50 
IU/ml penicillin and 50 µg/ml streptomycin in the presence of 10 ng/ml murine 
GM-CSF (Immunex, Seattle, WA) and 50 ng/ml murine IL-4 (R&D Systems, 
Minneapolis, MN). Non-adherent cells were re-plated on day 1 and cells still 
non-adherent at days 2 and 4 were removed from the cultures, with concomitant 
refreshment of culture medium. On day 7, non-adherent and loosely adherent cells 
were harvested. These cells were MHC class II+, CD11c+and CD11b+. From these, 
3x106 cells per well were plated with fresh culture medium together with 80 nmol 
phospholipid in PorA-liposomes and further incubated for 4 hours at 37ºC. As 
controls, cells were incubated in medium alone or with non-labeled liposomes. After 
incubation, cells were harvested and analyzed.  
 
Flow cytometry analysis 
For FACS analyses of human DC surface markers, cells were incubated with 
mouse serum (DAKO, Denmark) for blocking of unspecific binding sites and 
subsequently stained with fluorescein isothiocyanate (FITC) conjugated monoclonal 
antibody against human leukocyte antigen (HLA) DR (clone L243, Becton Dickinson, 
San Jose, CA, USA). Mouse IgG2a served as isotype control (clone X39, Becton 
Dickinson). Fixation was performed with 1% paraformaldehyde. The cells were 
analyzed by a FACS Calibur flow cytometer (Becton Dickinson) using the CellQuest 
software (Becton Dickinson). Dead cells were gated out based on their light 
scattering properties. For the studies with murine DC, the following was used: FITC-
labeled monoclonal antibody against CD11b (clone M1/70) and biotinylated mAb 
against CD11c (clone HL3) were obtained from BD PharMingen (San Diego, CA). 
Streptavidine-phycoerytrin was purchased from Becton Dickinson (San Jose, CA). 
M5/114 anti-class II [11] was kindly provided by Dr. Georg Kraal (Free University, 
Amsterdam, the Netherlands). Murine DC (1x105) were blocked with 5% 
heat-inactivated mouse serum in PBS for 30 min at room temperature (RT). Blocked 
cells were then washed with FACS buffer (PBS, 0.1% azide, 1% BSA) and incubated 
with relevant antibodies for 20 min at room temperature. After this time, cells were 
washed and, if required, incubated with a specific secondary antibody. Negative 
controls consisted of unstained cells, cells stained with isotype control antibody, or 
cells stained with only the secondary antibody. Cells were analyzed by flow 
cytometry using a FACSCalibur flow cytometer and Cell Quest software (BD 
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Biosciences). The Win MDI 2.8 program was kindly provided by Joseph Trotter 
(available on http://facs.scripps.edu/) and was used for further analysis of FACS-
data.  
 
Confocal laser scanning microscopy 
For staining of CD1a the human cells were harvested, washed with ice-cold 
PBS and fixed for 15 min. in 1% paraformaldehyde on ice. Staining was performed 
with a primary monoclonal mouse anti human CD1a antibody (clone BL6, 
Immunotech, Beckman Coulter AB, Sweden) followed by a FITC-conjugated donkey 
anti-mouse IgG (AffiniPure, Jackson Immunoresearch Laboratories, Inc., West 
Grace, PA, USA) in PBS with 4% BSA. The cell preparations were washed with PBS 
and mounted for CLSM. Visualization of fluorescent signals and transmitted light was 
performed with a Zeiss LSM 510 confocal microscope (Carl Zeiss, Jena, GmBH, 
Germany) equipped with an argon laser (458 and 488 nm) and a HeNe laser (543 
nm) using the LSM 510 software. Murine cells (1x105), incubated with 
PorA-liposomes under similar conditions as for flow cytometry studies, were washed 
with 2 ml PBS and subsequently fixed in 4% formaldehyde in PBS for 20 min at room 
temperature. After fixation, cells were washed twice with PBS and mounted on glass 
slides with FluorSave reagent (Calbiochem, San Diego, CA). Fluorescent and 
transmitted light microscope images of cells were taken simultaneously using a Leica 
TCS-SP microscope equipped with an 488 nm Argon, 568 nm Krypton and 633 nm 
HeNe laser and analyzed using Leica TCS-SP Power Scan software (Leica 
Microsystems, Rijswijk, the Netherlands). 
 
Results 
 
Characterization of liposomes 
The composition and characteristics of the liposome formulations are 
summarized in Table 1. The PorA-containing liposomes had a mean particle size of 
around 200 nm. Incorporation of mannosylated phospholipid resulted in formation of 
liposomes with less negative surface charge and larger size as compared to PG-
liposomes. TAP-liposomes exhibited, as expected, a high positive surface charge. 
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Table 1. Characteristics of PorA liposomes. 
Liposomes Composition PorA:lipid ratio 
(µg/µmol) 
Sizea 
(nm) 
PDb Zeta potentiala,c 
(mV) 
PG PC:PG:Chol (8:2:2) 15.0 180 ± 0.4 0.2 -54.2 ± 1.6 
Man PC:PG:Chol:Man-PE 
(8:2:2:0.6)  
26.0 279 ± 1.2 0.3 -37.3 ± 2.5 
PS PC:PS:Chol (8:2:2) 21.3 203 ± 2.3 0.3 -50.0 ± 0.1 
TAP PC:TAP:Chol (8:2:2) 29.5 204 ± 1.9 0.3 44.2 ± 1.4 
aValues represent mean ± S.D., n = 3.  
bPolydispersity: indication of the size distribution of the liposomes; ranges from 0.0 for a monodisperse 
to 1.0 for an entirely heterodisperse suspension. 
cZeta potential was measured in a 3% solution of sucrose. 
 
 
FACS analysis of liposome association with DC 
FACS analysis allows assessment of cell-associated fluorescence and was 
used to examine interaction of Texas Red- or DiD-labeled liposomes with DC. 
Immature DC were generated from human peripheral blood mononuclear cells and 
from murine bone marrow cells. We have previously reported the characteristic 
surface marker expression of normal human DC upon culturing under the described 
conditions (see Material and Methods). The human DC lack lineage-specific markers 
expressed on other leukocyte populations (CD3, CD14, CD19 and CD56) and 
express CD1a, CD40, MHC class I and II [12]. The level of CD83 expression is low 
on immature DC. The murine cultures were MHC class II+, CD11c+and CD11b+ and 
had a purity of approximately 90% (results not shown) comparable to DC described 
by Inaba et al. [10]. The human DC were incubated with the fluorescent liposome 
formulations at 37°C for 2 or 4 hours, harvested and stained with a FITC-labeled 
monoclonal mouse-anti-human HLA-DR antibody. By FACS-analysis, the percentage 
of double-positive cells (HLA-DR+, liposome-Texas Red+) of the gated cells was 
determined. For comparison, we also studied the interaction of liposomes with 
murine BMDC. Incubation was done with DiD-labeled liposomes for 4 hours and the 
percentage of DiD-positive cells was determined after gating of the DC similarly to 
the human DC. 
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In case of human DC, a striking difference in the percentage of double positive 
cells was observed after 2 hours incubation between the negatively charged PG- or 
PS-liposomes and the positively charged TAP-liposomes. While almost the entire DC 
population incubated with TAP-liposomes had high levels of the fluorescent marker 
associated, only less than 2% of the cell population had slightly increased levels of 
fluorescent marker associated when incubated with PS/PG-liposomes (Fig. 1). 
Increasing the incubation time to 4 hours did not change the number of double 
positive cells significantly. The same pattern was seen with murine bone 
marrow-derived DC (Fig. 2) although the frequency of fluorescence positive cells 
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Figure 1. Flow cytometric analysis of human DC after 
2h incubation of 2 × 105 cells with Texas red labeled 
liposomes (20 nmol phospholipid) or unlabeled 
liposomes followed by staining for HLA-DR (or IgG2a as 
control in A, lower right) with a FITC-labeled antibody. 
Experiments were done in triplicate. Panel A: dot plots 
showing double immunofluorescent cells of gated DC 
populations; upper left: unlabeled TAP-liposomes; upper 
right: labeled TAP-liposomes; lower left: labeled PG-
liposomes; lower right: IgG2a control. Panel B: 
histograms showing interaction of liposomes with gated, 
HLA-DR-positive DC (……unlabeled liposomes, — Texas 
red-labeled liposomes), upper panel: PG-liposomes; 
lower panel: TAP-liposomes. Panel C: percentage of 
HLA-DR/Texas red double positive cells of gated cells 
incubated with non-labeled liposomes was determined 
(corresponds to M1 in B).
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varied. These results indicate that the charge of the liposome formulation plays an 
important role for the level of association of the liposomes with DC. 
 
Effect of liposome mannosylation on their binding with and uptake by DC 
In order to study whether mannose receptor (MR)-targeting could enhance 
liposome binding to and uptake by DC, a mannosylated lipid was incorporated into 
the liposomes. A concentration-dependent increase in the percentage of double 
positive cells was observed in human and murine DC cultures (Fig. 3). Moreover, a 
time dependent increase in the percentage of double positive cells was seen after 4 
hours (results not shown). To test whether the MR could mediate the enhanced 
interaction, uptake of Man-liposomes was measured in the presence or absence of 3 
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C Figure 2. FACS analysis of murine DC after 4h incubation of 3 × 106 cells with DiD labeled or 
unlabeled liposomes (80 nmol phospholipid) followed 
by staining for MHCII (or second antibody alone as 
control in A, lower right) with a FITC-labeled antibody. 
Experiments were repeated at least twice. Panel A:
dot plots showing double immunofluorescent cells of 
gated DC populations; upper left: unlabeled TAP-
liposomes; upper right: labeled TAP-liposomes; lower 
left: labeled PG-liposomes; lower right: Isecondary 
antibody control. Panel B: histograms showing 
interaction of liposomes with gated, HLA-DR-positive 
DC (……unlabeled liposomes, — DiD-labeled 
liposomes), upper panel: PG-liposomes; lower panel: 
TAP-liposomes. Panel C: percentage of DiD positive 
cells of gated cells incubated with non-labeled 
liposomes was determined (corresponds to M1 in B)
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mg/ml of mannan in the medium, a bacterial polysaccharide that binds with high 
affinity to MR. At this mannan-concentration, maximum inhibition is achieved [13]. As 
shown in Fig. 3, mannan reduced the percentage of double-positive human DC to 
background levels when adding 200 nmol Man-liposomes to 2x105 DC. Addition of 
mannan to the medium of human DC cultures pulsed with TAP-liposomes had no 
effect on the percentage of double positive cells, while uptake of fluorescently labeled 
E. coli (i.e. whole bacteria with sugar residues in the surface) is completely inhibited 
by inclusion of mannan in the medium (data not shown). These results obtained with 
human DC indicate that uptake is mediated by MR. However, the same effect was 
not observed in the murine BMDC cultures (Fig. 3).  
 
M1
A
B
C
Figure 3: FACS analysis of human 
and murine DC after 2 hours 
incubation of 2x105 cells with Texas-
red labeled Man-liposomes (20 or 
200 nmol phospholipid) or unlabeled 
Man-liposomes (200 nmol
phospholipid) or Man-liposomes (200
nmol phospholipid) where 3 mg/ml 
mannan was included in the medium, 
followed by staining for HLA-DR or 
MHCII with a FITC-labeled antibody. 
Experiments were done in triplicate.
Panel A: Histogram showing 
interaction of liposomes with gated, 
HLA-DR-positive DC ( …. unlabeled 
Man-liposomes, ___ Texas-red 
labeled Man-liposomes). 
Panel B: Percentage of HLA-
DR/Texas red positive cells of gated 
cells incubated with non-labeled 
liposomes (corresponds to M1 in A).
Panel C: FACS analysis of murine 
DC after 4 hours incubation of 3x106
cells with DiD-labeled Man-
liposomes (concentrations as 
indicated) with or without 3 mg/ml 
mannan in the culture medium.
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Intracellular localization of liposomes by CLSM 
To obtain information about the cellular localization of DC-associated 
liposomes, CLSM was used. In order to study the localization of liposomes in DC, 
either intracellularly or on the DC membrane surface, human cells were incubated 
with fluorescent liposomes, then fixed and stained for surface CD1a expression. 
CD1a is considered as a human DC-specific marker under the used culture 
conditions. While incubation of DC with Texas red-labeled PG-, PS- and Man-
liposomes gave no detectable signal in CD1a-positive cells by CLSM, incubation with 
TAP-liposomes heavily stained the intracellular region of the CD1a-positive cells 
(Fig. 4). The nuclei were free of fluorescence. This shows that at least the fluorescent 
label is present intracellularly. The localization was examined in murine DC as well 
(Fig. 5). After 4h incubation of negatively charged (PG and PS) liposomes with 
murine DC, low levels of cell-associated fluorescence were observed. Incubation with 
mannosylated liposomes resulted in increased cell-associated fluorescence in 
contrast to what was observed in the human MoDC. In murine BMDC, the 
fluorescence was punctated and located intracellularly (Fig. 5). When positively 
charged liposomes were used, high levels of fluorescence associated with the cells 
were observed, both in the intracellular compartment and on the cell surface (Fig. 5). 
 
A B
C D
Figure 4 Two-color immuno-
fluorescence of the association of
TAP-liposomes with DC. Human
DC were incubated 2 hours with
Texas-red labeled liposomes
(Panels A-C) (red) or unlabeled
liposomes as control (Panel D),
fixed and stained with a primary
antibody to CD1a (Panels A-C) or
control IgG (Panel D) and a
secondary FITC-labeled anti-CD1a
antibody (green). Visualization was
done by CLSM. 
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Figure 5: Confocal analysis of interaction between DiD-labeled liposomes and murine DC; left: CLSM 
micrographs; right: phase contrast pictures. A: PG-liposomes, B: Man-liposomes, C: PS-liposomes, 
D: TAP-liposomes. Bars: 10 µm. 
 
Discussion 
 
Liposomes have the ability to enhance immune responses against 
incorporated peptide and protein antigens making liposomes interesting adjuvants for 
vaccine delivery [14,15,16]. Liposomal vaccine formulations are usually given as a 
limited number of small doses, either by intramuscular or subcutaneous injection. A 
part of their adjuvant effect is believed to be caused by the formation of an antigen 
depot at the injection site and/or by the facilitated delivery of antigen to antigen 
presenting cells [17]. 
A prerequisite for antigen presentation is the introduction of exogenous 
antigen into the cytosol or the endosomes of antigen presenting cells. Exogenous 
material including liposomal antigens is usually taken up by endocytosis and 
presented by the MHC class II presentation pathway. In addition, liposomes 
(especially pH-sensitive and fusogenic) have the ability to deliver antigens to the cell 
cytoplasm, and liposome-associated antigens are thus presented by the MHC class I 
[18]. The main research focus has until now been on macrophage-liposome 
interaction. The powerful antigen presenting function of DC, which is considered as 
the most important antigen presenting cell, led us to investigate how two types of DC 
cultures (murine bone-marrow derived and human monocyte-derived) interact with 
liposomes with different liposome-bilayer composition. 
A B
C D
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Our results establish that bilayer composition has a pronounced impact on the 
level of interaction and uptake of liposomes by human monocyte-derived and murine 
bone marrow-derived DC. While anionic PG- and PS-liposomes hardly interacted 
with human DC at all, we observed an intensive interaction of cationic TAP-
liposomes with both human and murine DC, resulting in dense intracellular 
localization of fluorescent label. This is in accordance with the published observation 
that cationic microparticles are phagocytosed by DC to a much greater extent than 
anionic particles [19]. The mechanism behind this is suggested to be an electrostatic 
interaction between the negatively charged cell surface and the net positively 
charged liposomal surface.  
This charge-effect is observed despite the presence of serum proteins in the 
medium that may adsorb onto microparticulate surfaces and modify their surface 
characteristics [20,21]. Specific serum proteins such as IgG, complement factors and 
fibronectin facilitate recognition and phagocytosis by antigen presenting cells of 
microparticles by adsorption to the surface [22]. Thiele et al. [21] hypothesize that the 
positive surface charge provides an initial strong trigger mediating recognition and 
uptake by DC, which is even superior to the presence of opsonins adsorbed to the 
particle surface.  
The differences we observe between human MoDC and murine BMDC in 
degree of liposome-DC interaction might be caused by differential interaction 
between the two cell types with serum proteins adsorbed onto the liposomal surface. 
Bias of results could be due to the presence of species-different serum components 
or serum-interacting components on the cell surfaces. Other factors that should be 
considered are the differences on the labels used, source of cells, culture conditions 
and differentiation patterns. 
The MR is a surface 175 kD C-type lectin with 8 carbohydrate recognition 
domains and has broad substrate specificity for sugars [23]. The MR is expressed on 
several different cell types, among them monocyte-derived human DC [13] and 
human DC derived from cord blood CD34+ hemopoietic progenitors [24], where it 
mediates efficient antigen presentation as well. The MR mediates phagocytosis of 
mannose-coated particles such as bacteria (i.e. E. coli) and yeast and endocytosis of 
mannosylated proteins that are taken up into vesicular structures where the ligand is 
released, and the MR is transported back to the cell surface [25]. The MR is thereby 
constitutively recycled between endosomes and the plasma membrane resulting in a 
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sustained capacity for antigen capture, concentrating large amounts of antigen 
intracellularly. Uptake of glycosylated antigen via the MR can enhance 100-10.000 
fold the uptake of soluble antigen in vitro [25,26]. After release from the MR, antigens 
are transported to MHC class II compartments and delivered to the MHC class II 
presentation pathway. We attempted to take advantage of this uptake mechanism by 
actively targeting the PorA liposome formulation to the DC mannose receptor by 
attaching a mannose residue to the phospholipid head-group. We found a time- and 
dose-dependent increase in uptake of Man-liposomes compared to conventional PG-
liposomes and in agreement with the results of Copland et al. [27]. Yet the interaction 
between DC and Man-liposomes was much weaker that in case of the cationic TAP-
liposomes.  
Whether the enhancement of the interaction by mannosylated liposomes is 
sufficient to affect the immunological outcome remains to be tested. In vivo, Man-
liposomes are not expected to show strong interactions with other, irrelevant cells, 
whereas TAP-liposomes may bind to any cell in a non-specific way. Thus, the net 
effect of mannosylation and the use of negatively charged liposomes might still be 
advantageous over the use of positively charged liposomes. Our results demonstrate 
that the interaction of a liposomal vaccine formulation with DC can be tuned in vitro 
by variation of the surface charge of the liposome and by the addition of targeting 
moieties. Other parameters such as liposome size and antigen/liposome ratio might 
be important for DC interaction as well. Another important question is how liposome-
mediated antigen delivery to DC influences the ability of DC to stimulate T-cells. 
Overloading of DC with antigen could induce tolerant T-cells [1]. Also, the liposomal 
antigen formulation may interfere in different ways (positively or negatively) with 
processes such as intracellular processing pathways, DC-maturation and antigen 
presentation. Human co-culture systems of antigen-loaded DC and peripheral blood 
mononuclear cells are currently investigated for a functional T-cell stimulation read-
out in response to antigen.  
Addition of mannan to the medium reduced the interaction with human 
monocyte derived DC to background level suggesting that uptake was specifically 
mediated by the MR. However, no blocking by mannan was observed in case of 
murine BMDC. The question arises whether the MR is involved in uptake of 
mannosylated entities by the latter DC type. Reis e Sousa et al. could not detect MR 
in lysates of purified murine Langerhans cells by Western blotting, although a 
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mannose specific uptake by the cells was identified [28]. The mannose-associated 
binding activity observed by us and by others in murine DC might thus be due to 
another (yet unidentified) receptor. Linehan et al. found no expression of MR on DC 
in vivo in thymus, lymph node, spleen and Peyer's patch of normal mice by in situ 
hybridization and immunocytochemistry [29]. This brings up the question to which 
extent cultured DC reflect the properties of DC in situ. Differences in MR-expression 
patterns in cultures of DC and by DC in situ are important to notice when 
investigating targeting potentials. A prerequisite for benefiting from a MR-targeting 
strategy to reach DC more efficiently is that the receptor is expressed by DC at the 
vaccine administration site and that this expression is sustained for a time period 
sufficient for antigen uptake.  
Though liposomes can be efficient in in vitro delivery of antigens to DC, it 
should be realized that additional co-stimulatory signals are necessary to 
successfully induce an immune response in vivo. Liposomes by themselves act as 
adjuvants. Furthermore, other immunostimulatory adjuvants can be incorporated into 
the lipid structures to further increase the adjuvant activity of liposomes. The concept 
of active targeting immunostimulatory drug delivery systems to antigen presenting 
cells is of evident interest for vaccinology, where an urgent need for the development 
of more effective vaccines exists [30]. 
In conclusion, liposome bilayer composition has an important effect on 
interaction with DC and might be critical for the vaccination outcome. 
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Abstract 
Potent liposomal PorA formulations containing various lipopolysaccharide 
(LPS) derivatives were developed. The following adjuvants were compared: the 
commonly used aluminum phosphate (AlPO4), and three LPS-like adjuvants: 
monophosphoryl lipid A (MPL), lipopolysaccharide (galE LPS) and the less toxic LPS 
mutant lpxL1. The immunogenicity in mice was evaluated and compared with that 
against an outer membrane vesicle (OMV) vaccine. The IgG isotype distribution and 
bactericidal activity were determined. Furthermore, PorA-specific proliferation of 
lymph node cells after immunization and re-stimulation in vitro was studied with 
selected formulations.  
Both AlPO4 and MPL were unable to improve the functional immunogenicity 
(i.e. bactericidal response) of liposomal PorA. Besides, when these adjuvants were 
used, the percentage of responders in the groups did not reach 100%. This was also 
observed with non-adjuvated PorA-liposomes or OMV. Of the adjuvants studied, only 
galE LPS and lpxL1 LPS were capable of increasing the immunogenicity and avoid 
non-responsiveness against PorA-liposomes. Importantly, the adjuvant activity of 
lpxL1 LPS was accompanied by an improved PorA-specific proliferation of lymph 
node cells and a concomitant increase in IL-2 production. In conclusion and 
considering its lower toxicity, lpxL1 LPS-adjuvated liposomes are superior to other 
formulations tested.  
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Introduction 
 
 Neisseria meningitidis serogroup B is the predominant cause of 
meningococcal infection in the Western world [1,2]. Traditional vaccines based on 
capsular polysaccharide [3] offer no protection against type B meningococci. 
Vaccines against this serogroup that are being developed by various groups [4,5] 
consist of outer membrane vesicles (OMV) extracted from (sometimes genetically 
modified) meningococcal strains, with one or more Porin A (PorA) subtypes 
embedded in them [6]. These vaccines have already been tested in clinical trials 
[7,8,9]. We previously demonstrated that purification of PorA from OMV induces a 
reversible loss of its capability to induce a protective (i.e. bactericidal) immune 
response. By incorporation of purified PorA into liposomes, the ability to induce 
bactericidal antibodies was fully recovered: liposomal PorA, in the absence of 
adjuvants, elicited a bactericidal response similar to that of (LPS-containing) OMV 
[10]. However, both with OMV and PorA-liposomes, the percentage of responding 
mice (i.e. with bactericidal activity in serum) in the immunization groups was below 
100%. The occurrence of non-responders should be avoided before introduction of 
new vaccines into human vaccination programs.  
Liposomes are very suitable as delivery vehicles for antigen, but they show a 
relatively low adjuvant activity [26]. The multimeric, particulate structure promotes 
uptake by antigen-presenting cells (APC) and co-incorporation of adjuvants may 
further improve the immune response. Bacterial cell wall components, such as LPS, 
activate APC through receptors on their membrane (e.g. CD14, TLR4) [11]. LPS is 
also responsible for reactogenicity due to the presence of lipid A [16]. Non-toxic 
alternatives for LPS with retained adjuvant activity are under development. Among 
them is monophosphoryl lipid A (MPL), a LPS derivative from Salmonella minnesota 
that has been tested as adjuvant in numerous human trials [12]. The removal of a 
phosphate and fatty acid group from lipid A (see Fig. 1) resulted in a molecule with 
decreased toxicity and retained adjuvant properties [13,14]. More recently, an lpxL 
mutant of N. meningitidis has been constructed containing penta- instead of 
hexaacylated lipid A (Fig. 1). The adjuvant activity of this lpxL1 LPS was similar to 
that of wild type N. meningitidis LPS, but its toxicity was substantially reduced. [16]. 
LpxL1 LPS is therefore an interesting candidate for inclusion in meningococcal 
vaccines.  
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Figure 1. Lipid A structure of LPS and derivatives used in this study. A: wild type LPS of Neisseria 
meningitidis, B: lpxL-mutant of Neisseria meningitidis, C: monophosphoryl lipid A from Salmonella 
minnesota. 
 
In this study we investigated the possibility to improve the immune response 
induced by PorA formulated in liposomes. Either MPL, galE LPS or lpxL1 LPS were 
incorporated in the liposomal bilayer of PorA-containing liposomes, whereas 
aluminum phosphate (AlPO4) was mixed with liposomes. The effect of these 
adjuvants on the PorA-specific humoral immune response was investigated. 
Furthermore, the in vivo activation of T-cells by selected liposomal formulations was 
determined after re-stimulation in vitro.  
 
O
OO
O NH
O
O
O
O
OH
NH
O
O
O
O
OH
O
OH
O OO
P
O
OH
O
O
OPOPO
O
O
O
O
O
O
O NH
O
OH
O
O
[oligosaccharide]
O P O P O
O
O
O
O
NH
O
O
O
O
OH
O
O O
NH3
+
NH3
+
O
OO
O NH
O
OH
O
OH
O
[oligosaccharide]
POPO
O
O
O
O
NH
O
O
O
O
OH
O
O P O P O
O
O
O
O
O
NH3
+
NH3
+
A
14 12
12
14
12
12
12
14 14
14 14
12
14
14
C
B
12 12
14
16
CHAPTER 6 
 
 136 
Materials and methods 
 
Materials  
All phospholipids used were synthetic. Dimyristoyl phosphatidylcholine (PC) 
was purchased from Rhône-Poulenc Rorer (Köln, Germany). Dimyristoyl 
phosphatidylglycerol (PG) was a gift from Lipoïd GmbH (Ludwigshafen, Germany). 
Cholesterol (Chol) and n-Octyl β-d-Glucospyranoside (OG) were obtained from 
Sigma (Zwijndrecht, The Netherlands). 
Meningococcal H44/76 galE LPS [15] and lpxL1 LPS [16] were isolated from 
whole cells by the hot phenol extraction method described by Westphal and Jann 
[17]. Monophosphoryl lipid A from Salmonella minnesota was purchased from Sigma 
and AlPO4 was obtained from Superfos Biosector (Veldbaek, Denmark).  
 
OMV preparation and PorA purification 
OMV were isolated from Neisseria meningitidis strain F91 (P1.7-2,4, PorB-, 
RmpM-, low expression of Opa/Opc) as previously described [10]. The obtained OMV 
were used for purification of PorA as described [10]. Prior to incorporation of PorA 
into liposomes, the protein was precipitated with 80% (v/v) ethanol at –20ºC and 
solubilized in 150 mM OG in 50 mM Tris-HCl, 150 mM NaCl pH 7.4 (TBS). 
 
Liposome preparation and characterization  
Liposomes were made of PC, PG and Chol in a 8:2:2 mol ratio by detergent 
dilution as previously described [18]. In short, appropriate amounts of each lipid were 
dissolved in chloroform/methanol (2/1, v/v) in a round bottom flask and a film was 
obtained by solvent evaporation in a rotavapor under reduced pressure. The film was 
solubilized in the PorA solution forming mixed micelles. The initial protein/lipid ratio 
used was 25 µg/µmol. For liposomes containing adjuvants in the bilayer (LPS, MPL 
or lpxL) the adjuvant dissolved in 150 mM OG in TBS was added to the mixed 
micelles in an initial protein/adjuvant ratio of 2 (w/w). Mixed micelles were rapidly 
diluted 11-fold in TBS, allowing the formation of liposomes. Subsequently, liposomes 
were pelleted by ultracentrifugation (160,000 × g, 1 h) and resuspended in TBS. 
Liposomes were filtered through sterile 0.45-µm filters. The particle size of PorA-
liposomes was measured by dynamic light scattering (DLS) as previously described 
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[10]. Protein content was determined according to Peterson [19] with BSA (Pierce, 
Rockford, IL) as standard. The phospholipid content was determined according to 
Rouser [20] with sodium phosphate as standard (Merck, Darmstadt, Germany). The 
amount of LPS-derived adjuvants (MPL, galE LPS, lpxL1 LPS) present in the 
liposomes was determined by gas chromatographic quantification of fatty acids as 
described in Chapter 2 of this thesis [21]. The correct folding of PorA into liposomes 
(i.e. trimerization) was analyzed by SDS-PAGE in ‘native’ gels as previously 
described [22]. Antigenicity of the P1.4 epitope of PorA P1.7-2,4 in liposomes was 
tested by an inhibition ELISA, with the monoclonal antibody MN20B9.34 as 
previously described [10]. 
 
Immunization studies  
Balb/cOlaHsd mice were obtained from Harlan (Horst, The Netherlands) and 
maintained under conventional conditions at the Central Animal Laboratory of the 
Netherlands Vaccine Institute. All experiments were done with 8-12 weeks old 
animals and were approved by the Animal Ethics Committee of the National Institute 
for Public Health and the Environment. 
Procedure A: mice (8 animals in each group) were immunized subcutaneously 
(1.5 µg protein, 0.25 ml/mouse) on day 0, 14 and 28. The mice were bled on day 42, 
and sera were collected and stored at -20ºC until analysis. 
Procedure B: mice (6 animals in each group) were immunized subcutaneously 
(0.25 ml/mouse) on day 0 and day 21 with 1.5 µg liposomal PorA (+/- lpxL1 LPS) or 
with liposomes (+/- lpxL1 LPS) without PorA. On day 31, inguinal lymph nodes 
located near the injection site were removed and pooled per two mice (3 
samples/group) for T-cell stimulation and cytokine production assays. 
 
Anti-PorA whole cell ELISA  
The antibody titer (total IgG and individual isotypes) of each individual mouse 
serum was determined by whole cell ELISA as described [23]. Neisseria meningitidis 
isogenic H44/76-based strain (B:15P1.7-2,4:L3,7,9) expressing P1.7-2,4 and the 
H44/76-derived mutant strain HI5 (lacking PorA) were used. Isotypes were 
determined with goat anti-mouse (GAM) Ig isotype-specific conjugates, labeled with 
horseradish peroxidase (HRP) (Southern Technology Associates, Birmingham, AL; 
dilution 1/5000, except for IgG1 1/2500). A four-parameter curve fit was made for the 
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optical density at 450 nm values obtained with serial dilutions of the sera, and the 
antibody titers were calculated as the reciprocal dilutions that gave 50% of the 
maximum absorbance. 
 
Serum bactericidal assay  
The serum bactericidal activity was measured as previously described [24] 
against the N. meningitidis strains: H44/76 (B:15P1.7-2,4:L3,7,9) and HI5 (PorA-). 
Sera from individual mice were heat inactivated for 30 min at 56ºC prior to use. 
Serum samples and bacteria were incubated for 10 to 15 min at room temperature 
before the addition of complement. A final concentration of 80% (v/v) baby rabbit 
serum was used as complement source (Pel-Freez Biologicals, Rogers, AR). As 
positive controls, the bactericidal anti-P1.4 (MN20B9.34) and anti-LPS 
(MN15A17F12) monoclonal antibodies were used. Also, test sera were incubated 
without complement as a negative control. The serum bactericidal titer was 
expressed as the reciprocal serum dilution showing more than 90% killing of the 
number of bacteria used.  
 
Cell culture and proliferation assay 
Lymph nodes of mice immunized according to procedure B were maintained in 
culture medium consisting of Iscove’s modified Dulbecco’s medium with 10% fetal 
calf serum, 50 µM β-mercaptoethanol, 100 IU/ml penicillin, 100 µg/ml streptomycin 
and 292 µg/ml glutamine. Pools of lymph nodes (2 mice/pool, 3 pools/group), were 
forced through a 70-µm filter. Cells were washed and cultured in U-bottom 96-wells 
plates at 2×105 cells/well in 200 µl medium, 0.5 µg liposomal PorA/ml or control 
liposomes with equivalent amounts of lipid (based on phosphorous content). ConA 
(Sigma), 8 ng/well, was used as positive control for proliferation. Cells were cultured 
at 37ºC. On day 3, 50 µl aliquots of the supernatants were taken and stored at -70ºC 
for cytokine determination, and replaced by culture medium (50 µl) containing 10 
U/well of recombinant IL-2 (Cetus Corp., Emerville, CA). Cells were further cultured 
for another 24 hours. On day 4, 0.5 µCi 3H-thymidine (Amersham, UK) was added for 
18 h, and incorporation of the radiolabel was determined using a liquid scintillation 
β-counter (LKB, Wallac, Turku, Finland). The stimulation index was calculated as the 
ratio of the radioactivity (cpm) obtained in the presence of PorA-liposomes to that 
obtained in the presence of control liposomes (without PorA).  
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Cytokine production during antigen-induced proliferation 
 The pattern of cytokine production by lymph node cells after stimulation for 3 
days with PorA-liposomes was assessed with a Luminex assay adapted to murine 
cytokines [25]. The concentration of IL-2 (i.e. a Th1 cytokine) and IL-10 (i.e. a Th2 
cytokine) was determined in supernatants of lymph node cultures using calibration 
curves of the corresponding cytokines.   
 
Statistical methods 
Before statistical analysis, antibody and bactericidal titers were log10 
converted. Antibody and bactericidal titers are expressed as the mean log10 titer of 
eight independent observations. Analysis of variance was used for statistical 
evaluation of the data. The significance of the differences between the mean values 
of the antibody titers was determined by the least-significant-difference (LSD) test at 
a confidence level of 95%. Bactericidal titers were compared with the Turkey-Kramer 
multiple comparisons test at a confidence interval of 95%. 
 
Results 
 
Preparation and characterization of liposomal PorA formulations 
Depending on the formulation, the final protein/lipid ratio (µg/µmol) of the 
PorA-liposomes varied from 24 to 32. In the formulations containing adjuvants, the 
protein/adjuvant ratio (w/w) was 2 for MPL-containing liposomes and approximately 
1.4 for liposomes containing meningococcal galE LPS and lpxL1 LPS (Table 1). The 
presence of adjuvants in the liposomal formulations resulted in a slightly larger 
particle size of the liposomes, ranging from 200 nm for non-adjuvated liposomes to 
ca. 250 nm for liposomes containing galE LPS (Table 1). The polydispersity ranged 
from 0.3 to 0.4, indicating a rather broad particle size distribution. 
PorA in liposomes (with or without adjuvants in the bilayer) was present as 
trimers, as observed in ‘native’ SDS-PAGE (not shown). Under denaturing 
conditions, the trimers were converted to monomers. No aggregates or fragments 
could be detected. The interaction of PorA with specific antibodies directed against 
loop 4 of the protein (i.e. antigenicity) was similar for OMV and liposomal PorA (Table 
1). These data indicate that the PorA conformation was preserved. 
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Table 1. Characteristics of PorA-liposomesa. 
a Data in this table are representative for PorA-liposomes used in the experiments described.  
b Particle size average ± SD of three measurements. 
c Polydispersity: indication of the size distribution of the liposomes; ranges from 0.0 for a 
monodisperse to 1.0 for an entirely heterodisperse dispersion. 
d Ratio between the protein concentration determined by ELISA and the protein concentration 
determined according to Peterson [27]. As a reference, the antigenicity of PorA in OMVs was 
arbitrarily set at 1. The results are shown as averaged values ± SD of three measurements. 
 
Humoral immune response to (adjuvated) liposomal PorA formulations 
The humoral immune response of (adjuvated) PorA-liposomes and OMV was 
tested in vivo after subcutaneous immunization of Balb/c mice according to 
procedure A. All formulations induced PorA-specific mean log10 IgG titers of 3 or 
higher (Table 2). Significantly higher mean IgG titers were obtained with 
PorA-liposomes adjuvated with galE LPS or lpxL1 LPS as compared to all other 
formulations, including OMV. No significant differences were found between the IgG 
titers induced by OMV, non-adjuvated PorA-liposomes, and liposomes adjuvated with 
AlPO4 or MPL. The IgG response against other structures than PorA was also 
investigated: the highest non-PorA specific titers were found in mice immunized with 
OMV, plain liposomes or PorA-liposomes adjuvated with lpxL1 LPS (Table 2).  
Determination of the subclass distribution of the anti-PorA specific antibodies 
confirmed that PorA-liposomes in the absence of adjuvants induced overall lower 
titers as compared to other formulations. PorA-liposomes adjuvated with galE LPS 
induced the highest IgG2a titers and these titers were, together with PorA-liposomes 
adjuvated with lpxL1 LPS, significantly higher than those induced by all other 
formulations. However, the IgG2a to IgG1 ratio was only increased for 
PorA-liposomes adjuvated with galE LPS and not for those adjuvated with lpxL1 LPS 
(Table 2). This indicates that galE LPS induces a Th1-type response.  
 
 
 
 
Adjuvant protein:lipid 
ratio (µg/µmol) 
protein:adjuvant 
ratio (w/w) 
Particle size 
(nm)b 
PDc Antigenicityd 
- 32 - 205 ± 7 0.4 0.94 ± 0.12 
MPL 24 2.0 242 ± 4 0.4 1.04 ± 0.11 
galE LPS 32 1.3 248 ± 7 0.3 0.87± 0.04 
LpxL1 LPS 29 1.4 219 ± 3 0.4 0.82 ± 0.05 
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Table 2. Total IgG and subclass distribution in sera of mice immunized with PorA-liposomes and 
OMVs. 
a The titer of each anti-PorA IgG isotype was determined by whole-cell ELISA and is expressed as the 
mean log10 titer. The means were compared by the LSD test with a confidence level of 95%: LSD0.05 
(IgG)=0.29; LSD0.05 (IgG1)=0.22; LSD0.05 (IgG2a)=0.25; LSD0.05 (IgG2b)=0.27; LSD0.05 (IgG3)=0.31. 
b Represented as the averaged IgG2a/IgG1 ratio of individual mice ± SD (8 mice/group). 
c Antibodies against other structures that PorA were determined by whole cell ELISA in plates coated 
with a N. meningitidis strain lacking PorA and their level is expressed as the mean log10 titer. The 
means were compared by the LSD test with a confidence level of 95%: LSD0.05 (IgG)=1.11. 
d OMVs contained 9.4% galE LPS relative to the total amount of protein present in the formulation.  
* significantly higher (groups compared inside the same IgG subclass). 
 
The results of the complement-dependent bactericidal assay are summarized 
in Fig. 2. PorA-liposomes adjuvated with galE LPS or lpxL1 LPS gave rise to serum 
bactericidal antibodies in all mice. Moreover, they induced a significantly higher 
bactericidal immune response as compared to all other formulations (Fig. 2). No 
differences in the bactericidal titers were found between OMV, PorA-liposomes 
without adjuvants, or adjuvated with AlPO4 or MPL. However, the number of 
responders in three of these groups was not 100% and varied: only PorA-liposomes 
adjuvated with MPL induced bactericidal antibodies in all mice. The bactericidal 
Anti-PorA titera Group Adjuvant 
IgG IgG1 IgG2a IgG2b IgG3 
IgG2a/IgG1 
ratiob 
Non- 
specific IgGc 
OMVs galE LPSd 3.20 3.32 3.46 3.44 2.58 1.05 ± 0.16 1.92 
liposomes - 3.02 3.01 2.98 3.09 2.40 0.99 ± 0.04 1.36 
liposomes AlPO4 3.21 3.13 3.34 3.43 2.49 1.07 ±0.10 0.27 
liposomes MPL 3.15 2.95 3.26 3.45 2.22 1.11 ±0.10 0.00 
liposomes galE  3.94* 2.96 4.18* 3.25 2.69 1.42 ±0.18 0.41 
liposomes LpxL1  3.74* 3.59* 3.76* 3.49 2.85 1.05 ± 0.10 1.57 
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Figure 2. Serum bactericidal
activity of mice immunized
with OMV and (adjuvated)
PorA-liposomes.  
Bars indicate the average
bactericidal activity of sera of
responder ± SEM. White
bars: groups with non-
responders; the number of
responders is indicated
above the bars.  
Black bars: groups with
100% responders.  
**: Bactericidal titers are
significantly higher than
those of all other groups
(p ≤ 0.005). 
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antibodies induced by all six formulations were PorA-specific, as these sera were not 
able to kill bacteria of N. meningitidis strain HI.5, lacking PorA (not shown). 
 
Cellular immune response to lpxL1-adjuvated liposomal PorA  
T-cells are important regulators of B cell responses. To investigate whether 
the strong adjuvating effect of lpxL1 LPS was related to an enhanced cellular 
immune response to liposomal PorA, we compared the PorA-specific proliferation of 
cells isolated from lymph nodes of mice immunized according to procedure B using 
non-adjuvated PorA-liposomes, PorA-liposomes adjuvated with lpxL1 LPS and the 
corresponding control liposomes.  
Figure 3. Proliferation and cytokine production of cells isolated from lymph nodes of mice immunized 
with non-adjuvated PorA-liposomes (Group 1) or PorA-liposomes adjuvated with lpxL (Group 2) and 
re-stimulated with the corresponding formulations. Panel A: Proliferation of cells. The bars indicate the 
stimulation index (SI) of individual pools in one group. The SI values are relative to the proliferation of 
cells of the same pool in the presence of liposomal formulations without PorA or adjuvants. See 
materials and methods for details. A stimulation index above 2 is considered significant. Panel B: 
Cytokine production (IL-2 and IL-10) by cells isolated from lymph nodes on day 3. White bars: IL-10; 
black bars: IL-2. Data are presented as averaged values ± SEM (n=3).*: p < 0.05 
 
PorA-specific proliferation was found in two of the three pools of lymph node 
cells from mice immunized with plain PorA-liposomes adjuvated with lpxL1 LPS. In 
contrast to this, none of the pools from animals immunized with plain PorA-liposomes 
(Fig. 3, panel A) or with lpxL1 LPS- or non-adjuvated liposomes without PorA (data 
not shown) showed PorA-specific proliferation. In parallel to these findings, cells 
isolated from lymph nodes of mice immunized with lpxL1 LPS-adjuvated 
PorA-liposomes produced significantly higher amounts of IL-2 but not IL-10, if 
specifically re-stimulated with PorA-liposomes, compared to those of mice immunized 
with non-adjuvated PorA-liposomes (Fig. 3, panel B). Altogether, these data indicate 
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that the use of lpxL1 LPS as adjuvant with PorA-liposomes results in an improved T-
cell response.  
 
Discussion 
 
Adjuvants are important modulators of vaccine responses and play an 
important role in the selection or increase of the immune response. In the present 
study we investigated the benefits of liposomes as carrier and LPS derivatives as 
additional adjuvant to improve the immune response against a meningococcal PorA. 
OMV were used as vehicle alternative and AlPO4 as an adjuvant alternative. 
Adjuvants can improve the immune response by: a) causing depot formation at the 
injection site; b) increasing cellular infiltration at the injection site, particularly of 
antigen presenting cells (APC); and c) improving antigen presentation to T-cells [26]. 
AlPO4 is one of the most commonly used adjuvants for human vaccines [26] 
and is also used with PorA-based meningococcal vaccines [7]. Aluminum salts 
induce Th2 responses, characterized in mice by induction of IgG1 and secretion of 
IL-4, IL-5, IL-6 and IL-10 by cells of the immune system [27,28]. In vaccines against 
N. meningitidis, however, a more Th1-directed response is preferred, as it results in 
B cell isotype switching to IgG2a production [29,30]. Murine IgG of the isotypes 2a 
and 2b are able to induce complement-mediated killing of bacteria [24], which is 
considered one of the correlates of protection against N. meningitidis in humans 
[31,32]. Our results show that the total IgG titers of sera of mice immunized with 
PorA-liposomes adjuvated with AlPO4 were not significantly increased compared to 
other groups (Table 2), nor were the IgG1 titers, in contrast with what one would be 
expect for a Th2 type adjuvant. In agreement with these results, the bactericidal 
activity of these sera was not improved when compared with non-adjuvated 
PorA-liposomes or OMV. Thus, the use of AlPO4, although generally used in 
PorA-vaccines [5,7,8] does not seem to have any beneficial effect.  
Significant titers against other structures than PorA were only observed for 
OMV, non-adjuvated liposomes or liposomes adjuvated with lpxL1 LPS. However, 
the PorA-unspecific IgG titers were not bactericidal. The specificity of these IgG 
remains unknown. The PorA-unspecific response is especially surprising for 
non-adjuvated PorA-liposomes. In the case of OMV or lpxL1 LPS-adjuvated 
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liposomes, the PorA-unspecific IgG could be raised against galE LPS or lpxL1 LPS, 
but this was not investigated. 
 LPS-derived adjuvants are known to direct the immune response towards Th1 
rather than Th2 [27]. Our results show that PorA-liposomes adjuvated with galE LPS 
or lpxL1 LPS induced significantly higher amounts of IgG2a than other formulations 
(Table 2). The IgG2a to IgG1 ratio, however, was only increased with galE LPS and 
not with lpxL1 LPS. This is in agreement with results of immunization of mice with 
outer membrane complexes (OMC) of the N. meningitidis mutant lpxL1 [33]. Despite 
the fact that only PorA-liposomes adjuvated with galE LPS showed a clear shift in the 
IgG2a-to-IgG1 ratio (i.e. a more Th1 type response), both galE LPS- and lpxL1 
LPS-adjuvated liposomes induced higher PorA-specific bactericidal titers when 
compared to the other formulations, with 100% responders in the groups (Fig. 2). 
This indicates that IgG2a titers as such result in increased bactericidal response, 
irrespective of a concomitant increase in IgG1 levels. In a previous study it has been 
shown that in sera of mice immunized with OMC isolated from a Neisseria 
meningitidis mutant without LPS, the IgG2a to IgG1 ratio was much lower than the 
one obtained with OMC isolated from wild-type meningococci [33]. However, in our 
study the IgG2a-to-IgG1 ratio obtained in sera from mice immunized with 
non-adjuvated liposomes did not decrease when compared to other formulations 
such as OMV. This might be due to the presence of LPS traces in the purified PorA 
used for preparation of the liposomes [10]. However, the presence of LPS traces in 
non-adjuvated liposomes did not result in adjuvant activity. The OMV used in our 
study also contained galE LPS. However, the adjuvant-to-PorA ratio in OMV was 
much lower than in adjuvated liposomes, which may be one of the reasons why the 
percentage of responding mice was below 100% (Fig. 2).  
The incorporation of MPL to liposomal PorA failed to increase the serum 
bactericidal activity of mice sera, although non-responsiveness of mice was absent. 
Moreover, the isotype distribution of MPL-adjuvated liposomes was comparable to 
that of PorA-liposomes adjuvated with AlPO4 or OMV (Table 2). It has been 
previously reported that MPL did not improve the bactericidal response of a 
recombinant liposomal PorA formulation [34]. In another study, higher doses of MPL 
were needed to stimulate dendritic cells (DC), as compared to LPS. Once stimulated, 
DC pulsed with MPL induced a mixture of Th1 and Th2 differentiation [35]. The dose 
of MPL used in our formulations was relatively low. Furthermore, PorA-liposomes 
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adjuvated with MPL probably induced a mixed Th1/Th2 response (at the IgG level) 
that did not result in increased serum bactericidal activity in mice.  
In our study the best adjuvant activity for PorA-liposomes was obtained with 
galE LPS and lpxL1 LPS. Since lpxL1 LPS has been shown to have a 100-fold 
reduced toxicity as compared to LPS [16], we investigated whether the strong 
adjuvant activity was related to an improvement in the cellular immune response. 
Indeed, PorA-specific proliferation of cells in the lymph nodes was only induced by 
PorA-liposomes adjuvated with lpxL1 LPS, and not by non-adjuvated 
PorA-liposomes. Proliferation of cells from mice immunized with PorA-liposomes 
adjuvated with lpxL1 LPS was accompanied by increased production of IL-2 by 
cultured cells, whereas the production of IL-10 did not increase (Fig. 3B). This is an 
indication of an enhanced Th1-type response. Further studies determining the 
production of other cytokines (e.g. INF-γ, TNF-α, IL-12), by proliferating cells are 
needed to confirm the Th1 type response induced by lpxL. 
In conclusion, our results indicate that both galE and the less toxic lpxL1 
mutant LPS can be used as a highly effective adjuvant in well-defined 
PorA-liposomes. Both MPL and AlPO4 were unable to improve the immunogenicity of 
PorA-liposomes. Although galE LPS was equally effective as lpxL1 LPS, its toxicity 
makes it less suitable for use in vaccines. The increased induction of bactericidal 
serum activity by lpxL1 LPS-adjuvated liposomes was accompanied by an improved 
stimulation of cellular immune responses. Furthermore, the use of lpxL1 LPS 
overcomes the problem of non-responsive subpopulations after vaccination against 
Neisseria meningitidis.  
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Abstract 
 
The purpose of our study was to investigate the possibility to 
microencapsulate PorA-liposomes and outer membrane vesicles (OMV) in 
biodegradable dextran- and mannan-based microspheres and the effect of the 
microencapsulation on the immunogenicity of PorA.  
Calcein-containing model liposomes, PorA-liposomes and OMV were 
encapsulated in dextran- or mannan-based microspheres using an aqueous 
two-phase system consisting of polyethylene glycol and methacrylated-dextran or 
-mannan solutions. Both types of microspheres were designed to have similar size 
and similar release profiles. The following in vitro characteristics were determined: 
size and size distribution, encapsulation efficiency, release profile in aqueous 
medium at 37ºC, integrity and antigen recovery of PorA after release. Finally, the 
immunogenicity of the formulations containing PorA was determined in mice after 
subcutaneous immunization. 
Liposomes were encapsulated in dextran- and mannan-based microspheres 
with a high efficiency (70-90%). During day 1 to day 5 of incubation no release of the 
model calcein liposomes was detected. All formulations exhibited zero-order release 
kinetics of calcein liposomes between day 5 and day 10 of incubation for the chosen 
conditions. The total release was 80% and 100% from mannan and dextran 
microspheres, respectively. Although the trimeric PorA conformation was preserved 
in the released liposomes and OMV, the antigen recovery was not 100%. The 
immunogenicity of PorA-liposomes and OMV encapsulated both in dextran and 
mannan microspheres was preserved.  
In conclusion, PorA-liposomes and OMV could be encapsulated in dextran- 
and mannan-based microspheres with high efficiency. The immunogenicity of 
encapsulated antigen was preserved.  
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Introduction 
 
Polymeric microspheres have been widely used as controlled release systems 
for antigens [1,2,3]. The most extensively studied polymeric microspheres are made 
of biodegradable and biocompatible polymers consisting of polylactic acid (PLA), 
polylactic-co-glycolic acid (PLGA) or mixtures of these [2,4,5]. The immunogenicity of 
microsphere-encapsulated vaccines can be varied to some extent by changing the 
physicochemical properties of the microspheres, e.g. size, surface properties and the 
release kinetics of the antigen from the microspheres [4]. Previous work has shown 
that mannosylated liposomes are efficiently taken up by dendritic cells (DC, see 
chapter 4 and 5). However the immunogenicity was not improved. We wondered how 
mannan microspheres, with their different characteristics, would perform. Dextran 
microspheres, a drug delivery system previously developed in our group, were 
studied in parallel. As compared to PLA/PLGA microspheres, mannan and dextran 
offer the following advantages: they are hydrophilic, they do not require organic 
solvents for their preparation and during the degradation phase no decrease of pH is 
occurring. This is particularly important when encapsulating proteins, as organic 
solvents and low pH may induce denaturation [6]. The microsphere preparation is 
based on the phase separation of a mannan-HEMA (hydroxyethyl methacrylate) or 
dextran-HEMA solution and a polyethylene glycol (PEG) solution. Upon 
polymerization, the HEMA attached to the mannan or dextran chains (Fig. 1) forms 
an oligomethacrylate chain, thereby crosslinking the dextran or mannan chains, 
resulting in microspheres with a hydrogel character. Dextran hydrogels and 
microspheres are degraded in time by hydrolysis of the carbonate esters. Factors to 
manipulate the release from dextran hydrogels and microspheres include water 
content and cross-link density [7,8,9]. These microspheres have been tested in vitro 
[10,11] and were well-tolerated in vivo [12]. It has also been demonstrated that 
liposomes are efficiently encapsulated in dextran microspheres and are released in 
their intact form in vitro after degradation of the microspheres [13].  
We used mannan from Saccharomyces cerevisiae yeast to prepare 
microspheres. This polysaccharide consists of an α-1,6-linked mannose backbone 
with a high percentage of α-1,2- and α-1,3-side chains of different composition 
(Fig. 1) [14]. The dextran used for preparation of the microspheres was derived from 
Leuconostoc spp. Dextran mainly consists of an α-1,6-linked dextrose backbone with 
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only a low percentage (ca. 5%) of α-1,2, α-1,3 and α-1,4 linked dextrose side chains 
[15] (Fig. 1).  
Figure 1. Structure of modified dextran (A) and mannan (B). The overall structures of the polymers 
are schematically indicated above the chemical structure of the HEMA-derivatized monomers. In 
dextran, HEMA is coupled to the 3C and 2C of a dextrose residue in the α-1,6-linked backbone of 
dextran [38]. In mannan, most HEMA groups are likely coupled to the 6C of the mannose residues of 
the grafts. D: dextrose; M: mannose; P: phosphate; GNAc: N-acetylglucosamine [14]. 
 
We have previously described the use of liposomes as antigen delivery 
system for the Neisseria meningitidis type B antigen PorA [16]. Liposomes offer a 
well-defined and versatile alternative for vaccines based on outer membrane vesicles 
(OMV) [17]. Here, we study the effect of encapsulation of both PorA-liposomes and 
OMV in dextran and mannan microspheres on the immunogenicity of PorA. Both 
dextran and mannan microspheres were designed to provide similar, relatively fast, 
release profiles (i.e. full release in less than 10 days) of the encapsulated antigen 
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(PorA-liposomes and OMV). No attempts were made to obtain microspheres with a 
more prolonged release or pulsed release for use in ‘single-shot’ vaccination 
schedules. It was intended to prepare microspheres with a mean size below 10 µm. 
Microspheres smaller than 10 µm can be taken up efficiently by antigen-presenting 
cells (APC) into phagosomes [2]. On the other hand, microspheres larger than 10 µm 
can provide an extracellular depot for secondary immune responses by way of B-cell 
stimulation [1,4,18]. In addition to this, mannan microspheres were designed to study 
the possibility to specifically target APC, because they express the mannose receptor 
(MR) on their surface [19]. The MR is able to take up saccharide-containing 
components by receptor-mediated endocytosis. After this, the MR is recycled to the 
surface of APC to repeat this process. Thus, the MR is capable to increase the 
uptake of mannosylated antigens or vehicles enormously as compared to the 
non-mannosylated antigen [20,21].  
The ultimate aim of our study is to investigate whether dextran- or 
mannan-based microspheres can improve the immunogenicity of encapsulated 
(physically entrapped, not covalently bound) antigen as compared to the 
non-encapsulated antigen (PorA-liposomes and OMV). As pointed above, the size 
and biophysical characteristics of the microspheres, their release properties, the 
presence of targeting ligands at their surface and the addition of co-entrapped 
adjuvants can likely modulate the immune response of encapsulated antigens. It is 
however very important that the antigen is released from the microspheres in its 
intact form. Thus, the aim of the present study was to evaluate whether 
PorA-liposomes and OMV could be entrapped with a high yield in dextran- and 
mannan-based microspheres and that the antigen could be released in its intact form 
capable to induce an immune response. 
 
Materials and methods 
 
Materials 
Dextran, mannan, hydroxyethyl methacrylate (HEMA), N,N,N’,N’-
tetramethylethylenediamine (TEMED) and calcein were purchased from Fluka 
(Buchs, Switzerland). 1,1’ carbonyldiimidazole (CDI) was obtained from Acros (Geel, 
Belgium). DNase (Benzonase), polyethylene glycol (PEG, Mw 20000), potassium 
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peroxodisulfate (KPS), chloroform and methanol were obtained from Merck 
(Darmstadt, Germany). Dimyristoyl phosphatidylcholine (PC) was purchased from 
Rhône-Poulenc Rorer (Köln, Germany). Dimyristoyl phosphatidylglycerol (PG) and 
egg phosphatidylcholine (EPC) were a gift from Lipoïd GmbH (Ludwigshafen, 
Germany). Cholesterol (Chol) and n-octyl β-d-glucopyranoside (OG) were obtained 
from Sigma (Zwijndrecht, The Netherlands). Triton X-100 was from BDH Laboratory 
Supplies (Poole, UK). 
 
Preparation and characterization of OMV and liposomes  
OMV were isolated from Neisseria meningitidis strain F91 (P1.7-2,4, PorB-, 
RmpM-, low expression of Opa/Opc) as previously described [16]. The OMV were 
used for purification of PorA as described [16]. Prior to incorporation of purified PorA 
into liposomes, the protein was precipitated with 80% (v/v) ethanol at –20ºC and 
solubilized in 150 mM OG in 50 mM Tris-HCl, 150 mM NaCl pH 7.4 (TBS). 
PorA-liposomes were made of PC, PG and Chol in a 8:2:2 molar ratio by detergent 
dilution as previously described [22]. The initial protein/lipid ratio used was 25 
µg/µmol.  
Calcein liposomes were prepared from EPC and Chol in a 2:1 molar ratio by 
lipid film hydration [23]. In short, appropriate amounts of each lipid were dissolved in 
absolute ethanol and a film was prepared by solvent evaporation in a rotavapor 
under reduced pressure. The film was hydrated by vigorous mixing with aid of glass 
pearls in 75 mM calcein in 50 mM Hepes, 150 mM NaCl, pH 7.4 (HBS). 
Subsequently, the liposomes were extruded through 0.2-, 0.1- and 0.05-µm 
polycarbonate filters. After extrusion, non-encapsulated calcein was removed by 
multiple ultracentrifugation steps (160,000 × g, 1 hour) (i.e. until no calcein could be 
detected in the supernatant), and the amount of encapsulated calcein was 
determined [24]. 
The mean particle size and polydispersity index of PorA-liposomes, calcein 
liposomes and OMV were measured by dynamic light scattering (DLS). The protein 
content of PorA-liposomes and OMV was determined according to Peterson [25] with 
BSA (Pierce, Rockford, IL) as standard. The phospholipid content of PorA-liposomes 
and calcein liposomes was determined according to Rouser [26] with sodium 
phosphate (Merck, Darmstadt, Germany) as standard. Trimer formation of PorA into 
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liposomes and OMV and integrity were monitored by SDS-PAGE in ‘native’ gels as 
previously described [27]. Antigenicity (ratio between the protein concentration 
determined by ELISA and the protein concentration determined according to 
Peterson [25]) of the P1.4 epitope of PorA in liposomes and OMV was tested by an 
inhibition ELISA, with the monoclonal antibody MN20B9.34, as described in chapter 
3 of this thesis. In this system, analysis of antigen bound to large particles is 
possible, as the antigen-antibody interaction takes place in solution. 
 
Preparation and characterization of dextran and mannan hydrogels and 
microspheres  
The molecular weights of dextran and mannan were determined by gel 
permeation chromatography with a column calibrated with dextrans of known 
molecular weights. Dextran had a weight average molecular weight (Mw) of 
32000 g/mol and a number average molecular weight (Mn) of 15000 g/mol. Mannan 
had a Mw of 57000 g/mol and a Mn of 34000 g/mol. HEMA-derivatized dextran (dex-
HEMA) and mannan (man-HEMA) were prepared as described by van Dijk-Wolthuis 
et al [28]. The degree of substitution (DS: the number of HEMA groups per 100 
dextran/mannan monomer units) as determined by 1H-NMR [28] was 2.6 for 
dex-HEMA and 4.8 for man-HEMA.  
Macroscopic hydrogels from dex-HEMA and man-HEMA with an initial water 
content of 70% (w/w) were made as previously described [7]. These macroscopic 
hydrogels were made to study the swelling properties of both derivatized mannan 
and dextran. The weight of the hydrogels was determined and used to calculate the 
swelling ratio (defined as the ratio of the weight of the hydrogels at time t (Wt) and the 
initial weight of the hydrogel (W0)). The swelling properties give an indication of the 
degradation rate of the hydrogels. 
Microspheres with an initial water content of 70% (w/w) were prepared 
according to Stenekes et al. [13]. The water content of dex-HEMA microspheres was 
calculated from the equilibrium dextran concentration with aid of a phase diagram 
[10], whereas the water content of man-HEMA microspheres was an estimation 
based on the phase diagram of dextran. In brief, solutions of 40% (w/v) PEG 20,000 
in HBS and 20% (w/v) dex-HEMA or man-HEMA in HBS were flushed for 10 min with 
nitrogen and subsequently transferred to a scintillation vial in a 10/1 (w/w) ratio (total 
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weight 5 g). The two-phase system was vigorously mixed for 1 min to create a water-
in-water emulsion, with the dextran-enriched phase as the discontinous phase. Next, 
the emulsion was allowed to stabilize for 15 minutes at room temperature, followed 
by addition of TEMED (100 µl, 20% v/v, adjusted to pH 7.0 with 4 M HCl) and KPS 
(180 µl, 50 mg/ml). This system was incubated for 30 minutes at 37°C to polymerize 
the methacrylate groups coupled to the mannan or dextran chains. Subsequently, the 
PEG phase was removed by three washing and centrifugation steps (first time 10 min 
at 2.2×103 × g, second and third time 5 min at 1.1×103 × g). The microspheres were 
resuspended in HBS and used immediately after preparation. The particle size and 
size distribution were measured with a laser light blocking technique (AccusizerTM, 
model 770, Particle Sizing Systems, Santa Barbara, CA, USA).  
PorA-liposomes, calcein liposomes or OMV were encapsulated in the 
microspheres by dissolving dex-HEMA or man-HEMA in the dispersion (final polymer 
concentration 20% (w/v)), followed by addition of this mixture to the PEG solution. 
The initial polymer/PorA ratio used was 3300 (w/w). For calcein liposomes, the 
amount of encapsulated lipid was equivalent to that of encapsulated PorA-liposomes. 
The subsequent steps of the microsphere preparation were unchanged. 
 
Encapsulation efficiency 
The encapsulation efficiency of liposomes is defined as the amount of 
liposomes in the microspheres divided by the amount of liposomes added to the two-
phase system × 100%. Because of interference of the microsphere formulations with 
the phosphate and/or protein assays the encapsulation efficiency of PorA-liposomes 
and OMV was estimated by using calcein liposomes as a model as described 
previously [13]. Briefly, freshly prepared microspheres were pelleted and 
resuspended in HBS containing 1% (w/v) Triton X-100. The addition of this detergent 
resulted in disruption of the liposomes encapsulated in microspheres and release of 
calcein into the surrounding buffer. The encapsulation was quantified by measuring 
the fluorescence of released calcein with a calibration curve made of (disrupted) 
calcein liposomes. The fraction of PorA-liposomes encapsulated in dextran 
microspheres was also determined by measuring the phospholipid content in the 
dextran microsphere pellet with the phosphate determination according to Rouser 
[26].  
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Release of OMV, liposomes and integrity of PorA 
After preparation, the microspheres were resuspended in 2.5 ml HBS and 
incubated at 37ºC in a shaking water bath. At different time points, the microsphere 
suspension was centrifuged (5 min, 1.1×103 × g), after which the supernatant was 
removed. Next, the microsphere pellet was resuspended in 2.5 ml HBS and further 
incubated. The amount of calcein liposomes in the supernatants was determined as 
described above [13]. The integrity of calcein liposomes was determined by 
measuring the fluorescence in the supernatant of dextran and mannan microspheres 
in the absence of Triton X-100. 
To determine the release profile of OMV from dextran and mannan 
microspheres and the integrity of PorA in the released OMV, the amount of PorA in 
both the supernatant and the resuspended microspheres was determined by an 
antigenicity assay, i.e. an inhibition ELISA as previously described [16]. For this 
purpose, microspheres were divided in aliquots and at each measuring point the 
antigen recovery of a different aliquot was determined and compared to the antigen 
content of non-encapsulated OMV. In parallel, the integrity of PorA in liposomes and 
OMV after complete release from microspheres was studied. Microspheres were 
incubated for 14 days at 37ºC. Then, samples were homogenized and analyzed by 
SDS-PAGE and ELISA, with non-encapsulated OMV and PorA-liposomes (mixed or 
not with empty microspheres degraded under the same conditions) as controls. 
 
Immunization of mice and serum analysis 
Balb/cOlaHsd mice were obtained from Harlan (Horst, The Netherlands) and 
maintained under conventional conditions at the Central Animal Laboratory of the 
Netherlands Vaccine Institute. All experiments were approved by the Animal Ethics 
Committee of the Netherlands Vaccine Institute.  
Mice (6-8 weeks old, 8 animals/group) were immunized subcutaneously on 
day 0, 14 and 28 with PorA-liposomes or OMV, encapsulated or not in dextran or 
mannan microspheres (1.5 µg protein per mouse, 0.25 ml). Blood samples were 
taken on day 14 and 28, and mice were bled on day 42. Sera were collected and 
stored at -20ºC until analysis.  
Antibody titers were determined for each individual serum against whole cells 
from the strains H44/76 (containing PorA) and HI.5 (lacking PorA) by ELISA as 
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described elsewhere [29]. A four-parameter curve fit was made for the optical density 
values (λ=450 nm) obtained with serial dilutions of the sera, and the antibody titers 
were calculated as the reciprocal dilutions corresponding to 50% of the maximum 
absorbance.  
The serum bactericidal activity was assayed against strains H44/76 and HI.5 
as described [30], using a final concentration of 80% (v/v) rabbit complement. Sera 
were heat-inactivated for 30 min at 56ºC prior to use. As positive controls, the 
bactericidal anti-P1.4 (MN20B9.34) and anti-LPS (MN15A17F12) monoclonal 
antibodies were used. Also, test sera were incubated without complement as 
negative controls. The serum bactericidal titer was expressed as the reciprocal 
serum dilution showing more than 90% killing of the number of bacteria used.  
Results of antibody and bactericidal titers are expressed as the mean log10 
titers of eight individual sera. Analysis of variance was used for statistical evaluation. 
The significance of the differences between the mean IgG values was determined by 
the least significant difference (LSD) test with a confidence level of 95%. This test 
could not be used for bactericidal titers, as some groups included both responders 
and non-responders. Values given are the average of the indicated responders ± SD. 
 
Results  
 
Characterization of macroscopic hydrogels  
The DS of dex-HEMA and man-HEMA used in our experiments was chosen in 
order to obtain similar degradation characteristics for dextran and mannan 
microspheres. Swelling characteristics are indicative of the hydrogel degradation 
rate. To simplify the choice of the DS, macroscopic hydrogels were made, as the 
preparation and swelling measurements of these macroscopic systems are easier 
than those of microspheres. The hydrolysis of the carbonate ester in the crosslinks 
resulted in a progressive swelling in time, followed by a dissolution phase for both 
dex-HEMA and man-HEMA hydrogels. The choice of a low DS for dex-HEMA, which 
would result in microspheres with a fast degradation rate, was based on previous 
studies [13]. For man-HEMA, a DS similar to that of dex-HEMA resulted in slower 
degradation rates (not shown). Comparable swelling kinetics and swelling ratios were 
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observed for hydrogels made of dex-HEMA and man-HEMA with a DS of 2.6 and 
4.8, respectively (Fig. 2).  
 
Characterization of the formulations 
The microspheres obtained with both dex-HEMA and man-HEMA had a 
volume number mean diameter D [3,0] that typically ranged between 6 and 9 µm. 
Microspheres with a size above 10 µm were also present, as can be concluded from 
the size distribution of mannan and dextran microspheres (Fig. 3). The 
characteristics of PorA-liposomes, OMV and calcein liposomes to be encapsulated in 
mannan and dextran microspheres are shown in Table 1. Both liposome types had a 
mean particle size between 120 and 220 nm, whereas OMV were larger, with a size 
above 300 nm. The lowest polydispersity was obtained for (extruded) calcein 
liposomes (i.e. 0.17). PorA-liposomes and OMV had a relatively high polydispersity of 
0.35 and 0.42, respectively. The antigenicity of PorA in liposomes and in OMV was 
similar.  
Figure 3. Volume weight diameter distribution D[3,0] of dextran (A) and mannan (B) microspheres. 
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Figure 2. Swelling behavior of
dextran-HEMA (squares) and
mannan-HEMA (triangles) hydrogels in
aqueous solution (pH 7.4, 37ºC). The
initial water content of the hydrogels
was 70% and the DS 2.6 and 4.8,
respectively. 
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Table 1. Characteristics of liposomes and OMV encapsulated in microspheres. 
a Polydispersity: indication of the size distribution of the liposomes; ranges from 0.0 for a 
monodisperse to 1.0 for an entirely heterodisperse suspension. 
b Ratio between the protein concentration determined by ELISA and the protein concentration 
determined according to Peterson [25]. As a reference, the antigenicity of PorA in the outer membrane 
(OMV) was arbitrarily set at 1. 
c[37]. 
 
The encapsulation efficiency of liposomes in mannan and dextran 
microspheres was determined by using calcein liposomes as a model (Table 2). As 
found previously [13], the encapsulation efficiency of liposomes in dextran 
microspheres was close to 100%. A similar encapsulation efficiency was found for 
PorA-liposomes in dextran microspheres, based on the phosphate determination. In 
contrast to the results obtained with dextran microspheres, the encapsulation 
efficiency of calcein liposomes in mannan microspheres was lower than 70%.  
Phosphate determination could not be used for mannan microspheres 
because the phosphate groups present in mannan (Fig. 1) interfered with the assay. 
Assessment of the encapsulation efficiency of OMV in both types of microspheres 
was not possible because of interference of the polymers in the protein determination 
and the insufficient sensitivity of the phosphate assay to measure the phosphate 
content of OMV. Therefore, the encapsulation efficiency of OMV in dextran and 
mannan microspheres and PorA-liposomes in mannan microspheres was assumed 
to be similar to that of calcein liposomes. 
Table 2. Encapulation efficiency of liposomes in mannan and dextran microspheres with an initial 
water content of 70%. 
Polymer DS Formulation Encapsulation 
Efficiencya (%) 
Mannan-HEMAb 4.8 Calcein liposomes 64 ± 4 
Dextran-HEMAb 2.6 Calcein liposomes 96 ± 5 
Dextran-HEMAc 2.6 PorA-liposomes 92 ± 7 
a Average ± SD of three independently prepared microsphere batches, based on fluorescence (calcein 
liposomes) or phosphate content (PorA-liposomes). 
b Encapsulation efficiency calculated based on calcein determination. 
c Encapsulation efficiency calculated based on the phospholipid content. 
 
In vitro release of liposomes and OMV from microspheres 
 The release of liposomes from dextran and mannan microspheres was 
investigated by using calcein liposomes (Fig. 4). The liposome release profiles for 
Formulation Composition Size (nm) PDa Antigenicityb 
PorA-liposomes PC:PG:Chol 218 0.35 0.94 
Calcein liposomes PC:Chol 126 0.17 - 
OMV Outer membrane lipidsc 362 0.42 1 
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dextran and mannan microspheres were comparable, and similar to previous results 
obtained with dextran microspheres [13]. During the first 5 days, only 10% of the 
encapsulated calcein liposomes was released. Apparent zero-order release kinetics 
were observed during the next 5 days, after which the release curves leveled off at 
100% release (for mannan) and 80% release (for dextran). Only marginal 
fluorescence was observed in the supernatants of calcein liposomes released from 
dextran microspheres before treatment with Triton X-100, indicating that the 
liposomes were intact upon release. In contrast, the liposomes released from 
mannan microspheres showed some fluorescence (20-30%), indicating 
destabilization of the liposome bilayer and leakage of the hydrophilic fluorescent 
marker. The low level of destabilization of the calcein liposomes occurred parallel to 
the degradation of mannan microspheres and release of the calcein liposomes.  
The release of OMV from microspheres was studied by measuring the antigen 
recovery of PorA both in the supernatant of the microspheres and in homogenized 
samples (Fig. 5). Before incubation at 37ºC (t=0), no antigen could be detected, 
indicating that OMV were localized inside the microspheres and therefore PorA was 
not accessible to monoclonal antibodies. The antigen recovery was significantly 
higher in homogenized samples than in supernatants. This indicates that part of the 
released OMV co-precipitated with intact microspheres and/or degradation products 
and, consequently, only a fraction of the OMV was measured in supernatants. In 
homogenized samples, the antigen recovery increased progressively in time and 
reached a maximum level at day 12. After this time, the antigen recovery in 
homogenized dextran microspheres seemed to decrease slightly, but this was not 
significant. Interestingly, homogenized mannan microspheres showed a drastic 
decrease of the antigen recovery after day 12. In contrast to what was observed for 
homogenized samples, no antigen was measured in supernatants of microspheres 
loaded with OMV during the first 5 days of incubation at 37ºC. After this time, the 
amount of antigen detected in the supernatants increased, reaching a maximum at 
day 12. In line with the decrease in antigen recovery observed for homogenized 
samples, the antigen recovery also decreased in the supernatants after day 12 
(Fig. 5). 
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In a separate experiment, the integrity of PorA liposomes and OMV after 
complete release from the microspheres was studied by ELISA and SDS-PAGE. The 
antigen recovery for PorA-liposomes and OMV in homogenates from microspheres 
incubated at 37ºC for 14 days is shown in Fig. 6. In these samples, only 20 to 50% of 
the initial antigen content (i.e. antigen content of the non-encapsulated 
PorA-liposomes or OMV) was recovered. A decreased recovery of antigen (50% for 
PorA-liposomes and 80% for OMV) was also observed when OMV or 
PorA-liposomes were incubated at 37ºC during 14 days mixed with empty mannan 
and dextran microspheres. However, the antigen recovery measured for 
PorA-liposomes or OMV was maintained after incubation for 14 days in the absence 
of microspheres (not shown).  
 
Figure 4. Cumulative release and
leakage of calcein liposomes from
dextran (squares) or mannan
microspheres (triangles). Closed
symbols: supernatants treated with Triton
X-100 (cumulative release); open
symbols: control supernatants, untreated
(cumulative calcein leakage). Values
represent the mean ± SD of three
independently prepared batches. 
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Figure 5. Antigen recovery of OMV
released from dextran (squares) or
mannan microspheres (triangles).
Microspheres were divided in alliquots
and at each measuring point the antigen
recovery of a different alliquot was
measured (both supernantant and
homogenized samples) and compared to
the antigen content of non-encapsulated
OMV. Closed symbols: homogenized
samples. Open symbols: supernatants.
Values are mean ± SD of three
independently prepared batches. 0
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Figure 7. SDS-PAGE of PorA released from dextran microspheres (left) or mannan microspheres 
(right). Lanes 1: released PorA-liposomes; lanes PorA: non-treated purified PorA; lanes 2: released 
OMV. Samples were taken from homogenized microspheres after 14 days incubation in aqueous 
solution (pH 7.4, 37ºC). Each sample was solubilized in sample buffer containing 0.05% SDS and 
incubated for 10 min either at room temperature (a-lanes) or at 100ºC (b-lanes). Numbers on the right 
indicate the position of molecular weight markers. 
 
The integrity of the PorA trimers in homogenates of microspheres loaded with 
PorA-liposomes and OMV was measured by ‘native’ SDS-PAGE [27] after 14 days 
incubation at 37ºC (Fig. 7, a-lanes). In all samples the protein was still present as 
trimers. When incubated at 100ºC, monomers were present (Fig. 7, b-lanes). 
Surprisingly, the monomer bands of release samples showed a slightly higher 
electrophoretic mobility than those of pure PorA.  
 
Immunogenicity of encapsulated PorA-liposomes and OMV 
The immunogenicity of PorA-liposomes and OMV encapsulated in dextran and 
mannan microspheres was studied in Balb/c mice. Two weeks after injection, bumps 
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Figure 6. Antigen recovery of PorA in
liposomes and OMV released from
dextran (white bars) or mannan (black
bars) microspheres after 14 days
incubation at 37ºC. The antigenicity is
expressed as percentage of the
antigenicity of non-encapsulated
samples. Samples were homogenized
prior to the measurement. Values are
mean ± SD of the measurements
performed on three independently
prepared batches. 
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containing residual amounts of microspheres were observed at the injection site, as 
determined by light microscopy (not shown). These bumps may be caused by a 
foreign body reaction, which has been previously observed with similar systems 
[12,31].  
Figure 8. IgG titers found in mice immunized with OMV (panel A) or PorA-liposomes (panel B). 
Squares: non-encapsulated; triangles: encapsulated in dextran microspheres; diamonds: 
encapsulated in mannan microspheres. Results are shown as averaged log10 titers of 8 mice ± SD. 
Arrows indicate the moments of immunization. 
 
The IgG titers of individual mice induced by PorA-liposomes and OMV, both 
free and encapsulated in dextran or mannan microspheres, were monitored in time 
(Fig. 8). In general, no substantial differences were observed between free antigen 
(i.e. PorA-liposomes or OMV) and antigen encapsulated in dextran microspheres. 
This was also true for OMV encapsulated in mannan microspheres. However, 
PorA-liposomes encapsulated in mannan microspheres elicited significantly lower 
IgG titers than non-encapsulated PorA-liposomes (Fig. 8B).  
The IgG subclass distribution was studied in sera of mice after 3 
immunizations (Table 3). Again, no significant differences could be found among the 
different formulations on the IgG subclass distribution, with substantial IgG2a and 
IgG2b titers. Both IgG2a and IgG2b subclasses are important, as they are able to 
activate complement and induce a bactericidal response [30].  
In order to determine the PorA-specificity of the immune response, IgG titers 
against other structures than PorA were measured using a Neisseria meningitidis 
strain that does not express PorA (HI.5 strain). In all groups, only serum of one or 
two mice showed low reactivity against HI.5 (not shown). This indicates that the 
response was largely PorA-specific.  
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The bactericidal titers induced in serum were similar for all formulations and 
were mainly directed against PorA (not shown). In the groups of mice immunized with 
PorA-liposomes encapsulated in mannan microspheres or OMV encapsulated in 
dextran microspheres, only 5 and 4 mice out of 8 mice, respectively, showed a 
bactericidal response. In the other groups all mice had bactericidal serum activity.  
 
Discussion 
 
In this study we investigated the possibility to encapsulate PorA-liposomes 
and OMV into dextran- and mannan-based microspheres and the effect of this 
microencapsulation on the PorA-specific immune response.  
The swelling behavior of macroscopic dex-HEMA and man-HEMA hydrogels 
gave a reasonably good indication of the degradation rate of the hydrogels. Although 
the DS of dex-HEMA was lower than that of man-HEMA, both systems showed 
comparable swelling kinetics and swelling ratios. This may be due to the fact that 
mannan is more branched than dextran (see Fig. 1), which may result in large 
amounts of intramolecular crosslinks fro mannan-HEMA and therefore similarly 
dense network for mannan and dextran microspheres. Macroscopic hydrogels were 
completely degraded in 7-8 days (Fig. 2). In line herewith, the release studies of the 
model calcein liposomes showed complete release after 10-11 days (Fig. 4).  
Calcein liposomes provided a useful model to investigate the encapsulation 
efficiency and the release of liposomes from microspheres. The encapsulation 
efficiency for both PorA-liposomes and calcein liposomes in dextran microspheres 
was high (~90%), despite differences in particle sizes between these liposomes and 
the larger polydispersity of PorA-liposomes. This is in agreement with previous 
studies, where smaller liposomes were encapsulated in dextran microspheres [13]. 
Unfortunately, the encapsulation efficiency of OMV in either dextran and mannan 
microspheres or PorA-liposomes in mannan microspheres could not be measured 
directly. The encapsulation efficiency of calcein liposomes in mannan microspheres 
was lower (64%) than for the dextran microspheres (96%). This might be due to the 
less favorable partition of the liposomes over the Man-HEMA/PEG two-phase 
system. 
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Calcein liposomes were less stable upon release from mannan than after 
release from dextran microspheres. As no instability of calcein liposomes was 
observed in the surrounding buffer during the first five days, we can conclude that the 
instability of the liposomes was not caused by the microsphere preparation. 
Degradation products of man-HEMA may be responsible for the observed 
destabilization of the liposomes and leakage of calcein. Furthermore, PorA (from 
OMV or liposomes) showed decreased antigen recovery upon release from both 
dextran and mannan microspheres (Fig. 6). This could be due to protein 
denaturation, or to binding of degradation products to the P1.4 epitope. Both 
possibilities would impede the interaction of PorA with the monoclonal Ab. The 
monomer bands of PorA in homogenates from microspheres incubated for 14 days at 
37ºC and visualized by SDS-PAGE gels were located lower than those of 
non-encapsulated PorA (Fig. 7), suggesting hydrolysis of the PorA polypeptide chain. 
However, this could also be due to the presence of the polymers and degradation 
products thereof, which might protect PorA against SDS-induced unfolding in linear 
monomers. This would result in a more globular form of PorA that would run faster in 
the SDS-PAGE gel. Decreased antigen recovery has been reported previously for 
tetanus toxoids released from PLGA microspheres [32]. In this case the decreased 
amount of released antigen was explained by surface adsorption of the toxoid to 
hydrophobic surfaces such as PLGA microspheres. In our system, however, the 
adsorption mechanism is probably different, as the polymers used are not 
hydrophobic. 
The release profiles measured in the supernatants of microspheres with 
calcein liposomes (fluorescence) or OMV (antigen recovery) were similar (Fig. 4 and 
5). In both cases, no release was detected the first 5 days of incubation and close to 
zero-order release was observed from day 5 to day 10. However, in homogenized 
samples the antigen was already detected after 2-3 days. Swelling of the 
microspheres and partial degradation of the crosslinks causes increased mesh size. 
This increased mesh size could allow the monoclonal antibodies to partially enter the 
microspheres and therefore interact with the antigen located near the microsphere 
surface.  
The particle size distribution of dextran and mannan microspheres showed 
that microspheres smaller and larger than 10 µm were present. These microspheres 
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will probably follow different processing pathways in vivo. The small microspheres 
can be taken up easily by APC, whereas the large microspheres cannot be 
phagocytosed but will probably provide a reservoir of antigen [2]. In Fig. 3, the 
particle size distribution is expressed as volume weight diameter. Provided that the 
encapsulation of the antigen (i.e. OMV and PorA-liposomes) was homogeneous in 
both microsphere populations, about 40-45% of the PorA dose would be present in 
the small microspheres (<10 µm) and 55-60% in the larger microspheres, which 
cannot be endocytosed by APC. The separation of the PorA dose in a fraction that 
can be phagocytosed and a fraction that cannot be phagocytosed may have 
consequences for the immunogenicity. Encapsulated PorA-liposomes or OMV 
maintained their immunogenicity as compared to non-encapsulated PorA 
formulations (Table 3). The presence of two types of microspheres, i.e. large and 
small microspheres may affect the immunogenicity of encapsulated antigens. The 
smaller microspheres are probably taken up by APC, where they may end up in 
endosomal compartments. As the degradation of ester bonds is catalyzed by 
hydroxyl ions [33], the acidic environment of the endosomes probably results in 
slowing down of the microsphere degradation, thereby inhibiting intracellular antigen 
release. Future studies are needed to determine the intracellular fate of small 
microspheres. Further, it would be interesting to compare the immunogenicity of 
small and large microspheres loaded with antigen. 
The use of modified mannan instead of dextran to prepare microspheres did 
not improve the immunogenicity of the encapsulated PorA. Mannan has been shown 
to have an adjuvant effect [34], presumably via recognition by the mannose receptor 
of APC. In the study by Apostopoulos et al., mannan conjugated to the antigen was 
used. In a recent study, the improvement of the uptake of mannosylated liposomes 
by APC expressing the mannose receptor has been related with the spacer length 
between the liposome and the mannose head group [35]. In our microspheres, the 
DS is quite low, which would result in large amounts of mannose residues on the 
surface of the microspheres. However, the orientation of the mannose residues at the 
microsphere surface is unknown and may not be optimal for interaction with the 
mannose receptor. Another reason for the lack of extra effect of mannan on the 
immune response as targeting device for APC as compared to dextran could be the 
presence of other receptors on the surface of APC with affinity for dextran. Indeed, it 
has been shown recently in mice that APC express a receptor homologue to 
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DC-SIGN with high affinity for dextran [36]. Whether or not this receptor also has 
affinity for mannan is unknown. Further studies are needed to determine the uptake 
of mannan and dextran microspheres by APC.  
In conclusion, in this study we have demonstrated that PorA-liposomes and 
OMV can be encapsulated with a high efficiency (70-90%) in dextran and mannan 
microspheres. In vitro studies showed that encapsulated calcein liposomes were 
released almost quantitatively. Although the antigen was not completely recovered, 
its trimeric structure was preserved. Importantly, in vivo studies revealed that the 
immunogenicity of the encapsulated antigen was maintained. This opens possibilities 
to use these systems for improved vaccines. Points for further investigation are the 
size of the microspheres, improvement of the antigen recovery, study of targeting to 
APC and co-encapsulation of adjuvants in the microspheres. Moreover, it can be 
foreseen that by combination of non-encapsulated antigens and microspheres 
varying in surface and release characteristics, single shot vaccines can be obtained. 
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Summary 
 
There is a great need for vaccines against Neisseria meningitidis serogroup B. 
This is especially important in Western European countries, were approximately two 
thirds of the cases of meningococcal disease can be attributed to serogroup B strains 
[1,2]. Against this serogroup, traditional vaccines based on capsular polysaccharides 
are not effective. The immunogenicity of the capsular polysaccharide of group B 
meningococci is low, due to structural similarity with epitopes expressed by host 
neural tissue [3]. During the search for vaccine candidates against serogroup B 
meningococci, most attention has been focused on PorA. Por A is considered as an 
immunondominant antigen [4]. The vaccine potential of PorA embedded in outer 
membrane vesicles (OMV) developed by different groups has been studied in various 
clinical trials [5,6,7]. The vaccine presently being developed by the Netherlands 
Vaccine Institute (NVI) is based on OMV purified from genetically modified 
meningococcal strains each expressing three different PorA serosubtypes (trivalent 
OMV) [8]. The vaccine contains a mixture of two different trivalent OMV, which 
together represent the majority of PorA serosubtypes circulating in the Netherlands 
and other European countries [9]. The serosubtype P1.7-2,4 is present in up to 40% 
of the serogroup B strains causing bacterial meningitis [2]. Thus, a PorA-based 
vaccine should cover at least this subtype. On the other hand, PorA P1.7-2,4 is one 
of the least immunogenic serosubtypes in OMV [5,10]. For these reasons, PorA 
P1.7-2,4 was the serosubtype of choice for our studies. The objective of the work 
described in this thesis was to improve the immunogenicity of PorA by optimization of 
the presentation form. For this purpose, three lines of investigation were followed: 
− A detailed study of physicochemical and immunochemical characteristics of 
PorA and its presentation form. The tools developed to characterize PorA and 
their presentation forms were used to monitor the stability of PorA formulated 
in different types of OMV.  
− Preparation of well-defined liposomal PorA formulations and exploitation of 
various targeting strategies for dendritic cells (DC). 
− Utilization of adjuvants co-incorporated in PorA-liposomes.  
In chapter 1, an introduction is given to meningococcal disease, the surface 
structures of meningococci and vaccine candidates against serogroup B 
meningococci. Also, mechanisms involved in the immune response after vaccination 
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are described. Furthermore, an overview is given on antigen delivery systems and 
adjuvants that can be used to obtain improved immunogenic PorA formulations. 
Finally, the aim and outline of this thesis are provided in this chapter.  
The composition of OMV may have an effect on the stability of the 
formulations. In chapter 2, three types of OMV were compared for their stability. The 
OMV investigated contained either one (monovalent) or three different PorA 
serosubtypes (trivalent), the latter with and without class 4 outer membrane protein 
(RmpM). OMV were sensitive to elevated temperatures (37ºC and 56ºC), resulting in 
destruction of the OMV structure and denaturation of PorA, followed by chemical 
degradation, as well as a decrease or complete loss of immunogenicity. When stored 
under conventional storage conditions (4ºC), all three OMV were stable for at least 
one year in both the liquid and the freeze-dried state. 
A purification method for PorA P1.7-2,4 was developed in chapter 3. Purified, 
lipopolysaccharide (LPS) depleted PorA was characterized in detail: its conformation 
was monitored by electrophoretic and spectroscopic techniques, its antigenicity was 
measured using a bactericidal anti-P1.4 monoclonal antibody and its immunogenicity 
was determine in Balb/c mice. No differences were detected in the conformation of 
purified PorA as compared to PorA embedded in OMV or outer membrane 
complexes (OMC). Although the ability of purified PorA to interact with a specific 
anti-P1.4 bactericidal monoclonal antibody was increased upon purification, purified 
PorA failed to induce a bactericidal antibody response in mice, as expected. The 
failure to induce a serum bactericidal response was also observed for heat denatured 
PorA in OMV. The immunogenicity of purified PorA was recovered upon 
incorporation into plain liposomes, i.e. in the absence of other adjuvants. These 
results led us to conclude that both the conformation and the presentation form of 
PorA dictate the quality of the immune response.  
Next, the possibility of improving the immunogenicity of liposomal PorA 
through targeting to DC was explored. Dendritic cells are the most efficient antigen 
presenting cells (APC), being able to initiate and modulate immune responses [11]. 
In chapter 4, the interaction with and uptake of PorA-liposomes by murine DC was 
studied. Several types of PorA-liposomes were used, differing in membrane 
composition. The liposomal formulations were designed to optimize their uptake by 
DC through different mechanisms: a) by targeting to the mannose receptor by use of 
mannosylated liposomes; b) by targeting to the phosphatidylserine (PS) receptor 
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using liposomes with PS in the bilayer or c) by a non-specific electrostatic interaction 
with DC, using positively charged liposomes. All these strategies resulted in 
improved liposome uptake by DC in vitro when compared to plain liposomes. The 
improved uptake was accompanied by increased expression of maturation markers 
and induction of IL-12 production. Liposomes targeted to the mannose receptor of 
DC were also found to target APC more efficiently in vivo: they showed enhanced 
localization in APC of draining lymph nodes after subcutaneous immunization, as 
compared to non-targeted liposomes. After immunization of mice, the percentage of 
responding mice per group was increased in groups immunized with targeted 
liposomes. However, in the responding mice, targeted liposomes showed equal 
functional immunogenicity (i.e. induction of bactericidal antibodies) as non-targeted 
liposomes and OMV. In conclusion, the marked positive effect of targeting observed 
in vitro was not translated to the in vivo response. 
In another set of experiments (chapter 5), the interaction with and uptake by 
DC of targeted and non-targeted liposomes (i.e. similar formulations as described in 
chapter 4) was studied in vitro both in human DC and murine DC. In these systems, 
liposomes targeted to the mannose receptor or interacting with DC through 
non-specific electrostatic forces showed enhanced association with and uptake by 
DC. The uptake of mannosylated liposomes could be blocked with mannan in the 
cultures with human DC, but not with murine DC. This difference was ascribed to 
differences in culture conditions and origin of the cells (monocyte-derived in the 
human system and bone-marrow derived in the murine system). The overall 
conclusion of these experiments was that liposomes could be efficiently targeted to 
both human and murine DC. 
In chapter 6, the use of adjuvants to improve the immunogenicity of PorA was 
explored. For this purpose, LPS-derived adjuvants: monophosphoryl lipid A (MPL) 
and the detoxified lpxL1 mutant of LPS were used. LPS-derived adjuvants were 
chosen because they are easily incorporated into the liposomes and their structure is 
similar to that of LPS, the natural adjuvant present in the outer membrane of 
meningococci. As a positive controls, liposomes were adjuvated with galE LPS, a 
toxic mutant of LPS with high adjuvant activity, and with AlPO4. An improved immune 
response (i.e. significantly increased induction of bactericidal antibodies and 100% 
responders in the groups) was observed with galE LPS and lpxL1 LPS. However, the 
type of response was different, as only galE LPS resulted in an improved Th1 type 
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immune response, with increased production of IgG2a antibodies relative to IgG1 
antibodies. This is desirable, as IgG2a and IgG2b subclasses are capable to activate 
the complement system and induce a bactericidal immune response [12]. In mice 
immunized with lpxL1 LPS-adjuvated liposomes an overall increase in the levels of 
IgG of all subtypes was observed. The increased induction of bactericidal serum 
activity observed in mice immunized with lpxL1 LPS-adjuvated liposomes was 
accompanied with an improved (PorA-specific) proliferation of lymph node cells after 
in vitro restimulation with PorA, as compared to non-adjuvated PorA-liposomes. In 
addition, proliferating cells produced high levels of IL-2 (a Th1 type cytokine), 
whereas the production of IL-10 (a Th2 type cytokine) was not increased. 
Biodegradable microspheres were investigated in chapter 7 as potential 
antigen delivery systems for both PorA-liposomes and OMV. Small microspheres 
(<10 µm) can be phagocytosed by APC and larger microspheres (> 10 µm) may act 
as a depot at the injection site while attracting APC. Dextran- and mannan-based 
microspheres with comparable size distribution were prepared containing 
PorA-liposomes or OMV. Both systems were designed to obtain a fast release of the 
antigen after administration. The ultimate purpose of these formulations is to improve 
the delivery of PorA to APC. Mannan, a polymer of mannose, has adjuvant properties 
[13]. Mannose residues located on the surface of the mannan microspheres may 
result in an improved microsphere uptake by APC and, consequently, in an improved 
immunogenicity of PorA-liposomes or OMV encapsulated in these microspheres. 
PorA liposomes or OMV were released in vitro from both dextran and mannan 
microspheres in a sustained manner between day 5 and day 10-11 when incubated 
at 37ºC. The trimeric structure of PorA was maintained after release from both 
microsphere types. Despite incomplete recovery of released antigen in vitro, the 
immunogenicity of microencapsulated PorA-liposomes and OMV was maintained. 
 
Perspectives 
 
From the studies presented in this thesis it is clear that liposomes are a very 
suitable presentation form for PorA. Not only are the physicochemical characteristics 
and the immunogenicity of the protein maintained, but liposomes also allow the 
incorporation of adjuvants and the coupling of targeting ligands to the surface of the 
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liposomes to enhance the PorA-specific immune response. Moreover, the bilayer 
building liposome components (phospholipids) have low intrinsic immunogenicity.  
In comparison with liposomes, the composition of OMV is not well defined. 
The composition of OMV varies among different strains and is also influenced by the 
growth conditions and the isolation method. Besides, the presence of a number of 
outer membrane proteins predicted by reversed vaccinology has been demonstrated 
[14]. These outer membrane proteins are not detected by conventional techniques 
(because they are normally present in minute amounts in the outer membrane) and 
add to the lack of knowledge about the exact composition of OMV. The presence of 
outer membrane proteins other than PorA may have a positive effect on the immune 
response against OMV, by inducing cross-reactive antibodies that would increase the 
coverage of the vaccine. Here again, the use of liposomes would be advantageous to 
separately study the contribution of each outer membrane protein to the 
immunogenicity of the vaccine.  
In chapter 2 of this thesis we demonstrated that both trivalent and monovalent 
OMV were stable for 1 year when stored at 4ºC. However, for a commercial product 
a shelf life of at least 2 years is desired. If stability of OMV in the liquid state for 
prolonged periods would turn out to be problematic (as might be derived from the 
accelerated stability studies at 37ºC and 56ºC), freeze-drying may be an alternative. 
In that case, however, the freeze-drying process of OMV has to be further 
investigated in order to prevent aggregation of the vesicles. This can be done by 
monitoring the effects of different process conditions, i.e. freezing rate, primary and 
secondary drying phase, or reconstitution [15] on their physicochemical stability and 
immunogenicity. The critical step(s) in these processes should be identified and 
optimized. Furthermore, the aggregation of OMV is possibly preventable by use of 
other lyoprotectants than sucrose (e.g. maltose, trehalose). The stability of the 
liposomal formulations used in other chapters of this thesis remains to be 
investigated. Liposomes can be prepared with high physical stability [16] and freeze-
drying of liposomes is feasible [17,18]. Because of the similarities between 
PorA-liposomes and OMV, the tools used to investigate the stability of OMV can also 
be applied for monitoring the stability of liposomal PorA formulations.   
In the experiments with liposomal PorA described in this thesis, PorA was 
purified from monovalent OMV. Another source of PorA that was not studied in this 
thesis are inclusion bodies derived from Escherichia coli. This recombinant PorA may 
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be advantageous to use with respect to purity and yield, as compared to PorA 
purified from OMV. Indeed, in the PorA purified from monovalent OMV, traces of 
neisserial LPS were still present (chapter 3). A study should be done comparing the 
structures of PorA derived from these two sources. The use of recombinant PorA 
allows the investigation of other important PorA serosubtypes as well. For instance, 
making an artificial trivalent OMV (i.e., liposomes containing three different 
recombinant PorA serosubtypes). In this way, the decreased immunogenicity that 
was observed for PorA P1.7-2,4 in trivalent OMV [5] can be studied in detail. 
Successful DC targeting in vitro is no guarantee for enhanced functional 
immunogenicity in vivo, as was shown in chapter 4. The lack of correlation between 
effects of targeting in vitro and bactericidal response in vivo may be due to the 
complexity of the interactions between liposomes and various cell types and tissues 
in vivo. For instance, the mannose receptor to which mannosylated liposomes were 
targeted is not only present on DC or APC, but in a variety of other cells and tissues 
as well. Also, there is not only one receptor with affinity for mannose, but a whole 
family of receptors [19]. In future studies, the use of more specific targeting ligands 
(e.g. use of monoclonal antibodies directed to receptors expressed exclusively by 
DC) may result in improved functional immunogenicity. It is difficult, however, to find 
a specific DC target. DEC-205, a receptor for endocytosis has been described as a 
possible specific target on DC [20]. However, it has been demonstrated that DEC-
205 is not only expressed by DC, but also by thymic, pulmonary and intestinal 
epithelia as well as B-cells [19]. A unique DC receptor is yet to be found. Antibodies 
against Fc receptors can also be used as targeting devices. Fc receptors are 
expressed on the surface of many APC (e.g. B-cells, macrophages) [21]. A question 
that remains to be answered is whether specific DC targeting is more effective in 
raising a functional immune response than targeting to APC in general.  
In addition to difficulties related with the extrapolation of in vitro data to in vivo 
effects, the predictability of animal experiments for the human situation remains a 
critical issue. This is illustrated by the fact that murine DC and human DC seem to 
differ regarding recognition and uptake of (targeted) PorA-liposomes (chapter 5). 
However, to further unravel and properly compare the interactions of antigen 
presentation forms with murine and human DC, efforts should be made to obtain 
well-characterized murine and human DC with similar characteristics (e.g. receptor 
and maturation markers expression). Furthermore, in vitro culture conditions should 
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be relevant to the in vivo situation of the cells. Also, the use of more specific targeting 
ligands for both human and murine DC can help to understand the pathways of 
antigen processing (e.g. uptake mechanism involved) that result in an improved 
immune response. With this information, more appropriate ligands could be designed 
and tested, coupled to antigen delivery systems (e.g. liposomes). 
The results presented in chapter 6 suggest that an enhanced PorA-specific 
Th1 type immune response correlates with an improved functional immunogenicity 
against meningococci. However, absolute and relative Th1 and Th2 type response 
levels leading to optimum protection against meningococcal disease are yet to be 
established. Further PorA-specific T-cell proliferation studies are needed to 
determine the production pattern of cytokines (e.g. IL-2, IL-10, INF-γ, TNF-α, IL-12) 
by activated T-cells and the kinetics of the production of these cytokines. This will 
help to confirm the type of response (Th1/Th2) induced by adjuvated PorA-liposomes 
and to gain insight in the desired characteristics of PorA-formulations. In follow-up 
studies, the effect of the formulation (e.g. use of other adjuvants, effect of targeting to 
DC) on the T-cell activation induced by liposomal PorA should be tested, in order to 
characterize in detail the type of T-cell responses associated with improved 
PorA-specific bactericidal responses. 
The studies presented in chapter 7 show that dextran- and mannan-based 
microspheres are promising delivery systems for PorA-liposomes or OMV, provided 
that optimization of the microsphere characteristics is pursued. The microspheres 
used in our studies had a rather broad size distribution, with small microspheres 
(size < 10 µm) and large microspheres (size > 10 µm). The presence of large and 
small microspheres results in mixed antigen processing routes. The small 
microspheres were probably taken up by APC, and would then end up in endosomal 
compartments. It cannot be predicted what would happen at the low pH of late 
endosomal compartments, as the degradation of microspheres is retarded by low pH, 
and the antigens may not become available in time for presentation by MHC 
molecules. Information regarding the release rate could be collected by monitoring 
the stability of antigen loaded in microspheres incubated at low pH. On the basis of 
this information, microspheres might be designed with faster release kinetics at low 
pH. In contrast to small microspheres, the larger microsphere particles will probably 
not be taken up by APC, but will rather form a depot at the injection site. The release 
of the antigen will occur upon degradation of the microspheres. Follow-up 
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experiments are needed to study the effect of the microsphere size on the 
immunogenicity of the encapsulated PorA formulations, i.e. separating large 
microspheres from small microspheres and studying the effect of microsphere size 
on the immunogenicity of the encapsulated antigen. Finally, the maintained 
immunogenicity of PorA-liposomes and OMV upon encapsulation brightens the 
prospects to use these formulations for single-shot PorA vaccination schedules. In 
our system, the antigen was released after 5 days of incubation at 37ºC. By 
modifying characteristics of the polymer (e.g. degree of substitution, type of 
crosslinks) and/or the microspheres (e.g. initial water content), longer delay periods 
for the release of encapsulated antigen can be obtained [22]. By combining in one 
injection immediately available PorA-liposomes or OMV with presentation forms that 
release the antigen pulse-wise after a delay time of weeks or even months, 
single-shot systems could be obtained. In these systems, one injection would mimic 
the immunization and booster administration of the vaccine. 
In this thesis, liposomes were studied as a presentation form for PorA, as an 
alternative for OMV. Other presentation forms, such as ISCOMs or virosomes remain 
to be studied. ISCOMs are very stable spherical micellar assemblies composed of 
the saponin mixture QuilA, cholesterol and phospholipids, which present membrane 
proteins as multimers. The use of ISCOMs may offer advantages as compared to 
plain liposomes because of the adjuvant effect derived from the presence of QuilA 
[23]. Another presentation form that may be suitable for PorA are virosomes. 
Virosomes have a similar structure to liposomes, but contain influenza hemagglutinin 
(HA) in addition to phospholipids. The presence of HA confers virosomes a fusogenic 
activity, and acts as a targeting device; binding to sialic acid residues present on 
APC [23]. These characteristics allow virosomes to stimulate both humoral and 
cellular immune responses.  
The PorA dose used in our immunization studies was relatively low (1.5 µg) as 
compared to the dose used in investigations from other groups (10-20 µg) [24,25]. A 
dose-response study was only performed with plain (i.e. non-targeted, non-adjuvated 
PorA) liposomes (chapter 3). In this case, the increase of the PorA dose did not 
result in increased immunogenicity. Based on this study, the lowest PorA dose tested 
(1.5 µg) was used for further experiments described in this thesis. Still, an even lower 
dose of PorA might have served to unmistakably observe enhanced immunogenicity 
of targeted and/or adjuvated liposomes as compared to plain ones. Additional studies 
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should be done with the (improved) PorA-liposomes to determine whether the PorA 
dose needed to induce a bactericidal response could be decreased or not.  
The administration route used in the immunogenicity studies described in this 
thesis was the subcutaneous route. The administration route chosen should be in 
accordance with the presentation form of the vaccine and the effect pursued. Thus, 
when studying presentation forms with specific targeting moieties for dendritic cells, 
the intradermal administration route could be advantageous. Through this route, the 
layer of Langerhans cells (immature DC) located in the epidermis [26] may be easily 
reached. However, the administration of vaccines via the intradermal route is difficult 
and the injections may be quite painful. Moreover, the mouse skin is very thin 
compared to human skin and only low volumes can be injected (maximal 100 µl per 
injection site). Attempts were made to administer targeted PorA-liposomes via the 
intradermal route (results not shown). This did not lead to improved immunogenicity 
of the formulations with respect to the subcutaneously administered ones. Studies 
with confocal microscopy on the localization of fluorescently labeled liposomes at the 
injection site reveled that only a small fraction of the liposomes administered was 
located near the immune cells of the skin, and the majority of the dose was located 
subcutaneously. To overcome the drawbacks of intradermal injections, new delivery 
devices are being developed. Among these are Macroflux® microprojection array 
patches [27]. In this system, antigens are coated as a dry film on the microneedles in 
the patch, and it was proven that the depth of skin penetration was sufficient to allow 
antigens to reach skin immune cells (i.e. Langerhans cells). Detailed formulation 
studies have to be done in order to adapt this system to (liposomal) PorA 
formulations.  
In conclusion, the studies presented in this thesis demonstrate the potential of 
liposomes as PorA delivery systems.  
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Achtergrond 
 
De meningokok ofwel Neisseria meningitidis is een gramnegatieve bacterie 
die bacteriële meningitis (hersenvliesontsteking, nekkramp) en bloedvergiftiging 
(sepsis) kan veroorzaken. Ongeveer 10% van de bevolking draagt N. meningitidis in 
de keelholte. In de meeste gevallen treden geen ziekteverschijnselen op. De bacterie 
wordt overgedragen via direct contact met nasaal of oraal slijm of via inademing van 
kleine druppeltjes, bijvoorbeeld door niezen of hoesten. In een klein aantal mensen 
leidt dragerschap tot meningitis of bloedvergiftiging. De meeste gevallen komen voor 
bij kinderen jonger dan vijf jaar en adolescenten. Tien tot dertig procent van de 
patiënten overlijdt aan de ziekte. In veel gevallen houdt de patiënt ernstig blijvend 
letsel over van de infectie  
In West-Europese landen wordt ongeveer twee derde van de infecties door 
meningokokken veroorzaakt door serogroep B. Daarom is er grote behoefte aan 
vaccins tegen N. meningitidis serogroep B. Traditionele vaccins tegen 
meningokokken, welke gebaseerd zijn op polysacchariden (suikerketens) uit het 
kapsel, zijn niet werkzaam tegen serogroep-B-meningokokken. Polysacchariden van 
serogroep B zijn namelijk nauwelijks immunogeen. Dit komt waarschijnlijk doordat 
hun structuur gelijkenis vertoont met die van suikerketens welke in de hersenen 
voorkomen. Tijdens het zoeken naar vaccinkandidaten werd de meeste aandacht 
gericht op PorA, een porievormend buitenmembraaneiwit. PorA is in staat 
bacteriedodende (bactericide) antistoffen op te kwekken en wordt beschouwd als een 
immunodominant antigeen. Bactericide antistoffen zijn nodig voor de bescherming 
tegen meningokokkenziekte. Het vaccin dat nu in ontwikkeling is bij het Nederlands 
Vaccin Instituut (NVI) is gebaseerd op buitenmembraanvesicles (in het Engels outer 
membrane vesicles, OMV). Deze worden gezuiverd uit genetisch gemodificeerde 
meningokokkenstammen waarin drie verschillende PorA’s tot expressie komen 
(trivalente OMV). Het vaccin is een mengsel van twee verschillende trivalente OMV, 
waarin de PorA’s vertegenwoordigd zijn die het meest voorkomen in Nederland en 
andere Europese landen. Van de door serogroep B stammen veroorzaakte 
meningitis gevallen wordt bijna 40% veroorzaakt door het subtype P1.7-2,4. Een op 
PorA gebaseerd vaccin zal dus dit subtype moeten bevatten. Aan de andere kant is 
PorA P1.7-2,4 een van de minst immunogeen subtypen in OMV. Om deze redenen is 
PorA P1.7-2,4 gekozen als model voor onze studies. 
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Het doel van het in dit proefschrift beschreven onderzoek was het verbeteren 
van de immunogeniciteit van PorA P1.7-2,4 door gebruik te maken van betere 
presentatievormen voor het eiwit. Om dit doel te bereiken werden drie 
onderzoeksrichtingen gevolgd: 
- Een gedetailleerd onderzoek van de fysisch-chemische karakteristieken en 
de formulering van PorA. De methoden ontwikkeld om PorA en de 
presentatievorm van PorA te karakteriseren werden gebruikt om de 
stabiliteit van PorA in verschillende OMV-types te bestuderen. 
- De bereiding van goed gedefinieerde liposomale PorA-formuleringen en 
het gebruik van moleculen aan het oppervlak van de liposomen die een 
verbeterde interactie met dendritische cellen (DC), een belangrijke celtype 
van het afweersysteem, tot stand brengen. 
- Het gebuik van adjuvantia, stoffen die in staat zijn de immunogeniciteit van 
(liposomaal) PorA te verbeteren.  
 
Opbouw van het proefschrift 
 
Hoofdstuk 1 geeft een introductie over de meningokokkenziekte en beschrijft 
de oppervlakte-eiwitten van meningokokken. Tevens wordt aangegeven welke van 
deze eiwitten mogelijke vaccinkandidaten zijn tegen serogroep-B-meningokokken. 
Vervolgens worden de mechanismen die het afweersysteem gebruikt na vaccinatie 
beschreven, samen met de mogelijke formuleringen en adjuvantia die gebruikt 
kunnen worden om de immunogeniciteit van PorA te verbeteren. Tenslotte worden 
het doel en de opbouw van het proefschrift aangegeven. 
De samenstelling van OMV zou een effect kunnen hebben op de stabiliteit van 
de formuleringen. In hoofdstuk 2 wordt de stabiliteit van drie verschillende typen 
OMV vergeleken. De in dit hoofdstuk bestudeerde OMV bevatten één PorA 
(monovalente OMV) of drie PorA’s  (trivalente OMV). Twee typen trivalente OMV zijn 
bestudeerd: met en zonder klasse-4-buitenmembraaneiwit (RmpM). Wanneer de 
OMV in vloeibare of gevriesdroogde vorm bewaard werden bij 4ºC, de standaard 
bewaartemperatuur, bleven ze gedurende minstens een jaar stabiel, ongeacht hun 
samenstelling. Na versnelde stabiliteitstudies, d.w.z. opslag bij 37ºC en 56ºC, waren 
duidelijke effecten waarneembaar: de structuur van zowel de vesicles als PorA ging 
verloren. Hierbij ging de immunogeniciteit van PorA gedeeltelijk of geheel verloren.  
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Een zuiveringsmethode voor PorA P1.7-2,4 werd ontwikkeld in hoofdstuk 3. 
Gezuiverd PorA werd in detail gekarakteriseerd: de vouwing van PorA werd 
bestudeerd met elektroforetische en spectroscopische technieken, de antigeniciteit 
(het vermogen herkend te worden door antistoffen) werd gemeten met gebruik van 
bactericide anti-P1.4-antistoffen en de immunogeniciteit (het vermogen om een 
immuunrespons op te wekken) werd bepaald in Balb/c-muizen. De conformatie van 
gezuiverd PorA kwam overeen met die van PorA in OMV of in 
buitenmembraancomplexen (OMC). Hoewel gezuiverd PorA een betere interactie 
met specifieke anti-P1.4-antistoffen (antigeniciteit) gaf dan PorA in OMV en in 
muizen antistoffen opwekte, bleken die niet functioneel, d.w.z. bacteriedodende te 
zijn, evenmin als gedenatureerd PorA. De functionele immunogeniciteit van 
gezuiverd PorA werd volledig hersteld tot het niveau verkregen met OMV als het in 
liposomen ingebouwd werd. De conclusie van deze studie is dat zowel de 
conformatie als de presentatievorm van PorA de kwaliteit van de immuunrespons 
bepalen.  
Vervolgens werd in hoofdstuk 4 de mogelijkheid onderzocht om de 
immunogeniciteit van PorA bevattende liposomen verder te verbeteren. Hiertoe 
werden aan het oppervlak van de liposomen structuren aangebracht waardoor dat ze 
makkelijker binden en vervolgens worden opgenomen door DC, welke beschouwd 
worden als de meest efficiënte antigeenpresenterende cellen (APC). De interactie 
tussen zulke doelzoekende PorA-liposomen en DC afkomstig van de muis (murine 
DC) werd onderzocht. De liposomale formuleringen werden zo gekozen dat de 
opname van PorA-liposomen door DC via verschillende mechanismen zou kunnen 
worden verbeterd: a) gemannosyleerde liposomen: liposomen die aan hun oppervlak 
voorzien zijn van mannosegroepen waardoor ze door de mannosereceptor op de DC 
herkend en via deze receptor opgenomen kunnen worden; b) liposomen voorzien 
van fosfatidylserine waardoor ze via de fosfatidylserinereceptor op de DC 
opgenomen kunnen worden; of c) positief geladen liposomen die aspecifieke 
elektrostatische interacties met negatief geladen DC aangaan. Elk van deze 
doelzoekstrategieën had een verbeterde opname van liposomen door DC, een 
verhoogde expressie van maturatiemarkers en inductie van IL-12-productie tot 
gevolg. Gemannosyleerde liposomen werden na immunisatie in hogere mate 
teruggevonden in lymfkliercellen dan ‘kale’ (negatief geladen), niet doelzoekenden 
liposomen. Het percentage muizen met bacteriedodende antistoffen was hoger in de 
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groepen die geïmmuniseerd waren met doelzoekende PorA-liposomen dan in de 
groep muizen die niet doelzoekende PorA-liposomen toegediend hadden gekregen. 
De concentratie aan bacteriedodende antistoffen in de muizen die geïmmuniseerd 
waren met doelzoekende liposomen was echter niet hoger dan in de muizen die niet 
doelzoekende liposomen of OMV toegediend hadden gekregen. De conclusie is dat 
het positieve effect van doelzoekende PorA-liposomen dat gezien werd in vitro niet 
volledig werd vertaald naar de respons in vivo.  
In andere experimenten (hoofdstuk 5) werd in vitro de interactie met en 
opname door DC van doelzoekende en niet doelzoekende liposomen (dezelfde 
formuleringen als in hoofdstuk 4 werden gebruikt) onderzocht in humane en murine 
DC. In beide systemen lieten gemannosyleerde liposomen en positief geladen 
liposomen een verhoogde associatie met en opname door DC zien. De opname van 
gemannosyleerde liposomen door humane DC werd geblokkeerd door mannaan, in 
tegenstelling tot murine DC. Dit verschil zou veroorzaakt kunnen zijn door de 
verschillende kweekcondities en oorsprong van de cellen (uit monocyten in het 
humane systeem en uit het beenmerg in het muissysteem). Uit deze studies werd 
geconcludeerd dat doelzoekende liposomen efficiënt afgeleverd kunnen worden aan 
humane en murine DC. 
In hoofdstuk 6 werden adjuvantia gebruikt om de immunogeniciteit van 
liposomaal PorA te verbeteren. Voor dit doel werden van LPS afgeleide adjuvantia 
gebruikt: het veelgebruikte monofosforyl lipid A (MPL) en een meningokokken LPS 
met verminderde toxiciteit, gemaakt door de zg. pxL1-mutant. De keuze van deze 
adjuvantia was gebaseerd op het feit dat deze makkelijk ingebouwd kunnen worden 
in liposomen en de structuur vergelijkbaar is met die van LPS, het endotoxine van 
meningokokken dat ook als adjuvans kan fungeren. Als positieve controles werden 
liposomen geadjuveerd met galE-LPS, een toxische mutant van meningokokken-LPS 
met een hoge adjuvansactiviteit, en met colloïdaal aluminiumfosfaat. Verhoogde 
immunogeniciteit (ofwel verhoogde productie van bacteriedodende antistoffen) werd 
gezien bij liposomen geadjuveerd met galE-LPS en lpxL1-LPS. Het type 
immuunrespons was echter anders omdat alleen galE-LPS een betere Th1-type 
respons veroorzaakte met een verhoogde productie van IgG2a-antistoffen ten 
opzichte van IgG1-antistoffen. Dit is gewenst omdat IgG2a- en IgG2b-antistoffen het 
complementsysteem kunnen activeren om bacteriën te doden. In muizen die 
geïmmuniseerd waren met lpxL1-LPS-geadjuveerde PorA-liposomen waren de 
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serumconcentraties van alle IgG-isotypen verhoogd ten opzichte van niet-
geadjuveerde liposomen. Geïsoleerde lymfklierknopen van muizen die 
geïmmuniseerd waren met lpxL1-geadjuveerde liposomen lieten, na restimulatie 
in vitro met PorA, een sterkere PorA-specifieke celproliferatie zien ten opzichte van 
niet-geadjuveerde liposomen. Tegelijkertijd produceerden deze cellen ook grote 
hoeveelheden IL-2 (een Th1-type cytokine), terwijl de productie van IL-10 (een 
Th2-type cytokine) niet was verhoogd. 
Afbreekbare microsferen werden in hoofdstuk 7 onderzocht op hun 
toepasbaarheid als afgiftesystemen voor PorA-liposomen en OMV. Kleine deeltjes 
(< 10 µm) kunnen opgenomen worden door antigeenpresenterende cellen (APC), 
terwijl grotere deeltjes (> 10 µm) op de injectieplaats als depot kunnen fungeren en 
daarbij wellicht APC aantrekken. De gebruikte microsferen waren gebaseerd op 
dextraan of mannaan en hadden een vergelijkbare grootte. In de microsferen waren 
porA of OMV ingebouwd. Beide systemen waren ontwikkeld om ingebouwde PorA-
liposomen of OMV na toediening snel af te geven. Het uiteindelijke doel van deze 
formuleringen was een verbeterde aflevering van PorA aan APC. Mannaan, een 
polymeer van mannose, heeft adjuvanseigenschappen. Mannoseresiduen aan het 
oppervlak van de microsferen zouden herkend kunnen worden door APC 
veroorzaken, waardoor de immunogeniciteit van de ingebouwde PorA-liposomen of 
OMV verbeterd zou kunnen worden. Tijdens in vitro incubatie (37ºC) van beide typen 
microsferen (dextraan en mannaan) werden PorA-liposomen en OMV tussen dag 5 
en dag 11 gelijkmatig afgegeven. De trimeerstructuur van PorA na afgifte uit beide 
microsferen was behouden. De immunogeniciteit van de ingebouwde 
PorA-liposomen en OMV bleef gehandhaafd ondanks het feit dat het antigeen niet 
volledig afgegeven werd.  
 
Conclusie 
 
Dit proefschrift toont aan dat liposomen heel geschikte presentatievormen zijn 
voor op PorA gebaseerde vaccins. De fysisch-chemische karakteristieken en de 
immunogeniciteit van het eiwit blijven behouden. Bovendien kan de immunogeniciteit 
van PorA verbeterd worden door adjuvantia en APC-herkennende moleculen in de 
liposomen in te bouwen.  
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Introducción 
 
Neisseria meningitidis, también llamados meningococos, es una bacteria 
gram-negativa causante de meningitis y septicemia. Aproximadamente un 10% de la 
población es portadora de esta bacteria en la laringe, sin desarrollar síntomas de la 
enfermedad. Este tipo de bacterias se transmiten bien por contacto directo con las 
mucosas nasales y orales, o bien por inhalación de pequeñas partículas que 
contienen la bacteria, por ejemplo por estornudos o tos. En un pequeño número de 
casos, el portador de la bacteria desarrolla la enfermedad. La mayoría de los casos 
de meningitis o septicemia se dan en niños menores de cinco años y en 
adolescentes, de los cuales entre el 10 y el 30% de los casos son mortales. 
Existe una gran necesidad de vacunas contra la meningitis causada por 
meningococos del serogrupo B. Esta necesidad es especialmente acuciante en 
países de Europa occidental, donde prácticamente dos tercios de las infecciones 
causadas por meningococos son atribuibles al serogrupo B. Vacunas tradicionales, 
basadas en polisacáridos (azúcares) de la cápsula bacteriana, no son efectivas 
contra meningococos del serogrupo B, ya que los polisacáridos del serogrupo B no 
producen una respuesta inmunológica adecuada. Probablemente esto se deba a la 
similitud entre las estructuras de estos polisacáridos y otros azúcares presentes en 
tejidos cerebrales. Durante la búsqueda de antígenos que pueden ser utilizados en 
vacunas contra meningococos del serogrupo B, ha suscitado el mayor interés PorA, 
una proteína que forma poros en la membrana exterior de la bacteria. La mayor 
parte de los anticuerpos que se dirigen hacia esta proteína son capaces de destruir 
bacterias por medio de mecanismos que implican la activación del sistema del 
complemento, lo cual es supuestamente necesario para la protección contra 
infecciones causadas por meningococos. La vacuna que está en desarrollo en el 
Instituto Holandés de Vacunas (Nederlands Vaccin Instituut, NVI) está basada en 
vesículas aisladas de la membrana exterior de la bacteria (en Inglés: outer 
membrane vesicles, OMV), purificadas de meningococos genéticamente 
modificados, los cuales expresan tres subtipos diferentes de PorA (OMV trivalentes). 
La vacuna consiste en una mezcla de dos tipos de OMV trivalentes, en la que las 
distintas moléculas de PorA representan a la mayoría de los subtipos que circulan en 
los Países Bajos y Europa occidental. PorA del subtipo P1.7-2,4 está presente en 
aproximadamente un 40% de los meningococos aislados en pacientes. Así, una 
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vacuna basada en PorA debe contener este subtipo. Por otra parte, PorA P.17-2,4 
es uno de los subtipos menos inmunogénicos en OMV. PorA P1.7-2,4 ha sido 
elegido como modelo en esta investigación. El objetivo del trabajo descrito en esta 
tesis es la mejora de la respuesta inmunológica dirigida contra PorA P1.7-2,4, por 
medio del uso de formas de presentación más adecuadas. Para conseguir este 
objetivo, se han seguido tres líneas de investigación: 
- La investigación detallada de las características físico-químicas de PorA y 
sus formas de presentación. Los métodos desarrollados para caracterizar 
PorA y sus formas de presentación han sido utilizados para el estudio de 
la estabilidad de PorA en varios tipos de OMV. 
- La preparación de formulaciones liposomales de PorA bien definidas y el 
uso de moléculas en la superficie de dichas fórmulas específicamente 
dirigidas hacia células dendríticas (CD), que constituyen uno de los tipos 
de células más importantes del sistema inmunológico. 
- El uso de compuestos capaces de mejorar la respuesta inmunológica de 
antígenos pobres, también llamados adyuvantes, incorporados en las 
fórmulas liposomales de PorA. 
 
Organización de la tesis 
 
El capítulo 1 es una introducción sobre la meningitis, las estructuras de la 
superficie de meningococos y los posibles candidatos para vacunas contra la 
meningitis causada por meningococos del serogrupo B. Asimismo, se describen los 
mecanismos que generan la inmunidad creada por vacunas y las posibles 
formulaciones que pueden utilizarse para mejorar la respuesta inmune de PorA. Por 
último, se introducen los objetivos y organización de la tesis.  
Dado que es probable que la composición de las OMV afecte a la estabilidad 
de las formulaciones, el capitulo 2 de esta tesis está dedicado a estudiar la 
estabilidad de tres tipos de OMV diferentes. Las OMV estudiadas contienen un solo 
subtipo de PorA (OMV monovalentes) o tres subtipos de PorA (OMV trivalentes). 
Igualmente, se han estudiado dos tipos de OMV trivalentes, que contienen o no 
proteína de la membrana exterior de clase 4 (también llamada RmpM). Las OMV 
demostraron ser susceptibles a temperaturas elevadas (37ºC o 56ºC), lo cual dio 
lugar a la destrucción de la estructura vesicular de las OMV, la desnaturalización y 
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degradación de la proteína, y la pérdida parcial o total de la capacidad de inducir una 
reacción inmunológica. OMV de los tres tipos estudiados, mantenidas a 4ºC, son 
estables al menos durante un año en forma líquida ó liofilizadas. 
En el capítulo 3, se aborda la descripción de un método para la purificación 
de PorA P1.7-2,4. Asimismo, se caracteriza de forma detallada PorA purificada y 
parcialmente libre de lipopolisacárido (LPS): la conformación de la proteína se 
estudió por medio de métodos electroforéticos y espectrofotométricos, la 
antigenicidad de la proteína se precisó con anticuerpos monoclonales bactericidas 
específicos, y la capacidad de inducir une respuesta inmune fue determinada en 
ratones Balb/c. No se detectaron diferencias en la conformación de PorA purificada o 
PorA en OMV o en complejos de la membrana exterior (en Inglés: outer membrane 
complexes, OMC). Aunque la proteína purificada demostró una mejor capacidad de 
interacción con anticuerpos monoclonales, de acuerdo con resultados previos de 
otros grupos, PorA purificada no fue capaz de inducir anticuerpos bactericidas en 
ratones. De la misma forma, PorA desnaturalizada por calor tampoco indujo 
anticuerpos bactericidas en ratones. Por otra parte, la respuesta inmune producida 
por PorA fue completamente recuperada al formular la proteína en liposomas, sin 
necesidad de añadir adyuvantes. La conclusión de este capítulo es que tanto la 
conformación de la proteína como su forma de presentación determinan el tipo de 
respuesta inmunológica obtenida con el antígeno. 
El siguiente paso (capítulo 4) consistió en valorar la posibilidad de 
incrementar la respuesta inmunológica de PorA en liposomas por medio de 
vectorización a células dendríticas. Este tipo de células son presentadoras de 
antígenos muy eficientes y pueden considerarse únicas, ya que son capaces de 
iniciar y modular la respuesta inmune. En este capítulo se investigó la interacción e 
internalización de PorA liposomal en CD de ratón. Para ello, se produjeron diferentes 
tipos de liposomas, con diferentes composiciones de la membrana liposomal. Estos 
liposomas han sido diseñados como sistemas de vectorización de CD: a) 
vectorización dirigida hacia receptores de manosa en la membrana de CD 
(liposomas con residuos de manosa en la superficie); b) vectorización dirigida al 
receptor de fosfatidilserina (liposomas con fosfatidilserina en la membrana); o c) por 
medio de interacciones no específicas, de tipo electrostático entre liposomas con 
carga positiva y la membrana celular (cargada negativamente). Estas tres 
estrategias dieron como resultado una mejora de la interacción e internalización de 
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liposomas por parte de las CD. Al mismo tiempo, se incrementaron de los niveles de 
expresión de marcadores de maduración celular en CD y producción de interleukina 
12 (IL-12) por parte de éstas. En un siguiente paso, el uso de liposomas 
vectorizados hacia el receptor de manosa en CD tuvo como consecuencia un 
incremento de la internalización de liposomas por células presentadoras de 
antígenos (CPA) en ratones: la localización de estos liposomas se incrementó en 
nódulos linfáticos eferentes tras administración subcutánea, comparada con la 
localización de liposomas no vectorizados. El porcentaje de animales que mostraron 
producción de anticuerpos bactericidas fue superior en ratones inmunizados con 
liposomas vectorizados que en ratones inmunizados con liposomas no vectorizados 
o OMV. A pesar de esto, los niveles de anticuerpos bactericidas en ratones con 
respuesta fueron similares en todos los grupos. En conclusión, el efecto 
marcadamente positivo observado en cultivos celulares no se traslada 
completamente en la respuesta inmunológica. 
En otros experimentos, descritos en el capítulo 5, la interacción e 
internalización por CD de liposomas vectorizados o no (formulaciones similares a las 
usadas en el capítulo 4) se estudió en cultivos celulares de CD de origen humano o 
de ratón. En ambos sistemas, el uso de liposomas vectorizados hacia el receptor de 
manosa o vectorizados por medio de interacción electrostática, obtuvo como 
resultado un incremento de la interacción e internalización por CD. En cultivos de CD 
de origen humano, la interacción de liposomas vectorizados con manosa se puede 
bloquear usando manan, un polímero de manosa, lo cual no fue observado en 
cultivos de células de ratón. Esta diferencia puede estar causada por las diferentes 
condiciones de los cultivos, o por el diferente origen de las células (monocitos en el 
caso de las CD de origen humano, o de la medula ósea en ratones). La conclusión 
de este estudio es que liposomas conteniendo PorA pueden ser eficientemente 
vectorizados hacia CD. 
El capítulo 6, se centró en investigar el uso de adyuvantes para mejorar la 
respuesta inmune contra PorA en liposomas. Así, se estudiaron adyuvantes 
derivados de LPS: monofosforil lípido A (MPL) y el menos tóxico lpxL1 mutante de 
LPS. La elección de estos adyuvantes se basó en el hecho de que estas sustancias 
se pueden incorporar fácilmente en la membrana de liposomas y su estructura es 
similar a la de LPS, el adyuvante natural, aunque extremadamente tóxico, producido 
por meningococos. Se utilizaron como controles liposomas que contenían un 
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derivado de LPS, galE LPS, tóxico aunque con buena actividad adyuvante, o 
mezclados con AlPO4. A partir de ahí se observo un incremento en la respuesta 
inmune de PorA (es decir, en el nivel de anticuerpos bactericidas en suero de 
ratones inmunizados) en liposomas que contenían galE LPS y lpxL LPS. De todas 
maneras, la reacción inmune obtenida con estas formulaciones fué diferente: galE 
LPS indujo una respuesta de tipo Th1, con incremento en la producción de 
anticuerpos del tipo IgG2a. Esto es beneficioso, ya que anticuerpos de los tipos 
IgG2a e IgG2b son capaces de activar el sistema del complemento necesario para 
una actividad bactericida. En ratones inmunizados con liposomas con el adyuvante 
lpxL1 LPS, los niveles de todos los tipos de IgG se incrementaron, en comparación 
con animales inmunizados sin adyuvantes. El incremento en los niveles de 
anticuerpos bactericidas en ratones inmunizados con liposomas con el adyuvante 
lpxL1 LPS fue acompañado de una mejora en la proliferación (específica hacia PorA) 
de células en los nódulos linfáticos tras la re-estimulación en cultivos con PorA, y en 
comparación con ratones inmunizados en ausencia de adyuvantes. Al mismo 
tiempo, las células en proliferación producen también niveles incrementados de IL-2 
(una citoquina de tipo Th1), mientras que la producción de IL-10 (una citoquina de 
tipo Th2) no se incrementa. 
El uso de microesferas biodegradable como sistemas de transporte de PorA 
en liposomas y OMV se estudió en el capítulo 7. Microesferas de pequeño tamaño 
(< 10 µm) pueden ser internalizadas por células presentadoras de antígenos (CPA) y 
microesferas de mayor tamaño (> 10 µm) pueden actuar como depósito en el lugar 
de administración, atrayendo así a CPA. Se prepararon microesferas basadas en 
dextran y manan con similar distribución del tamaño que contenían OMV o 
liposomas con PorA. Ambos sistemas fueron desarrollados para liberar en poco 
tiempo tras la administración del antígeno encapsulado. El objetivo final de estas 
formulaciones es mejorar la respuesta inmune contra PorA, por medio de una mejora 
de la internalización de PorA por CPA. Manan, un polímero de manosa, también 
tiene propiedades adyuvantes. Los residuos de manosa situados en la superficie de 
las microesferas probablemente mejoran la interacción e internalización por las CPA, 
lo que puede resultar en una mejora de la respuesta inmunológica contra PorA en 
liposomas o OMV encapsulados en las microesferas. Tanto liposomas como OMV 
son rápidamente liberados de las microesferas in vitro entre los dias 5 y 10-11 de 
incubación a 37ºC. La estructura de PorA (formando trímeros en la membrana) se 
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mantuvo tras la liberación de los dos tipos de microesferas. A pesar de que la 
liberación del antígeno no fué total, la respuesta inmune inducida por PorA en 
liposomas o OMV encapsulados en microesferas se mantuvo similar a la respuesta 
de estas formulaciones no encapsuladas. 
 
Conclusión  
 
Esta tesis doctoral demuestra que las formulaciones liposomales son muy 
favorables como formas de presentación para vacunas basadas en PorA. No 
solamente las características físico-químicas y la respuesta inmunológica producida 
por esa proteína se mantienen en su formulación en liposomas, sino que además 
este tipo de formulaciones también permite la incorporación de adyuvantes y 
moléculas en la superficie de los liposomas para la vectorización de éstos, lo cual 
resulta en una mejora de la respuesta inmune producida por PorA.  
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AlPO4   aluminum phosphate 
APC   antigen presenting cell 
BCR   B-cell receptor 
BMDC   bone marrow-derived DC 
BSA   bovine serum albumin  
CD   circular dichroism 
Chol   cholesterol 
CLSM   confocal laser scanning microscopy 
CTL   cytotoxic T lymphocytes 
DC   dendritic cell 
Dex   dextran 
DiD   3,3,3’,3’-tetramethylindocarbocyanine, 4-chlorobenzenesulfonate 
DLS   dynamic light scattering 
(DM)PC  dimyristoyl phosphatidylcholine 
(DM)PE  dimyristoyl phosphatidylethanolamine 
(DM)PG  dimyristoyl phosphatidylglycerol 
(DM)TAP  dimyristoyl trimethylamoniumpropane 
DOC   sodium deoxycholate 
ELISA   enzyme-linked immunosorbent assay 
EM   electron microscopy 
EPC   egg phosphatidylcholine 
FBS   fetal bovine serum 
FACS   fluorescence activated cell sorting 
FDA   food and drug administration 
FITC   fuorescein isothiocyanate 
GAM   goat anti-mouse 
GM-CSF  granulocyte macrophage colony stimulating factor 
Gnd-HCl  guanidinium hydrochloride 
GPC   gel permeation chromatography 
GC   gas chromatography 
HEMA  hydroxyethyl methacrylate 
HLA   human leukocyte antigen 
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HRP   horse-radish peroxidase 
Ig   immunoglobulin 
IL   interleukin 
IM   inner membrane 
KDO   keto-deoxyoctonate 
LPS   lipopolysaccharide 
LSD   least significant difference 
MAb   monoclonal antibody 
Man   mannose/mannosylated 
MFI   mean fluorescence intensity 
MHC   major histocompatibility complex 
MoDC   monocyte-derived DC 
MPL   monophosphoryl lipid A 
MR   mannose receptor 
NATrA  N-acetyl tryptophan amide 
NATyA  N-acetyl tyrosine amide 
NspA   Neisserial surface protein A 
OG   octylglucopyranoside 
OM   outer membrane 
OMC   outer membrane complexes 
OMP   outer membrane protein 
OMV   outer membrane vesicles 
Opa   Opacity protein 
PD   polydispersity index  
PorA   porin A 
RmpM   reduction modifiable protein M 
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Th   T helper 
TCR   T-cell receptor 
Trp   tryptophan 
Tyr   tyrosine 
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